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 V 
Thesis Summary 
 
 
Kidney biopsy is the current gold standard diagnostic test for intrinsic renal 
disease but requires hospital admission and carries a 3% risk of major 
complications. Current non-invasive prognostic indicators such as urine protein 
quantification have limited predictive value. Better diagnostic and prognostic tests 
for chronic kidney disease (CKD) patients are therefore a major focus for industry 
and academia. An alternative approach is the quantification of urinary microRNAs 
(miRNAs): short, non-coding RNAs that regulate gene expression post-
transcriptionally.  
This project investigated the utility of urinary miRNA expression analysis as a 
method for non-invasive diagnostic/prognostic testing for CKD. A technique was 
developed for quantifying miRNAs in urine samples from control subjects and 
diabetic nephropathy (DN) patients with a coefficient of variation below 10%. The 
stability of endogenous miRNAs was demonstrated in urine samples from 
unaffected individuals and DN patients. Two populations of urinary miRNAs were 
identified: those associated with exosomes and those associated with AGO2, a 
component protein of the RNA-induced silencing complex.  
Expression of over 750 urinary miRNAs in pooled urine samples from DN 
patients was compared with that in corresponding control samples using TaqMan 
Array Human microRNA Card analysis. Statistically significant differences in 
expression of a subset of putative disease-associated miRNAs were then 
replicated in individual urine samples, and these data were supported by ROC 
curve analyses. Expression analysis of these target miRNAs in defined nephron 
segments was observed using laser capture microdissection of renal biopsy 
tissues followed by miRNA detection by RT-qPCR. Subsequent renal cell line 
analysis pinpointed miRNA cellular origins, and miRNA release into conditioned 
tissue culture medium in response to disease stimuli was also observed. 
These experimental data reveal a pattern of urinary miRNA expression 
changes in DN and present putative mechanisms by which these differences in 
abundance might come about. 
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Chapter 1 – Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
The overall purpose of the work carried out during the PhD research project 
described in this thesis was to develop approaches to urinary miRNA 
quantification as novel, non-invasive biomarkers for the diagnosis and prognosis 
of diabetic nephropathy. In order to have a complete understanding of the 
potential of urinary biomarkers, in this introduction I have first considered how the 
kidney makes urine. To this end, before outlining the biogenesis and role of 
miRNAs in kidney disease, this introduction section will briefly describe the 
structure of the kidney and the different compartments of the nephron. As the 
basic structural and functional unit of the kidney, the nephron is ultimately 
responsible for urine production. The structural changes in diabetic nephropathy 
that subsequently result in functional impairment are also described.  
 
1.1 Kidney 
1.1.1 Kidney structure 
 
The kidneys are a pair of organs located in the back of the abdomen that in a 
healthy adult human are approximately 10 cm in length, 6 cm wide and have a 
thickness of 3 cm. The surface of the kidneys is covered by the renal capsule, a 
connective tissue layer rich in fibroblasts and collagen fibres that preserves the 
structure of the kidneys and provides protection from injury. The peripheral part of 
the kidney consists of the cortex and the medulla. The medulla is composed of 
medullary pyramids with the base of each pyramid facing the renal cortex. It 
appears striated because it contains the straight tubular structures known as the 
descending and ascending limbs of the loop of Henle, the collecting tubule, and 
blood vessels. The cortex is the outer portion of the kidney and consists of renal 
corpuscles, convoluted tubules, descending and ascending straight tubules, and 
an extensive vascular supply.  
The nephron is the basic structural and functional unit of the kidney. The 
afferent arteriole provides blood to the glomerular capillaries, which then leaves 
via the efferent arteriole. In the majority of glomeruli, the efferent arteriole then 
divides into a capillary network supplying the renal tubules. The nephron begins 
at the renal corpuscle, which is composed of the glomerulus with a tuft of 
capillaries surrounded by a double-layer of cup-shaped epithelial cells known as 
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the Bowman’s capsule. The cavity of the capsule leads to the proximal renal 
tubule, which is separated into convoluted and straight sections. The straight part 
continues into the descending limb of the loop of Henle, which then ascends to 
become the distal tubule, firstly the straight part and then the convoluted distal 
tubule. The convoluted distal tubule is connected to the cortical collecting duct by 
a connecting tubule [1]. 
 
 
Figure 1.1. Basic kidney anatomy 
The illustrations were adapted from the excellent review by Kurts and colleagues [2].  
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1.1.2 Nephron 
1.1.2.1 Nephron compartments 
 
As stated before, the first part of the nephron is composed of the glomerulus 
and Bowman’s capsule, and functions as the filtration apparatus of the kidney. 
The glomerulus is composed of endothelial cells, mesangial cells and podocytes, 
while the Bowman’s capsule is characterised by simple squamous epithelium. 
The glomerular filtration barrier (GFB) comprises 3 layers: a capillary 
endothelium, a basal lamina and a podocyte layer, with the basal lamina located 
between the other two layers. 
The GFB defines the characteristic of the glomerular ultrafiltrate. Water, small 
and midsized solutes of mass <10 kDa can cross the GFB directly. For molecules 
of mass >10 kDa, passage is restricted and charge selection applies, while 
molecules >100 kDa cannot be filtrated. Fluid filtered through the glomerulus 
flows to the proximal convoluted renal tubule that consists of epithelial cells 
covered by densely packed microvilli, the loop of Henle that is made up of simple 
squamous epithelial cells, and the distal convoluted tubule lined with simple 
cuboidal cells [2].  
 
The endothelium 
The glomerular endothelial cells are responsible for haemostasis, trafficking of 
leucocytes and vasomotor tone regulation through the secretion of endothelin, 
platelet derived growth factor and the secretion of nitric oxide and prostacyclin 
[3]. Glomerular endothelial cells have the unique structural feature of 
fenestrations that constitute 20-50% of the endothelial cell surface and facilitate 
the exchange of substrate between intra and extravascular compartments [4]. 
The fenestrations are approximately 60 nm in diameter, and since albumin has a 
diameter of 3.6 nm, this suggests that endothelial cells are only partly responsible 
for the selective permeability of the glomerular barrier [5]. An endothelial cell 
surface layer (ESL) covers the luminal side of the blood vessel and this is 
implicated in processes such as blood coagulation, angiogenesis and capillary 
barrier function [6]. The ESL is composed of glycocalyx and endothelial cell 
coating. Glycocalyx is formed by soluble plasma components and is composed of 
large amounts of glycoprotein, such as proteoglycans, and/or 
 5 
glycosaminoglycans. With a typical thickness of approximately 200 nm the 
glycocalyx plays an active role in restricting the passage of macromolecules and 
permitting the passage of water and small solutes [7]. The normal endothelium is 
also characterised by its capacity to maintain blood flow [8] and initiate the 
inflammatory centre by recruitment of leucocytes [9]. 
 
The mesangium 
The mesangial cells are localised in the centre of the glomerulus and, together 
with the extracellular matrix (ECM), are responsible for maintaining the structure 
and function of the GFB. They are adjacent to endothelial cells on the opposite 
side of the glomerular basement membrane to the podocytes. They contract or 
relax in response to a number of vasoactive agents, and this event may modify 
the glomerular ultrafiltration coefficient [10]. Mesangial cells express platelet-
derived growth factor-ß receptor (PDGFß-R) [11], together with transforming 
growth factor beta (TGF-ß), a key mediator in kidney disease progression, 
interleukin-1 (IL-1), and insulin-like growth factor (IGF) [11]. These cells also 
express angiotensin-II receptors [12] and produce mesangial ECM components 
[13]. 
 
The glomerular basement membrane (GBM) 
The GBM is composed of the basal lamina, approximately 300-370 nm thick 
that lies between the glomerular endothelial cells and podocytes. The basal 
lamina is composed of laminin, type IV collagen, sulphate proteoglycans and 
glycoproteins. 
These components are located in specific regions of the lamina: 
- the lamina rara externa, on the podocyte side, is well provided with 
polyanions responsible for preventing the passage of negatively charged 
molecules; 
- the lamina rara interna, on the endothelial side; 
- the lamina densa, overlaps the rara externa and rara interna, and is 
characterized by the presence of type IV and XVIII collagen, perlecan and 
agrin responsible for both increasing the anionic charge and connecting 
the endothelial cells and podocytes to the membrane. 
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Molecules larger than 70 kDa, or with a radius greater than 3.6 nm, do not 
cross the filtration barrier, while those with a mass below 70 kDa that are 
negatively charged are also repulsed [1,14]. 
 
The podocyte 
Podocytes are differentiated, highly specialized cells of mesenchymal origin, 
which subsequently undergo phenotypic transition and acquire a partial epithelial 
characteristic, an apical and a basolateral membrane. The podocyte cellular 
architecture is characterized by a cell body with interdigitating foot processes that 
are separated by a filtration slit approximately 25-60 nm wide, and covered by the 
slit diaphragm. Podocytes are connected to the GBM via foot processes that 
represent the basolateral domain, and are characterized by a contractile 
apparatus composed of myosin II, α-actin, talin and vinculin. The cell body is 
characterized by the presence of proteins such as vimentin and desmin, and 
small microtubules. The apical membrane is composed of glycoproteins, these 
are negatively charged and therefore play a role in regulating filtration across the 
GBM [6,15,16]. Proteins that form the slit diaphragm, such as the main protein 
component nephrin, are crucial for maintaining normal glomerular permeability 
and regulating passage of molecules across the GBM on the basis of the size, 
charge and physical configuration [17]. 
 
The parietal cell 
The parietal cells form a single layer of simple squamous epithelium attached 
to the Bowman’s basement membrane with a thickness of 0.1-0.3 μm. Like 
podocytes, they are derived from a common ancestral mesenchymal progenitor 
and have the ability to respond to injury by de-differentiating into an embryonic 
phenotype, while under homeostasis they differentiate into glomerular podocytes. 
Between parietal cells, tight junction proteins and cadherins help to prevent 
the passage of proteins into the extra-glomerular space, and these cells are 
therefore considered a second glomerular barrier to filtered proteins [17-19] 
 
The proximal tubular cell 
The proximal tubule is the portion of the nephron that receives the ultrafiltrate 
from the glomerulus and leads to the loop of Henle and is divided into a 
convoluted and straight portion. Cuboidal epithelial cells make up the convoluted 
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proximal tubule, with the apical-luminal surface bordered with millions of microvilli 
that increase the surface area for absorption/transport. On the basolateral side, 
mitochondria supply energy for transport. Proximal tubular cells (PTC) have a key 
role in renal function: they are responsible for reabsorbing glucose, hormones, 
vitamins and peptides filtered by the glomerulus. These cells also control the 
acid-base balance and excrete metabolic end products [20]. 
The convoluted tubule is followed by the loop of Henle, which is organized into 
3 sub-sections composed of squamous epithelial cells with limited cytoplasm and 
small numbers of mitochondria: 
- The thin descending limb which is permeable to water but not to salt; 
- The thin ascending limb that is impermeable to water and passively 
permeable to salt; 
- The thick ascending limb which is responsible for the transport of salt 
from the lumen 
The loop of Henle then becomes the distal convoluted tubule, which is 
composed of cuboidal cells. Shorter than the proximal tubule, the distal tubule 
shows infolding of the basolateral membrane and its cells are rich in 
mitochondria. The distal convoluted tubular cells are responsible for the final part 
of sodium and water reabsorption, and hydrogen and potassium secretion [21]. 
 
1.1.2.2 Functions of the nephron compartments 
 
Nephrons are responsible for producing urine and maintaining homeostasis, 
via control of electrolytes, acid-base balance and removal of toxins and waste 
products. Additional roles include blood pressure regulation and production of 
hormones like renin, calcitriol and erythropoietin [8,21]. 
 
 
Urine production and maintenance of homeostasis 
 
Filtration 
Urine formation begins with blood filtration in the renal corpuscle. Blood 
arrives via the afferent arteriole, flows in the glomerulus under pressure, and is 
filtered through the GBM according to its composition. Molecules with a radius  
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below 1.8 nm such as water, ions, glucose or insulin pass through freely, while 
those with a radius between 1.8 and 4.2 nm, or above 4.2 nm, have restricted 
access or cannot pass through the barrier. In addition, the overall negative-
charge of the GFB impedes passage of negatively charged molecules but 
facilitates the passage of positively charged ones. The non-filterable components 
of the blood, mainly blood cells, platelets and some plasma proteins, leave via 
the efferent arteriole.	  
 
Reabsorption  
Reabsorption is the process by which approximately 60-80% of solutes and 
water that cross the GFB each day are absorbed again by endocytosis in the 
proximal convoluted tubule. It is regulated by active transport, osmosis and 
diffusion and is divided into two steps. Molecules are initially transported from the 
tubule to the interstitium, and subsequently to the peritubular capillaries. 
The composition of the ultrafiltrate produced in the Bowen’s capsule space 
changes in the proximal tubule due to the reabsorption of substances including 
glucose, amino acids, vitamins and electrolytes. Sodium is reabsorbed mainly at 
the proximal tubule, but in lower amounts also in the loop of Henle, distal tubule 
and collecting duct. Sodium reabsorption involves the Na+/K+ ATPase pump 
where Na+ is primarily moved passively from the lumen to the tubular cells. 
Subsequently, Na+ is actively transported from the tubular cell into the interstitial 
fluid within the lateral space and, finally, into the peritubular capillary. 
 
Secretion 
Substances such as toxins, antibiotics, hydrogen ions, creatinine or molecules 
present in surplus in the blood are secreted directly from the distal convoluted 
tubule. Secretion has two fundamental roles: to remove waste products and to 
maintain acid-base balance. The combination of these secreted substances with 
water and other waste products constitutes urine, which is then ready to move 
from the kidney to the bladder via the ureters in readiness for excretion [1,9-
11,20,22,23].  
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Hormone secretion 
 
In response to renal hypoxia, the renal mesangial and tubular cells produce 
erythropoietin (EPO), which promotes the formation of red blood cells in the bone 
marrow. In addition, the kidney is responsible for the formation of calcitriol, the 
active form of vitamin D, from cholecalciferol. Calcitriol has a role in regulating the 
concentration of calcium and phosphate in the bloodstream and bone 
remodelling. The juxtaglomerular apparatus, located near the vascular pole of the 
glomerulus, is an integral part of the maintenance of sodium homeostasis and 
renal haemodynamics by the renin-angiotensin aldosterone system (RAAS) [23-
26]. 
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1.2 Kidney diseases 
1.2.1 Chronic kidney disease (CKD) 
 
Chronic kidney disease (CKD) is characterised by a progressive loss of renal 
function, as evidenced by a reduction of the volume of glomerular filtrate 
produced per min, or glomerular filtration rate (GFR), to less than 60 mL/min per 
1.73m2 on at least 2 occasions for more than 3 months. A UK cross-sectional 
study conducted in over 130,000 adults indicated a prevalence of CKD stage 3-5 
of 8.5%, higher in females (10.6%) than in males (5.8%) [28]. This value is likely 
to underestimate true CKD prevalence, since GFR is untested in a significant 
proportion of the population [27]. The prevalence of CKD in the USA has been 
estimated at 13% [28], and in Australia at 13.4% for stages 1–5 and 7.8% for 
stage 3–5 [29]. The estimated cost of CKD to the NHS in England in 2009-2010 
was £1.4 billion / year, 1.3% of the total NHS annual budget [30]. 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NKF-KDOQI) classified CKD into 5 stages on the basis of kidney damage and 
level of renal function estimated as GFR [31]. 
 
- Stage 1, GFR more than 90 mL/min per 1.73m2 
- Stage 2, GFR between 60-89 mL/min per 1.73m2 
Both of these stages require the presence in urine of persistence of 
protein (proteinuria), albumin (albuminuria) or red blood cells 
(haematuria), or structural abnormalities.  
- Stage 3, GFR between 30-59 mL/min per 1.73m2 
- Stage 4, GFR between 15-29 mL/min per 1.73m2 
- Stage 5, GFR less than 15 mL/min per 1.73m2. This stage may be 
described as established renal failure or end stage renal disease (ESRD). 
 
In general, CKD stages 1 and 2 are asymptomatic. Indeed, its presence may 
not become obvious until disease is well established, and has led to CKD being 
referred to as a “silent killer” [32]. 
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1.2.1.1 CKD biomarkers 
 
GFR is used to estimate renal function, providing a measure of how well the 
kidneys are working, and is usually approximately 120 mL/min. Since GFR 
cannot be measured directly, it is estimated as endogenous creatinine clearance, 
the volume of blood plasma that is cleared of creatinine per unit of time. 
Creatinine is a molecule produced during normal muscle breakdown. It is 
proportional to the muscle mass, and is filtered and not absorbed by the kidney. 
Creatinine clearance is calculated by multiplying the creatinine concentration 
in the collected urine sample (Cu) per the urine flow rate (V) and dividing by 
creatinine concentration in plasma (Cp) i.e. GFR = (Cu x V) / Cp. Creatinine 
clearance is frequently corrected for body surface area and compared to the 
average size of an adult male (mL/min/1.73 m2). However, the variation in 
creatinine clearance is not sensitive enough to detect CKD, since it is susceptible 
to non-renal and/or analytical effects such as ingestion of cooked meat, 
inaccuracies in urine collection or method/analyser used, and there is inter-
laboratory variation [33]	  
The upper limit of protein in urine is around 150 mg/24 h, equal to a 
protein:creatinine ratio (PCR) of 15 mg/mmol. Albumin, one of the main proteins 
in the blood, is the most abundant protein detectable in urine in most 
nephropathies. A normal mean value for albuminuria is 10 mg/day, 
microalbuminuria is defined as 30–300 mg/day, equivalent to an 
albumin:creatinine ratio (ACR) of >2.5 mg/mmol in men and >3.5 mg/mmol in 
women. Macroalbuminuria is defined as an urinary albumin output exceeding 300 
mg/day (ACR >30 mg/mmol) [31,34,35]. 
New biomarkers have emerged for monitoring renal function including cystatin-
C and uric acid [36]. Cystatin-C has a molecular weight of 13 kDa and is normally 
filtered and reabsorbed, in pathological conditions its serum levels increase. In 
normal conditions, uric acid is eliminated through the kidney, but during CKD its 
levels raise [37]. Additional biomarkers for kidney cellular injury include nephrin 
and podocin, podocyte-specific markers, that are found at elevated levels in the 
urinary sediment of diabetic nephropathy patients [38]. The main biomarkers 
used for renal disease, including those that have been recently discovered, have 
been expertly and comprehensively reviewed in the context of pathophysiological 
processes [39]. 
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Currently, the gold standard diagnostic test for kidney disease is the renal 
biopsy, an invasive procedure where a small sample of tissue is removed and in 
3% of the cases complications such as bleeding or infection may occur. The CKD 
biomarkers described above have been useful, but additional biomarkers are 
needed, particularly for diagnosis of early stage CKD, since current disease 
markers are not specific and sensitive enough to predict the outcomes of 
individual CKD patients. In many cases, outcome will be influenced by factors 
involved in renal perfusion, and presently available biomarkers are not capable of 
discriminating either the cause or the location of the injury. 
Albuminuria has been used as a marker for glomerular disease but lacks 
specificity, by the time significantly increased albuminuria is detectable extensive 
renal damage may already be present. In addition, slower progression of CKD 
may be accompanied by a reduction in proteinuria, while a faster decline may be 
associated with a proteinuria increase [40]. Blood urea nitrogen (BUN) and 
cystatin-C are influenced by non-renal events such as protein intake, 
dehydration, liver activity, gastrointestinal bleeding and steroid use, or muscle 
mass, age and sex. Given both the complexity of this pathology and the multitude 
of factors involved in the progression/complications of CKD, more informative 
biomarkers are under study/in demand for efficient classification of disease 
progression, morbidity, and mortality. 
 
1.2.1.2 CKD progression 
 
Many conditions and factors that damage the kidney contribute to CKD 
progression. Diabetes is the most important cause of renal disease, followed by 
vascular disease (primarily hypertension) [41]. Other conditions that cause CKD 
include glomerulonephritis, pyelonephritis, polycystic kidney disease, and 
systemic lupus erythematosus. 
The national kidney foundation found additional risk factors that correlated with 
CKD included old age (> 60 years old), genetic factors, autoimmune disease, 
obesity, sedentary life style, drug abuse and family history of kidney disease [34]. 
Irrespective of their origins, most kidney diseases appear to share common 
pathways to glomerular and tubular fibrosis via mechanisms involving common 
signalling pathways and cytokines such as TGF-ß, platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), connective tissue growth factor (CTGF) 
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and endothelin. Disease progression is also characterised by increased ECM 
synthesis [42].  
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1.2.2 Diabetic Nephropathy 
 
Diabetic nephropathy (DN) is the principal cause of CKD in the UK and the 
second most common cause of end-stage renal disease (ESRD), constituting 20-
50% of all patients requiring renal replacement therapy or kidney transplantation. 
Classification of DN is determined by urinary albumin excretion along with 
increase in blood pressure and decline in GFR [43,44]. 
Morgensen and co-workers classified DN into 5 stages: 
Stage 1 – Early hypertrophy and hyperfunction associated with excretion of 
albumin in the urine 
Stage 2 – Glomerular lesion without sign of clinical disease and elevation of GFR 
and urinary albumin excretion 
Stage 3 – Development of DN with higher albumin excretion 
Stage 4 – Clear DN characterised by persistent proteinuria (> 0.5g/24h) 
Stage 5 – End-stage renal failure with uraemia [45] 
  
DN can occur following either type 1 diabetes (T1DM) or type 2 diabetes 
(T2DM). Presentation of DN in T1DM is ascribable to the above classification, 
while the DN in T2DM is frequently accompanied by the presence of other 
chronic diseases or conditions such as obesity, hypertension or cardiovascular 
disease [46,47]. Differences in the patterns of renal damage caused by T1DM or 
T2DM have also been reported [47]. In T1DM, renal damage is the consequence 
of long-term exposure to hyperglycaemia, and it is characterized by the 
accumulation of ECM proteins that leads to increased mesangial size [48]. 
Glomerular and tubular basement membrane thickening and tubulointerstitial 
fibrosis and glomerulosclerosis are also seen. Initially, subjects exhibit 
hyperfiltration (high value of GFR), and possibly, microalbuminuria, while when 
the disease progress (usually after 15-20 years), GFR decreases gradually and 
microalbuminuria is succeeded by moderate proteinuria. Eventually, severe 
proteinuria is seen in the final pathological stage [48].  
In pure T2DM, classical DN is seen in a minority of cases, often those with 
diabetic retinopathy and normal body mass index (BMI). Other patients may 
manifest a more complex renal injury, including tubulointerstitial and vascular 
lesions. Approximately 30% of T2DM patients have hypertension [49,50]. 
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1.2.2.1 Factors involved in development and progression of DN 
 
Glucose 
Hyperglycaemia is the leading cause of DN and, together with hypertension, is 
one of the main reasons for renal hypoperfusion, glomerular hypertension and 
hyperfiltration [51]. Glomerular hypertrophy is one of the first consequences of 
elevated circulating glucose levels, followed by an accumulation of ECM proteins 
that causes a thickening of the glomerular and tubular basement membranes. 
Later, capillary barrier and basement membrane are affected by non-enzymatic 
glycosylation factors. In addition, concomitant ECM accumulation of collagen IV, 
fibronectin, laminin and thrombospondin with collagen I and III cause mesangial 
matrix hypertrophy [52,53]. 
High circulating glucose concentrations cause oxidative stress and the 
production of reactive oxygen specie (ROS) that is, in turn, responsible for DNA 
damage and upregulation of TGF-ß, plasminogen activator inhibitor-1 (PAI-1), 
ECM protein expression and the induction of apoptosis [54]. Metabolic 
abnormalities in mesangial cells have been reported following treatment with high 
glucose concentrations of 23-30 mM [54]. This condition induces TGF-ß 
production that leads to increased expression of GLUT1 mRNA and protein, 
causing enhancement of glucose uptake [55]. Another effect of TGF-ß induction 
in mesangial cells is an increase in collagen IV and laminin production [56]. 
Further work in the same cells has shown that PDGF, which has an important 
role in angiogenesis, is also activated after incubation with high glucose and 
causes an increase of TGF-ß1 expression [57]. Hyperglycaemia also up-
regulates vascular endothelial growth factor (VEGF) expression in podocytes and 
vascular permeability [58]. 
Advanced glycosylation end products (AGE) are glycosylated proteins formed 
following onset of hyperglycaemia and have a key role in the progression of DN. 
Galler and colleagues showed that ESRD patients have double the amount of 
tissue AGEs in comparison with healthy subjects [59]. AGE accumulation in the 
GBM and ECM modifies ECM-ECM and ECM interactions [60]. AGEs regulate 
different intracellular events, such as the activation of protein kinase C (PKC), 
mitogen activated protein kinase (MAPK), and transcription factors such as 
nuclear factor κB (NF-κB) [61,62].  
 16 
The PKC family is a group of enzymes responsible for phosphorylation of 
serine and threonine residues on intracellular proteins involved in basement 
membrane regulation or growth factor expression [63]. Enhancement of PKC 
activity was identified in diabetic rats and cells treated with high glucose 
concentrations [63]. It has also been shown that high PKC expression is 
responsible for endothelial dysfunction with reduction of nitric oxide production 
and up-regulation of endothelin-1 and VEGF [64]. PKC activation also results in 
increased endothelial permeability to albumin, kidney hypertrophy, inhibition of 
mesangial cell proliferation and accumulation of mesangial ECM [62,65-67]. 
 
Hypertension 
Hypertension is another main risk factor for renal disease. It has been 
reported that 70% of diabetic patients are affected by hypertension, but DN is 
also the main cause of hypertension in subjects with T1DM [68]. Damage to 
kidney vasculature occurs as a result of increased blood pressure, which reduces 
the capacity of the kidney to filter fluid and waste products, resulting in increased 
proteinuria [69]. High blood pressure can also be a consequence of CKD, and 
may result from a reduction in kidney function due to other factors, along with 
increased blood volume [70].  
Factors associated with hypertension include increased renal sodium 
reabsorption, activation of the RAAS, up-regulation of ET-1 and ROS, and down-
regulation of nitric oxide (NO). It has been reported that increased extracellular 
fluid volume resulted in loss of salt balance and RAAS activation, leading to a 
direct reduction of NO which, in turn, effected vasoconstriction and loss of 
vasodilator effect [69]. Increased angiotensin II production is attributable to 
prolonged hyperglycaemia, which increases the production of mesangial matrix 
proteins and inhibition of mesangial matrix degradation [69]. Another 
consequence of angiotensin II induction is the production of TGF-ß in resident 
renal cells that concurs with ECM accumulation [71]. Moreover, angiotensin II 
stimulates synthesis in vascular smooth muscle cells of proteins such   as collagen 
I, but not collagen IV, and  increases levels of insulin-like growth factor 1 (IGF-I), 
PDGF-A, basic FGF and TGF-ß [13]. 
In high glucose conditions, angiotensin II binds to its type 1 receptor (AT1R) 
activating extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase 
(JNK) and p38 MAPK signaling, and production of activator protein-1 (AP-1) and 
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cyclic adenosine monophosphate (cAMP) response element-binding (CREB) 
protein are enhanced. The result is an increase of ECM synthesis and cell 
growth. Association of angiotensin II with its AT1R is also responsible for 
vasoconstriction in vascular smooth muscle cells and increased sodium 
reabsorption in the PTCs [72]. 
In normal conditions, vascular endothelial cells release substances that have 
opposite effect than the RAAS. These cells produce nitric oxide (NO) that induces 
relaxation and vasoconstriction in vascular smooth muscle cells. Hypertension 
and hyperglycaemia increase oxidative stress and decrease excretion of NO, 
there reducing its vasodilator function [72]. 
ET-1 is produced in the vascular endothelium and stimulates mesangial cell 
proliferation and hypertrophy, ET-1 expression is increased in insulin resistant 
type 2 diabetic subjects [73]. 
 
Inflammation 
Inflammatory processes are also important in DN pathogenesis, with leukocyte 
infiltration and cytokine activity apparent at every disease stage [2]. Hypertension 
and hyperglycaemia stimulate ET-1 production and activate neutrophils, induce 
monocyte chemoattractive factor-1 synthesis by endothelial cells, and increase 
expression of cell adhesion molecules such as intercellular adhesion molecule 1 
(ICAM-1) [74]. Different stimuli, such as hyperglycaemia, hyperinsulinemia, 
AGEs, ROS and angiotensin II act on different kidney cell types, inducing 
intracellular signalling cascades such as MAPK and JAK-STAT pathways. Each 
of those pathways involves circulating inflammatory cells, driving the 
development and progression of DN [75].  
NF-κB is a transcription factor that has been implicated in inflammation in DN, 
and activates inflammatory cytokines as well as cell adhesion proteins [75]. NF-
κB is stimulated by oxidative stress and plays a role in mesangial cells activation 
leading to renal injury [76]. In DN patients, NF-κB drives the transcription of 
genes encoding chemokines, effector molecules of immunity, inflammatory 
cytokines and cell adhesion molecules, as well as metalloproteinases and tissue 
factors [75]. Hasegawa and colleagues have demonstrated that both tumour 
necrosis factor-alpha (TNF-α ) and IL-1, produced by AGEs, may have a role in 
development of DN [75,77]. Sassy-Prigent and co-workers have demonstrated an 
increase of IL-1 in the renal cells of DN rats which induced the expression of 
 18 
other proinflammatory molecules such as ICAM-1, VCAM-1 and E-selectin [78]. 
The latter chemokines increase vascular endothelial permeability [75] and have 
been implicated in early structural abnormalities such as glomerular basement 
thickening [79]. IL-1-stimulated mesangial cell proliferation leads to increased 
expression of fibronectin and ECM proteins [79]. 
IL-18, an immunoregulatory cytokine member of the IL-1 family, is also more 
abundant in the serum and urine of DN patients. IL-18 concentration has been 
correlated with urinary albumin excretion rate and plays a key role in early renal 
dysfunction [80]. Miyauchi and colleagues have shown increased expression of 
IL-18 in renal biopsies from DN patients, and the same workers also found that 
this increase was due to TGF-ß–stimulated MAPK activation [81]. IL-18 is 
secreted by monocytes/macrophages and stimulates expression of interferon 
gamma (INF-γ), IL-1 and TNF-α, as well as endothelial cell apoptosis and up-
regulation of ICAM-1 [82]. 
Increased IL-6 expression was found in the serum of DN patients with 
macroalbuminuria [76] and also in mesangial, interstitial and tubular cells from 
DN biopsy samples [83]. IL-6 expression also has a role in renal disease 
progression and is correlated with mesangial proliferation, tubular atrophy and 
increase of fibronectin [84]. 
TNF-α is a proinflammatory chemokine that is produced by monocytes and 
macrophages, but also by renal cells such as mesangial, endothelial and PTCs 
[85-87]. The effects of TNF-α are mediated by its two specific receptors: the 
ubiquitously expressed epithelial-cell receptor tumour necrosis factor receptor 1 
(TNFR1), and tumour necrosis factor receptor 2 (TNFR2), a myeloid-cell receptor. 
Receptor activation induces the signaling pathways responsible for apoptosis and 
necrosis, reduction of glomerular filtration, increase of endothelial permeability, 
promotion of oxidative stress culminating in an increase in albumin’s permeability 
and renal hypertrophy [75]. TNF-α-induced hemodynamic instability between 
vasodilatory and vasoconstrictive mediators leads to intraglomerular blood flow 
and GFR alterations [88]. Up-regulated TNF-α expression has been shown in 
glomerular and epithelial tubular cells in a diabetic rat model [89], as well as in 
human renal cortex and urine samples, where it is also correlated with urine 
albumin extraction [75]. TNF-α also induces expression of cell adhesion 
molecules ICAM-1 and VCAM-1. ICAM-1 is mainly expressed in endothelial, 
epithelial and mesangial cells in the kidney, while VCAM-1 in endothelial and 
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smooth muscle cells. ICAM-1 and VCAM-1 have a pivotal role in T­cell migration 
into the kidney, and increased ICAM-1 and VCAM-1 expression has been shown 
in several DN models, and is associated with DN progression [90,91].  
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1.3 miRNA 
1.3.1 miRNA discovery 
 
The first miRNA identified was lin-4 in C. elegans by Victor Ambros and his 
colleagues in 1993. They discovered that this gene, important for controlling C. 
elegans larval development, did not encode a protein but two small transcripts of 
approximately 61 and 22 nucleotides (nt) in length. The longer one was predicted 
to fold into a stem loop and it was suggested to be the precursor of the shorter 
one which had antisense complementarity to multiple sites in the 3’ UTR on 
target messenger RNAs (lin-14) in order to block its gene expression [92].  
After this discovery, no similar noncoding RNAs were found in nematodes or 
other species until 2000 when Reinhart and Slack [93,94] found let-7 in C. 
elegans. This new miRNA was considered a heterochron switch gene that 
encodes for a 21nt RNA complementary to the 3’UTR of different genes (lin-14, 
lin-28, lin-41, lin-42 and daf-12) and that may control the temporal sequence of 
events in C. elegans development [93]. In the same year, Pasquinelli identified 
that the same miRNA, let-7, was conserved in samples from a wide range of 
species as vertebrate, ascidian, hemichordate, mollusc, annelid and arthropod, 
[95] implicating a more universal function for these genes in animals. 
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1.3.2 miRNA biogenesis and regulatory functions 
 
miRNAs can be situated both in previously not annotated regions of the 
genome and in introns or exons of protein coding genes with the same orientation 
as the predicted mRNA. The first are generally classified as “intergenic” and are 
regulated by an independent promoter, while the second, called “intronic”, are 
controlled by the promoter of the host gene [96,97]. However, some reports, 
suggest that even these intronic miRNAs may be transcribed by their own 
promoter [98]. miRNAs can also be located in clusters in the genome and usually 
these are co-regulated and expressed sharing also the primary transcript [99]. 
However recently it was discovered that miRNAs located in clusters of a host 
gene’s intron can be transcribed independently and different pri-miRNAs can be 
the result of alternative splicing situated near these regions of the genome [97].  
The biogenesis starts in the nucleus with the transcription by the polymerase II 
(pol II) or polymerase III (pol III) of a primary miRNA transcript (pri-miRNA), a 
single stranded RNA a few thousand of nucleotides long and characterised by a 
stem-loop structure [100,101]. The pri-miRNA is then cleaved into a small hairpin 
structure the pre-miRNA long 60-70 nt containing both the 5’ and 3’ arm of the 
mature miRNA. This process is performed by a protein complex know as “the 
microprocessor”. It is constituted of an RNase III endonuclease Drosha, a 160 
kDa protein, composed by two tandem RNase III domains and a double-stranded 
RNA-binding domain and a cofactor, DiGeorge syndrome critical region gene 8 
(DGCR8) that it is believe to assist Drosha in substrate recognition [102,103].  
The process described above is typical of the intergenic miRNAs, instead, the 
coding-intronic miRNA situated in an intron of a protein coding gene are 
transcribed by pol II as part of the precursor mRNA (pre-mRNA). Subsequently, 
the pre-mRNA through a splicing process, still not fully clear, produces the 
miRNA [104].  
The pre-miRNA is then actively transported from the nucleus to the cytoplasm 
by export receptor Exportin-5 and a Ran-GTP. The hydrolysis of Ran-GTD to 
Ran-GDP allows the release of RNA in the cytoplasm while the exportin-5 helps 
in the cytoplasm translocation process and prevents the nuclear degradation by 
stabilising the pre-miRNAs [105,106].  
Once in the cytoplasm the pre-miRNA is cleaved by a second polymerase III, 
Dicer, into a small double strand RNA duplex 21-24 nt long and composed by 
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both the mature miRNA and its complementary strand. Dicer contains a long N-
terminal ATPase/Helicase domain, a DUF283 domain, two tandem RNase III 
nuclease domains at the C-terminal and a PAZ domain, named after the proteins 
Piwi, Argonaute and Zwille, that bind to the 3’ end of the small RNAs [102,107].  
After the production of a 21-24nt miRNA duplex, one strand is loaded into the 
miRNA-induced silencing complex (RISC) composed by the transactivating 
response RNA-Binding Protein (TRBP) that recruits Argonaute 2 (AGO2), a major 
component of the RISC complex and other proteins. Usually the RISC complex 
selects the single strand RNA that has the lowest thermodynamic stability at its 5’ 
terminus and it is considered the guide. Originally it was considered that the other 
strand not incorporated in the RISC complex and denominated as star (*) was 
degraded. However, it was shown that also this strand could be loaded into the 
Argonaute complex and target mRNAs [102,108,109]. 
miRNAs’s function is to regulate the expression of their mRNA target mainly 
by two post transcriptional mechanisms: mRNA cleavage or translational 
repression. Both mechanisms involve the presence of Ago proteins (AGO1-4), 
core components of RISC complex. These proteins contain four domains: 
• N-terminal 
• PAZ (Piwi-Argonaute-Zwille) domain that anchors the 3’ end of guide 
miRNA 
• MID domain that has high specificity for the 5’ end of the miRNA and also 
can discriminate between the four bases at that extremity  
• PIWI element that has endonuclease activity and mediates RNA cleavage 
[100].  
During the cleavage process, the miRNA binds the mRNA with a perfect or 
near perfect match via a Watson-Crick base paring mechanism in a sequence 
between their 2nd and 8th nucleosides of their 5’ extremity, called the seed 
sequence. However recent advances in miRNA studies reported that alternative 
mechanisms of miRNA regulation also exist. These include the binding in the 
5’UTR of the mRNA as well as in the open reading frame or also the possibility 
that miRNA may also activate gene expression by binding to the promoter of the 
target gene [110,111]. mRNA degradation occurs via endonucleolytic cleavage 
by AGO2 protein [112] or because the mRNA poly(A) tail is removed by 
deadenylases guided by a partial complementarity with miRNA [113]. 
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During translational repression, miRNA and mRNA are associated with some 
mismatch in the target sequence causing a repression of the mRNA target. This 
semi-complementarity between miRNA and mRNA allows that one miRNA can 
recognise and therefore inhibit a large number of mRNA simultaneously and one 
mRNA can be identified by multiple miRNA [102] (Figure 1.2).  
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Figure 1.2. miRNA biogenesis pathway 
MicroRNAs, produced by canonical biogenesis pathway, are transcribed from genomic 
DNA in the nucleus as long primary microRNAs (pri-miRNA) by RNA polymerase II (Pol 
II). The pri-miRNA transcript acquires a stem–loop structure and it is processed by 
Drosha in association with DGCR8 RNase III complex into a precursor miRNA (pre-
microRNA). In the non-canonical miRNA pathway, miRNA are transcribed directly as 
endogenous short hairpin RNAs (endo-shRNAs) or derive directly by splicing from introns 
(mirtrons) [114]. Pre-miRNAs are then exported by Exportin-5 and RAN-GTP-dependent 
process to the cytoplasm. In the cytoplasm, pre-microRNAs are processed by Dicer and 
transactivation-response RNA-binding protein (TRBP) RNase III enzyme complex into the 
mature double-stranded RNA complexes. The mature microRNAs (single­stranded RNA) 
are incorporated into the RNA-induced silencing complex (RISC) complexes and are 
ready to interact with specific mRNA targets. The illustration was adapted from [115]. 
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1.3.3 miRNA and the kidney  
 
miRNAs are detectable in a wide range of body fluids and usually their 
expression is also tissue specific [116]. Several studies also revealed that kidney 
tissue is rich in miR-192, miR-194, miR-215, miR-216, miR-146a, miR-886 and 
miR-204 [25]. Some miRNAs, such as miR-192, miR-126, miR-145 and miR-30 
are more expressed in the renal cortex, glomerular endothelium, mesangial and 
podocytes respectively [117,118]. miRNAs involvement in kidney regulation and 
development is now evident. Indeed knockdown of Dicer, DGCR8 or miR-30a-5p 
causes defects in pronephric tubules and delayes epithelial differentiation of the 
pronephric duct [119]. Other miRNAs, such as miR-335 and miR-34a are linked 
to kidney senescence, as their overexpression in mesangial cells inhibits the 
expression of superoxide dismutase 2 (SOD2) and thioredoxin reductase 2 
(Txnrd2) and consequent increase of ROS [120]. 
Renal biopsies of patients with hypertensive nephrosclerosis have higher 
expression of miR-200a, miR-200b, miR-141, miR-429, miR-205 and miR-192. In 
the same work it was also shown that zinc finger E-box-binding homeobox 1 
(ZEB1), the transcriptional repressor of e-cadherin, was also negatively regulated 
by miR-429 while E-box-binding homeobox 2 (ZEB2) was inversely regulated 
with miR-200a, miR-200b and miR-429 [121]. miR-200b targets also the Na/H 
exchange factor-1, a regulator of ion transport in apical membrane, while miR-
302a controls two proteins important for the water homeostasis, aquaporin 1 and 
4 [122]. 
Most of the miRNAs involved in renal disease are TGF-ß regulated [123]. miR-
200 family for example, targets ZEB1 and ZEB2 , two regulators of the epithelial-
mesenchymal transition and collagen deposition [124]. Reduction of miR-200a 
was observed in fibrotic kidneys in diabetic nephropathy and in cells that had 
undergone epithelial to mesenchymal transition (EMT) in response to TGF-β, 
while over-expression of this miRNA suppresses renal fibrosis [125]. 
miR-21 is also up-regulated in response to TGF-ß signalling and implicated in 
fibrosis. Knockdown of miR-21 corresponds to a reduction of mesangial 
expansion by affecting collagen I/IV and FN1 expression, while miR-21 inhibition 
corresponds to a decrease in Akt phosphorylation mediated by TGF-ß [126,127]. 
Increase of miR-21 expression was also detected in renal transplant patients with 
fibrotic kidney disease [128] and in urine of renal fibrosis in patients with IgA 
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nephropathy [129]. miRNAs participation in salt-induced hypertension and renal 
injury in Dahl salt-sensitive rats show that miR-29b regulates genes involved in 
extracellular matrix formation (as collagen genes, matrix metalloproteinase 2 and 
integrin beta 1) and mediates protection from renal medullary fibrosis in those 
rats [130]. Decrease of miR-29b level was found in proximal tubular cells, primary 
mesangial cells, and podocytes treated with TGF-ß1, while the extracellular 
matrix proteins were increased [130]. miR-29b was also found to be correlated 
with proteinuria and renal function in IgA nephropathy [129] but decreased in 
serum of diabetic patients [131].  
It was also reported that miRNAs control the polycystic kidney disease (PKD) 
genes and they also mediated functional effects. For example, polycystic kidney 
disease 2 (PKD2) gene is targeted by miR-17 and the same miRNA can promote 
cell proliferation in HEK cells by targeting PKD2 [132]. miR-15 is another miRNA 
involved in the regulation of the expression of cell cycle regulator Cdc25A in both 
rat polycystic kidney disease (PKD) model and patients in cystic liver tissues 
[133]. 
 
1.3.3.1 miRNA and diabetic nephropathy 
 
The first work of miRNAs involvement in diabetic nephropathy was published in 
2007 and described an increase of miR-192 in the glomeruli isolated from 
C57BL/6 mice injected with STZ. miR-192 expression was up-regulated after 
treatment of mesangial cells with TGF-ß and this led to an increase of collagen 1-
alpha 2 synthesis by direct inhibition of ZEB2 by miR-192 [134]. Similar results 
were shown also by Chung et al. in rat PTCs via a Smad3-dependent mechanism 
[135]. An anti-fibrotic instead of a pro-fibrotic role of miR-192 was demonstrated 
by Krupa in human renal PTCs after incubation with TGF-ß. This miRNA down-
regulated ZEB1 and ZEB2 and suppressed E-cadherin expression. This study, 
originating from our group, also showed that miR-192 expression was down-
regulated in renal biopsies from advanced diabetic nephropathy patients and this 
was correlated with both structural (tubulointerstitial fibrosis) and functional 
(reduced estimated glomerular filtration rate) indicators of renal damage [136]. 
Similar results to Krupa were shown by Wang et al. in PTCs and in kidneys from 
diabetic apoE (apolipoprotein E)-deficient mice and rat. Also in this study 
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reduction of miR-192 was linked to TGF-β1-mediated repression of E-cadherin 
[137].  
As just described, miR-21 is a pro-fibrotic miRNA whose expression increases 
after TGF-ß treatment and in renal cortices of type 1 and type 2 diabetic mouse 
models [126,137] and it contributes to renal fibrosis by mediating MMP9/TIMP1 
[138]. These results were also confirmed by Fiorentino et al. in kidneys from 
diabetic mice compared to control, in a mesangial cell line grown in high glucose 
conditions and also in kidney biopsies from diabetic patients compared to healthy 
controls [139]. miR-21 abundance was also found in urinary sediment of chronic 
kidney disease patients and correlated with the rate of renal function decline and 
risk of progression to dialysis-dependent renal failure [140]. 
An opposite role is played by miR-29, which is considered an anti-fibrotic 
miRNA and plays a protective role during renal injury. Mesangial cells, tubular 
epithelial cells and podocytes under diabetic conditions and treated with TGF-ß 
show a reduction in miR-29 levels and in contrast it was shown that kidney cell 
lines treated with an inhibitor of the miR-29 promoter, stimulate the expression of 
fibrotic markers [141-143]. Human miR-29 family is formed by 3 mature 
members: miR-29a, miR-29b and miR-29c, encoded by two gene clusters, 
sharing a common seed region sequence and target overlapping sets of genes 
but it is known that they may have different regulation and subcellular distribution 
[144]. Also miR-29a, as well as miR-29b, decreased in a human epithelial cell line 
after treatment with high glucose condition and lead to increased collagen IV 
expression [142]. An opposite role is played by miR-29c that was found to be 
highly expressed in glomeruli from db/db mice and endothelial cells and 
podocytes cultured under high glucose conditions [145]. The same work showed 
also that miR-29c inhibition decreases albuminuria and mesangial matrix 
accumulation in db/db mice. 
miR-200 family (miR-200a, miR-200b, miR-200c, miR-429, and miR-141) are 
miRNAs amply studied for their role in maintaining epithelial differentiation in non-
renal contexts and their expression is reduced in cells that are treated with TGF-ß 
and that undergo EMT [124]. Decrease of miR-200a and miR-141 was found in a 
mouse model of diabetic nephropathy [146]. However opposite results were 
shown for miR-200b and miR-200c in glomeruli from type 1 (streptozotocin) and 
type 2 (db/db) diabetic mice and in mouse mesangial cells treated with TGF-ß in 
vitro [147]. 
 28 
Other miRNAs implicated in diabetic nephropathy are miR-124 and miR-93. 
The first was found to be up-regulated in kidney of diabetic rats while the second 
one is down-regulated in db/db mice glomeruli and podocyte/endothelial cells 
subjected to high glucose concentrations [148]. 
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1.3.4 miRNA as possible biomarkers 
 
An ideal biomarker should fulfil multiple criteria. It should exhibit specificity and 
sensitivity, ability to differentiate pathologies from healthy states and be present 
at early stages of the disease. It should in addition be obtainable via a non-
invasive method but still capable of being detected in a rapid and precise way 
[149]. Since miRNAs can fulfil most of those criteria, lately, there is a great and 
growing interest in the use of miRNAs as possible biomarkers in different kinds of 
disease [150,151]. Also it is possible to detect them outside the cells and more 
specifically in the serum, plasma, urine and most of the biologic fluids [116,152]. 
For example, miRNAs are being explored as potential biomarkers for 
cardiovascular disease, including different circulating miRNAs patterns for 
myocardial infarction, heart failure, atherosclerotic disease, T2DM and 
hypertension [153]. Zampetaki and colleagues, while analysing the miRNAs 
profile in plasma of 80 patients with T2DM, found that miR-126, miR-15a, miR-
29b and miR-223 were reduced while miR-28-3p was elevated. Interestingly, 
reduction of miR-126, miR-15a and miR-223 were already detectable years 
before any diabetes manifestation. miR-126 was not the only miRNA mainly 
associated with this pathology, but was also down-regulated in atherosclerotic 
CAD [154,155]. miRNAs dysregulation have been associated also with other 
diseases, including different cancers [156,157], chronic lymphocytic leukaemia 
[158] and nervous system diseases [159]. 
Recently, miRNAs were detected in urine, urinary sediment and serum of 
patients with kidney disease [128,140,160-162]. Some of the previously 
mentioned miRNAs such as miR-21, miR-29 and miR-93 were detectable in urine 
and considered a biomarker of fibrosis in IgA nephropathy patients [128]. Other 
miRNAs, miR-10a and miR-30d, were identified in urine samples, but not in 
serum, of a mouse model of renal ischaemia-reperfusion and streptozotocin-
diabetes induced renal injury. Their expression and correlation with the degree of 
kidney injury, make these 2 miRNAs a novel urine-based biomarker for this injury 
[163]. Argyropoulos et al. found that urinary miRNA profiles vary across the 
different stages of DN. In this study it was found that 27 miRNAs are differently 
regulated in different stages of diabetic renal disease. Decrease of miR-323b-5p 
and increase of miR-429 were associated with appearance of micro-albuminuria, 
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while miR-589 and miR-323b-5p showed an increasing trend in the urine of 
patients with nephropathy [164].  
Another study conducted on 159 children affected by nephrotic syndrome, 
reported that miR-30a-5p, miR-151-3p, miR-150, miR-191, and miR-19b in serum 
and miR-30a-5p in urine were found to be increased in this syndrome and 
suggested the possible utility of those miRNAs as potential diagnostic and 
prognostic biomarkers [165].  
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1.3.5 miRNA packing in body fluids 
 
What makes miRNAs so attractive as possible biomarkers is their apparent 
stability in tissues and biological fluid, even under extreme pH and temperatures, 
RNase activity, extended storage and multiple freeze–thaw cycles [166,167]. This 
protection from degradation may occur as result of different events that involve 
RNA sequence structure, packing in extracellular vesicles such as microparticles 
(MP) and exosomes [168], incorporation in apoptotic bodies [169] or association 
with RNA binding proteins [170] or lipoprotein complexes [171]. 
 
1.3.5.1 miRNA and extracellular vesicles (EVs) 
 
Extracellular vesicles are membrane vesicles of endosomal or plasma 
membrane origin and their classification is based on their origin and biological 
function or biogenesis. Based on cellular origin and biological function it is 
possible to identify vesicles secreted by neutrophils or monocytes (Ectosomes), 
by platelets or endothelial cells in blood (Microparticles), by cardiomyocytes 
(Cardiosomes), purified from serum of antigen-fed mice (Tolerosomes), extracted 
from seminal fluid (Prostatosomes) or linked with adeno-associated virus vectors 
(Vexosomes) [172].  
Classification based on the biogenesis identified microvesicles (MVs), 
exosomes and apoptotic bodies. Microvesicles (MVs) are small plasma 
membrane derived particles that are released from different cell types into the 
extracellular space by outward budding and fission of the plasma membrane. 
Their size varies from 100nm to 1μm and they are formed by exocytotic budding 
of cell membranes and characterised by a plasma membrane rich in negatively 
charged phospholipids while on the surface these exhibit antigens of the cells 
from which they originate [173]. Exosomes have an endosomal origin, derived 
from the endolysosomal pathway and have a size ranging from 30 to 100nm. 
They are retained within the multivesicular bodies as a result of endosome 
compartmentalization and are released when the latter fuse with the cell 
membrane while microvesicles are shed from the plasma membrane surface 
[174]. Apoptotic bodies are the biggest vesicles with a size between 1 and 5 μm 
and are formed in the last step of apoptosis [175]. All EV can be found in different 
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body fluids such as urine, blood (plasma and serum), ascites, breast milk [176] 
and they have a direct role in different biological process by directly activating 
receptor on the surface of different cells via protein binding or lipid ligands and 
their effectors are released into recipient cells [168,172,177]. Recently it was 
shown that exosomes participate in different biological functions including 
angiogenesis, cell proliferation, tumour cell invasion or immune response to 
neighbouring or distant cells [178]. It has also been shown that in diverse 
biological functions, protein, mRNA and miRNAs are transferred between cells in 
a selective way [179,180] and functionally active extracellular miRNAs can be 
taken up and affect gene expression in the recipient cells [168]. Interestingly, it 
was shown that the exosome RNA profile is different from the RNA profile of the 
parental cells, suggesting that this packing is selective [181]. Circulating 
exosomal miRNAs are studied also as possible biomarkers in different 
pathologies as colon cancer [182], pituitary tumors [183] or pulmonary diseases 
[184]. It was shown that exosome secreted into the urine may originate from 
different nephron segments [185,186] with an RNA integrity profile alike the 
mRNA of kidney. Furthermore, a study of proteomic analysis of urinary vesicles 
confirmed the presence of 21 proteins known to be involved with specific renal 
diseases [186]. Differently, miR-29c and miR-200 expression in urinary 
exosomes were identified by Lin-Li in patients with diabetic nephropathy, focal 
segmental glomerulosclerosis and IgA nephropathy [187] suggesting also the 
possible use of urinary exosome miR-29c as a possible non-invasive marker for 
renal fibrosis since it correlated with both renal function and the degree of 
histological fibrosis [160]. An increment of miR-145 in exosomes was detected in 
patients with microalbuminuria, in an animal model of early diabetic nephropathy 
and mesangial cell-derived exosomes treated with high concentrations of glucose 
[188]. 
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1.3.5.2 miRNA and RNA-binding proteins  
 
Recent studies have highlighted that miRNAs stabilization might be also due 
to association with RNA-binding protein and not only with microparticles as firstly 
demonstrated by Arroyo and Turchinovich [170,189]. Arroyo, using differential 
centrifugation and size exclusion chromatography showed that the 90% of the 
miRNAs were not incorporated in microvesicles but bound to a ribonucleoside 
complex, specifically with Argonaute2 (AGO2). This association was also 
responsible for miRNAs stability in plasma [170]. Similar results were also 
showed in Turchinovich paper where most of the plasma and cell culture media 
miRNAs have a non-vesicular origin and were associated with AGO proteins 
[189]. Following studies showed that circulating miRNA in human blood plasma 
can be immunoprecipitated with AGO1 and AGO2 antibody, however AGO-
specific miRNA profiles in blood cells differed from the ones in plasma suggesting 
that most of the circulating miRNAs may originate from non-blood cells [190]. In 
HEK-293 cells, it has been shown that GW182 also plays a key role in protecting 
AGO-bound miRNAs from being degraded [191]. A recent article demonstrated 
also that human platelets, activated by thrombin, release miR-233 associated 
with AGO2 to endothelial cells via microparticles, suggesting an even more 
complex mechanism of intercellular exchanges and stability of miRNAs [192]. 
Moreover, another study established that for 3 weeks miRNAs associated with 
Argonaute complex are stable and ready to be recruited into RISC complex after 
external stimuli activation [193]. miRNAs stability and exportation can also be due 
to association with other RNA-binding proteins as for example nucleophosmin. 
Wang and colleagues showed that  conditioned serum-free tissue culture 
medium, from a variety of cell types, contained 197 proteins, 12 of which were 
known as RNA-binding proteins. One of these, nucleophosmin, mainly located in 
the nucleolus, was shown by immunoprecipitation to bind to miRNAs and in 
addition, incubation of this protein with the synthetic miR-122 proved that this 
protein was involved in miRNAs protection from RNase A digestion and not only 
in the exporting process [194]. 
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1.4 Aims 
The aim of this thesis was to investigate the potential of miRNAs as novel, 
non-invasive biomarkers for the diagnosis and prognosis of DN.  
The aim of my studies was to contribute to development of biomarkers for 
CKD patients. These are needed since those available at present are not 
sufficiently sensitive and specific enough to predict disease outcome. At the 
beginning of this PhD project, miRNAs were known to play a key role in 
regulation of gene expression in a number of diseases. However, comparatively 
little was known about the abundance of urinary miRNAs. Indeed, an established, 
robust method for urinary miRNA extraction and detection was not available. 
 
The specific objectives were: 
 
• To develop a robust and non-toxic technique for extraction and detection 
of urinary miRNAs  
• To establish the stability of endogenous urinary miRNAs in samples from 
unaffected individuals and DN patients 
• To investigate differences in urinary miRNA expression profiles between 
diabetic nephropathy patients and healthy individuals, and thereby identify 
potential disease biomarkers 
• To locate the nephron tissue compartments, and more precisely the 
kidney cell types, expressing the putative disease-associated miRNAs 
identified by the above aims 
• To analyse expression of selected miRNAs in cells and conditioned media 
from in vitro diabetic nephropathy models 
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CHAPTER 2 – Materials and Methods 
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2.1 Samples  
2.1.1 Urine samples collection and preparation 
 
Second morning urine samples were collected from 20 DN patients admitted 
to the University Hospital of Wales, Cardiff, between January and May 2012, and 
20 urine samples from unaffected volunteer control subjects from the Institute of 
Nephrology, School of Medicine, Heath Hospital, Cardiff. All donors gave 
informed written consent. pH, glucose, ketones, leucocytes, nitrite, protein, blood 
and haemoglobin were detected through test strips (Combure 7 Test, Roche) for 
whole urine samples. Urine samples were centrifuged at 2,000 g for 10 min at 
4°C to remove living cells. 
 
The supernatants were divided as followed:  
• 3 aliquots of 300 μl each for RNA extraction  
• 3 aliquots of 800 μl for protein:creatinine ratio 
• residual urine was stored in a fresh sterile universal container 
and were stored at -80° until experiments. 
 
Information on renal function (defined as eGFR), protein:creatinine ratio, CKD 
stage, blood glucose level, age, sex and date of collection were obtained for all 
the patient samples. 
 
 
 
 
 
 
 
 
 
 
 
 37 
2.1.2 Urine sample and preparation (PCOS) 
 
Urine samples were collected from 17 patients with PCOS (Polycystic ovary 
syndrome) admitted to the University Hospital of Wales, Cardiff between 
February and September 2012, and 15 control subjects. Urine collection from 
these patients and controls was part of collaboration with Dr. Aled Rees at the 
Centre for Endocrine and Diabetes Sciences, Cardiff University School of 
Medicine. All donors gave informed written consent. pH, glucose, ketones, 
leucocytes, nitrite, protein, blood and haemoglobin were detected through test 
strips (Combure 7 Test, Roche) for whole urine samples. Urine samples were 
processed as described in 2.1.1. 
 
2.1.3 Tissue sample collection and preparation by laser capure 
microdissection (LCM) 
 
Five formalin-fixed paraffin embedded (FFPE) archived renal biopsies from 
unaffected people were used to isolate glomeruli, proximal tubular and distal 
tubular profiles using the Arcturus Pixcell IIe infrared laser enabled LCM system 
(Applied Biosystems). From each biopsy, two 6-μm sections were obtained. One 
of these was stained with an antibody anti-CD10, while the other section was 
used to isolate glomerular, proximal tubular and distal tubular nephron 
compartments. CD10 staining was used to identify these structures as the CD10 
antigen is expressed at the surface of glomerular and proximal tubular cells, but 
not distal tubular cells. This staining was carried out by Mr. Dilwyn Havard at the 
Histopathology Department, University Hospital of Wales, Cardiff. The tissues 
were cut, placed in the middle third of an uncharged, uncoated glass slide (VFM 
White coat slides CellPath Ltd) and stained according to the method by Espina et 
al. [195]. 
 
Using infrared laser, the target tissue was bonded to a polymer membrane 
located on a cap (Arcturus ® Capsure ® Macro LCM caps – Applied Biosystems) 
placed onto the slide which when lifted removes the highlighted tissue. These 
experiments were carried out with guidance from Dr. Christopher Carrington at 
the Institute of Nephrology, Cardiff University School of Medicine. 
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2.1.4 Cell culture 
2.1.4.1 Human conditionally immortalised glomerular endothelial cells 
(CiGEnC) 
 
Two T75 flasks of human conditionally immortalised glomerular endothelial 
cells (CiGEnC) were kindly donated by Dr. Simon Satchell from the Academic 
Renal Unit at the University of Bristol. Dr Satchell’s research group have 
successfully conditionally transformed normal human glomerular endothelial cells 
using a technique restoring functional telomerase activity and introducing the 
simian virus 40 large tumour antigen (SV40LT). A temperature-sensitive (ts) 
SV40LT construct was used to allow conditional immortalization (ci), that is, 
enhanced proliferation at a permissive temperature, while the SV40LT element 
can be “switched off” by transfer to a non-permissive temperature. At this 
temperature, cells take on a mature phenotype not seen in cells constitutively 
expressing SV40LT [196]. 
 
Cells were cultured in endothelial growth medium 2 microvascular (EGM-2-
MV, CC-3202, Lonza) containing foetal calf serum (5%) and growth factor as 
supplied, excepting VEGF unless otherwise stated. 
 
Cell were grown to confluence at 33°C, trypsinized, and reseeded in a fresh 
flask at a dilution 1:3. Cell were grown to confluence before transferring to 
incubation at the non-permissive temperature of 37°C [197]. 
 
2.1.4.2 CiGEnC stimulation 
 
CiGEnC at 33°C were seeded in 12-well plates; after 5 d cells were transferred 
to 37°C and, after further 5 d, were growth arrested for 24 h and then treated with 
TNF-α (10 ng/mL), VEGF (20 ng/mL), TGF-ß1 (1 ng/mL) or IL-6 (1 ng/mL) at 
either 5 mM or 25 mM glucose concentration for 24 h. The cells obtained from 
each well were used for RNA extraction as described on page 42. 
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2.1.4.3 Human proximal tubular epithelial cell line HK-2 and podocyte cell 
line 
 
HK-2 cells 
The human proximal tubular epithelial cell (PTC) line HK-2 (human kidney-2) 
was established by transduction of primary proximal tubule cells from adult 
human kidney with human papilloma virus (HPV 16) E6/E7 genes [198]. Cells 
immortalized this way retain many features of primary cells, are not tumorigenic 
in experimental animals, and do not grow in soft agar and exhibit contact 
inhibition [198]. 
 
HK-2 cells show close similarities to the phenotype and function of primary 
PTCs [199,200]. For instance, they are positive for alkaline phosphatase, 
gamma-glutamyl transpeptidase, leucine aminopeptidase, acid phosphatase, 
cytokeratin, integrin alpha-3 beta-1 and fibronectin; but negative for factor VIII-
related antigen, 6.19 antigen and CALLA endopeptidase [199,200]. They also 
exhibit PTC characteristics such as sodium dependence, pholorizin-sensitive 
sugar transport and increased production of cAMP in response to parathyroid, but 
not to antidiuretic hormone. Moreover, many aspects of PTC biology, including 
those directly relevant to this project, have been studied in this laboratory and 
shown close similarity between HK-2 and primary PTCs [199,200]. 
 
HK-2s were maintained in a 1:1 mixture of Dulbecco’s Modified Eagle’s 
Medium (GIBCO/Invitrogen, Paisley, UK) and Ham’s F12 (Sigma, Poole, UK), 
supplemented with 10% (v/v) fetal calf serum (FCS) (Biosera, Ringmer, UK), 20 
mM HEPES, 2mM L-glutamine, 5 μg/ml transferrin, 5ng/ml sodium selenite and 
0.4μg/ml hydrocortisone (Sigma). Fresh growth medium was added to cells every 
two d until confluent. Cells were cultured at 37°C in a humidified incubator (Cll 
House 170, Heto Holten, Derby, UK) in an atmosphere of 5% CO2 and then they 
were used in experiments, or subcultured at ratio 1:3. 
 
For subculture, 10X solution of trypsin/EDTA (Sigma) diluted with PBS (1:10) 
was added to the cells. After 10 minutes, equal volume of culture medium 
containing 10% (v/v) FCS was added, cell suspension transferred to a tube, and 
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centrifuged for 5 minutes at 1200 g at room temperature. The cells were 
resuspended in culture medium and seeded into new culture flask or plates. 
 
Podocytes 
A human podocyte cell line (ATC) exhibiting temperature dependent 
expression of SV40-T gene has previously been developed by Professor Moin 
Saleem at the Academic Renal Unit, University of Bristol. In brief, at the 
permissive temperature (33°C) these cells proliferate. However, on transfer to the 
non-permissive temperature of 37°C, they enter growth arrest and express 
markers of in vivo differentiated podocytes such as nephrin, podocin, CD2AP and 
synaptopodin, as well as slit diaphragm markers [201]. 
 
Podocytes were propagated and seeded at 33°C in RPMI – 1640 medium 
(Sigma) with 10% FCS (Biosera, Ringmer, UK), 100X Insulin Transferrin 
Selenium G supplement (Invitrogen) diluted 1 in 100, 100X L-Glutamine 200mM 
(Invitrogen) diluted 1 in 100 and Penicillin/ Streptomycin (Invitrogen) diluted 1 in 
100 in medium. 
 
When cells were approximately 60% confluent they were incubated at 37°C for 
14 d during which time they underwent growth arrest and differentiated into 
“mature” podocytes. Stimulation experiments were performed on these 
differentiated or so-called “mature” podocytes. 
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2.2 RNA analysis 
2.2.1 RNA extraction 
2.2.1.1 RNA extraction urine samples 
 
At the start of this project, there was no clearly validated protocol for urinary 
miRNA extraction. Initial experiments using three isolation protocols on control 
urine samples were compared to identify the best one to take forward. Two 
commercially available kits for RNA and/or miRNA extraction from urine samples 
were used: the Norgen kit (Cat. No 29000) was used according to the 
manufacturer’s recommendations, while the Qiagen miRNA-easy mini kit (Cat. 
No 217004) was used with minor modifications recommended by Andreasen et 
al., using 1 µg of Carrier RNA (MS2 RNA, Roche Cat. No 10165948001) per 750 
µl of QIAzol reagent [202]. The third protocol used TRI-Reagent RNA Isolation 
Reagent (Life Technologies, Cat. No AM9738) and chloroform extraction 
according to manufacturer’s guidelines. 
Total RNA/miRNA extracted and mean A260/A280 purity ratios from each 
extraction protocol varied. TRI-Reagent provided the greatest RNA recovery, but 
yields were highly variable. It was not possible to accurately estimate RNA yield 
and purity using the above Qiagen protocol since carrier RNA was used. 
Following the results obtained from this first study (see 3.2.1.1) the Qiagen 
protocol was used for further analyses.	  
For RNA isolation using the chosen Qiagen miRNeasy kit (Qiagen), urine 
samples from DN Patients and PCOS patients and controls were processed 
according to the manufacturer’s recommendation with the following modifications. 
After mixture and incubation at room temperature for 5 min of 750 μl of QIAzol 
plus Carrier RNA (MS2 RNA, Roche) with 250 μl of urine sample, 0.5 pM of spike 
in Caenorhabditis elegans (cel-miR-39) (Ambion, Cat. No 4464066, Part No. 
MC10956) was added to each sample. Subsequently, 200 μl of chloroform was 
added per sample, and samples were incubated at room temperature for 2 min 
and then spun for 15 min at 12,000g at 4°C. At that point, the manufacturer’s 
protocol was followed, with the entire aqueous phase from each sample loaded 
onto a single affinity column. RNA extracts were then stored at -80°C until 
analysed. 
 
 42 
2.2.1.2 RNA extraction tissue sample from LCM samples 
 
The polymer membrane on the LCM caps was removed and miRNAs were 
extracted using RecoverALL™ Total Nucleic Acid Kit according to the 
manufacturer’s protocol with the following two main modifications. Firstly, 
deparaffinisation step was not carried out, as this was previously performed 
before LCM. Secondly, 1 μg of carrier (MS2 RNA Roche) was added during the 
nucleic acid isolation stage. 
 
2.2.1.3 RNA extraction from CiGEnC cell line 
 
Total RNA was prepared with TRI-Reagent from CiGEnC, human lung 
fibroblasts (a kind gift from Dr. Adam Midgley at the Institute of Nephrology, 
Cardiff University School of Medicine), human PTC line HK-2 and podocytes. TRI 
Reagent combines phenol and guanidine thiocyanate in a monophasic solution to 
rapidly inhibit RNase activity. Cells were lysed in 1 ml of TRI-Reagent solution 
and incubated at room temperature for 5 min to allow for complete dissociation of 
nucleoprotein complexes. The homogenate was then separated into aqueous 
and organic phases by addition of 200 μl of chloroform and centrifuged at 
12,000xg for 15 min at 4ºC. Then, the RNA was precipitated from the aqueous 
phase by adding 500 μl of isopropanol and repeating the centrifugation step after 
10 min of incubation at room temperature. The samples were then washed 3 
times with 75% ethanol and centrifuged for 5 min at 12,000g. RNA was then 
eluted in 15 μl of nuclease-free water. Purity and concentration of RNA samples 
were assessed using the NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific). An equal volume (1 μl) of sample was measured at 260 nm and 280 
nm. 
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2.2.2 miRNA detection 
 
miRNAs were analysed in whole samples by two-step quantitative reverse 
transcription – polymerase chain reaction (RT-qPCR). 
 
2.2.2.1 Reverse transcription  
 
To evaluate recovery of RNA/miRNA using different extraction procedures, 
miRNAs were assayed using two different methods according to the respective 
manufacturer’s instructions:  
• High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
using a specific primer for each miRNA  
• miRCURY LNATM Universal RT microRNA PCR system (Exiqon) following 
the manufacture’s protocol  
 
High Capacity cDNA Reverse Transcription Kit 
Reverse transcription (RT) was performed using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Cat. No 4368814). The RT 
master mix for one reaction was composed of: 4.25 μl of water, 1.5 μl 10 x 
Reverse Transcription Buffer, 0.15 μl 100mM dNTP, 0.1 μl 40 U/μl RNase 
Inhibitor (New England BioLabs® Inc, Cat. No M0307S,), 1 μl 50 U/μl MultiScribe 
Reverse Transcriptase and 3 μl 5x RT-primer specific for each miRNA. Then, 10 
μl of the RT master mix was added to 4 μl of water plus 1 μl of RNA for the urine 
samples or 5 μl containing 10 ng total RNA for the cell lines, and incubated on ice 
for at least 5 min. The RT non-template control (RT-NTC) negative control 
reaction contained an equal volume of water instead of RNA. The following 
thermal cycler profile was used: 30 min at 16°C, 30 min at 42°C, 5 min at 85°C, 
followed by cooling to 4°C. The cDNA was diluted with water 1:3, and 4 μl were 
used in qPCR, performed as described in the section 2.2.2.2.  
 
2.2.2.2 Quantitative polymerase chain reaction 
 
For each gene analysed, the master mix for each reaction was prepared by 
combining 1 μl of gene-specific set of PCR-primers and TaqMan probe for each 
 44 
miRNA (designed and supplied by Applied Biosystems), 5 μl of water and 2 x 
Universal PCR Master Mix with No AmpErase UNG composed of an optimized 
solution of thermostable DNA polymerase, deoxynucleotides, and the passive 
reference dye ROX (Applied Biosystems, Cat. No 4440047). A total of 16 μl of 
gene-specific master mix was distributed to appropriate wells on an Optical 96-
Well Fast Plate (Applied Biosystems) and subsequently, 4 μl of pre diluted cDNA 
or water for the NTCs was added. The plate was sealed with a MicroAmp Optical 
Adhesive Film (Applied Biosystems) and qPCR was performed on a ViiA7 Real-
Time PCR System (Life Technologies), using the manufacturer’s recommended 
cycling parameters: 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 
min at 60°C. The list of TaqMan assays used in this study is given in Table 2.1, 
below. 
 
miRNA assay Catalogue Number 
cel-miR-39 Part. Number 4427975 
Assay ID 000200 
hsa-miR-16 Part. Number 4427975 
Assay ID 000391 
hsa-miR-192 Part. Number 4427975 
Assay ID 000491 
hsa-miR-191 Part. Number 4427975 
Assay ID 002299 
hsa-miR-126 Part. Number 4427975 
Assay ID 002228 
hsa-miR-29b Part. Number 4427975 
Assay ID 000413 
hsa-miR-200b Part. Number 4427975 
Assay ID 002251 
hsa-miR-212 Part. Number 4427975 
Assay ID 000515 
hsa-miR-155 Part. Number 4427975 
Assay ID 002623 
 
Table 2.1. TaqMan assays used in this study 
 
2.2.2.3 RT-QPCR data analysis 
 
For qPCR data analysis, Viia 7 software and GraphPad Software version 5.0a 
were used. Relative expression was calculated using the 2-∆∆CT method [203]. 	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2.2.2.4 miRNA profiling in urine samples by TaqMan®Array Human 
MicroRNA Cards  
 
Urine procession and RNA extraction 
Urine samples were processed as describe in section 2.1.1 and RNA was 
isolated using the miReasy kit (Qiagen) as described in 2.1.1.1. 
 
Reverse transcription (RT) and pre-amplification 
miRNAs were reverse transcribed using the Megaplex Primer Pools (Human 
Pools A v2.1 and B v3.0) with a predefined pool of up to 381 reverse transcription 
(RT) primers for each Megaplex Primer Pool. To assess the level of specific 
miRNAs in individual urine samples, a fixed volume of 3 μl of RNA solution was 
used as input in each RT reaction. Each RT reaction was performed according to 
the manufacturer’s recommendations: 0.8 μl of pooled primers were combined 
with 0.2 μl of 100 mmol/L dNTPs including dTTP, 0.8 μl of 10 x RT Buffer, 0.9 μl 
of MgCl2 (25mmol/L), 1.5 μl of Multiscribe reverse transcriptase (50 U/μl) and 0.1 
μl of RNAsin (20 U/μl) to a final volume of 7.5 μl. 
Each RT reaction was set up in an Applied Biosystems 7900HT thermo cycler 
as follows: 16°C for 2 min, 42°C for 1 min and 50°C for 1 s for 40 cycles, followed 
by incubation at 85°C for 5 min.  
 
RT reaction products were then amplified using Megaplex PreAmp Primers 
(Primers A v2.1 and B v3.0). A 2.5 μl aliquot of the RT product was combined 
with 12.5 μl of Pre-amplification Mastermix (2 x) and 2.5 μl of Megaplex PreAmp 
Primers (10 x) to a final volume of 25 μl. The pre-amplification reaction was 
performed by heating the samples at 95°C for 10 min, 55°C for 2 min and 72°C 
for 2 min, followed by 12 cycles of 95°C for 15 s and 60°C for 4 min. Finally, 
samples were heated at 99.9°C for 10 min to ensure enzyme inactivation. 
 
Pre-amplification reaction products were diluted to a final volume of 100 μl and 
the diluted pre-amplification products from controls and DN were pooled as 
follows: 
 
Pool 1 control = 5 female urine samples; average age= 44.8 
Pool 2 control = 5 female urine samples; average age= 57.6 
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Pool 3 control = 5 male urine samples; average age= 35.2 
Pool 4 control = 5 male urine samples; average age= 53.2 
 
Pool 1 Patient = 5 CKD urine sample; stage 3 and eGFR between 43.3 and 36 
mL/min per 1.73m2 
Pool 2 Patient = 5 CKD urine sample; stage 3 and eGFR between 35 and 31 
mL/min per 1.73m2 
Pool 3 Patient = 5 CKD urine sample; stage 4/5 and eGFR between 27.3 and 23 
mL/min per 1.73m2 
Pool 4 Patient = 5CKD urine sample; stage 4/5 and eGFR between 22 and 12.9 
mL/min per 1.73m2 
TaqMan miRNA array 
TaqMan®Array Human MicroRNA Cards A and B were used to quantify 754 
human miRNAs. In each array, three endogenous controls and a negative control 
were included. Card A focused on more highly characterized miRNAs, while Card 
B contained many of the more recently discovered miRNAs along with miR* (miR 
star) sequences. Initial microarray screening was carried out using pools of 
diluted pre-amplification product from 20 individuals with DN, and from 20 
controls. The expression profiles of miRNAs in urine samples were determined 
using the Human TaqMan miRNA Arrays A v2.1 and B v3.0 (Applied 
Biosystems). PCR reactions were performed using 450 μl of the TaqMan 
Universal PCR Master Mix No AmpErase UNG (2X) and 9 μl of the diluted pre-
amplification product to a final volume of 900 μl. Aliquots of 100μl of this PCR mix 
were dispensed to each port of the TaqMan microRNA Card. The fluidic card was 
then centrifuged and mechanically sealed. qPCR was carried out on an Applied 
Biosystems 7900HT thermo cycler using the manufacturer’s recommended 
program. The list of these products is in Table 2.2, below. 
 
Products Catalogue Number 
TaqMan® Array Human MicroRNA A+B Cards Set v3.0 4444913 
Megaplex™ RT Primers, Human Pool Setv3.0 4444745 
Megaplex™ PreAmp Primers, Human Pool A v2.1 4399233 
Megaplex™ PreAmp Primers, Human Pool B v3.0 4444303 
TaqMan® PreAmp Master Mix Part Number 4391128 
 
Table 2.2. TaqMan miRNA array products 
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2.2.3 mRNA detection 
2.2.3.1 Reverse transcription 
 
The cDNA was generated using High Capacity cDNA Reverse Transcription 
Kit (Cat. No 4368814, Life Technologies) from 1 μg of RNA of each sample. 
Briefly, 1 μg of total RNA in 10 μl of water was added to 10 μl of the RT mix 
containing 2 μl of 10 x RT buffer, 0.8 μl of 25 x dNTP Mix (100 mM), 2 μl of 10 x 
RT random primers, 1 μl of MultiScribe™ Reverse Transcriptase, 1 μl of RNase 
inhibitor and 3.2 μl of nuclease-free water. The thermal profile used was: 10 min 
at 25°C, 2 h at 37°C and 5 s at 85°C, followed by cooling at 4°C. RT reactions 
were diluted by adding 60 μl of water, and then used for the qPCR or stored at -
20°C as required. 
 
2.2.3.2 Quantitative polymerase chain reaction. 
 
qPCR was performed on a ViiA7 Real-Time PCR System (Life Technologies). 
GAPDH, VEGFR-2, vWF, PECAM-1, PAI-1 reaction products were quantified by 
Power SYBR® Green PCR Master Mix (Cat. No 4367659, Life Technologies) with 
300 nM gene-specific primers. The amplification of a single PCR product was 
confirmed by melting curve analysis. The nucleotide sequences of the used 
primer pairs can be found below: 
 
 
 
The primers were designed using Primer-BLAST, against mRNA sequences 
taken from the NCBI database, to amplify all known splice-variants. To avoid 
amplification from DNA genomic, primers were designed to span intron-exon 
junctions. PCR product length was ideally around 100-150 bp.  
Gene Primer Reverse Primer Forward 
GAPDH TGACGAACATGGGGGCATCA AGCCGCATCTTCTTTTGCGT 
VEGFR2 CCAGTGTCATTTCCGATCACTTT GGCCCAATAATCAGAGTGGCA 
vWF GCCCTGGTTGCCATTGTAATTC AGCCTTGTGAAACTGAAGCAT 
PECAM1 TCGGAAGGATAAAACGCGGTC CCAAGGTGGGATCGTGAGG 
PAI-1 CGGTCATTCCCAGGTTCTCT TCTCTGCCCTCACCAACATTC 
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2.3 Analysis of urinary miRNA stability 
2.3.1 Addition of urine to the RT step  
	  
Exogenous C. elegans cel-miR-39 (0.05 pM) was spiked into 4 control urine 
samples during the RNA extraction step (see 2.2.1.1). Subsequently, different 
percentages of urine (0, 0.1, 0.5, 1 and 5%) were added to the RT reactions. The 
endogenous miR-16 and the exogenous cel-miR-39 were then detected by RT-
QPCR as previously described (see 2.2.2.1 and 2.2.2.2). 
 
2.3.2 Room Temperature analysis urine analysis over 24 h  
 
Urine samples from 6 control subjects and 4 proteinuric DN patients were 
collected as previously described (see 2.1.1). Subsequently, C. elegans cel-miR-
39 was spiked into each sample at time zero and the urine samples were stored 
at room temperature over 24 h. Aliquots of 250 μl from each sample were 
isolated after 0, 1, 2, 4, 8 and 24 hours RNA extracted, the endogenous miR-16 
and the exogenous cel-miR-39 were detected by RT-qPCR as described 
previously (see 2.2.2.1 and 2.2.2.2).	  
	  
2.3.3 RNase treatment of urine 
 
Two 2.5 ml aliquots were taken from each of 5 urine samples from control 
subjects and 5 from proteinuric DN patients. Negative control reactions were 
composed of urine aliquots, 0.5 pM of cel-miR-39 and 250 μl of RNase storage 
buffer were added, the latter replaced by 0.1 mg/ml of RNase A (RPA Grade; Life 
Technologies (Ambion), AM2272) in the treated samples. Following incubation of 
1 control sample in duplicate at 37°C, aliquots of 250 μl were removed after 1, 5, 
10, 15, 30, 60 min, 750 μl of QIAzol plus 1 μg of carrier RNA added, and stored 
at -80°C. RNA was isolated and miR-16 detected as described above (see 
2.2.2.1 and 2.2.2.2). Following analysis, the experiment was then repeated at the 
30 min time-point using 10 samples. 
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2.3.4 Proteinase K treatment of urine 
 
Urine samples from 2 control subjects and 5 proteinuric DN patients were 
incubated at 55°C +/- 50 μg/ml of proteinase K (P-2308; Sigma-Aldrich, 
Gillingham, Dorset, UK). Aliquots of 250 μl were removed after 0, 10, 20, 30, 40, 
50 and 60 min, 750 μl of QIAzol plus 1 μg of carrier RNA added, and samples 
were stored at -80ºC. RNA was isolated and miR-16 detected as described above 
(see 2.2.2.1 and 2.2.2.2). Following analysis, the experiment was then repeated 
at the 30 min time-point with urine samples from 5 control subjects and 5 
proteinuric DN patients. 
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2.4 Exosome isolation and characterization 
 2.4.1 Purification of extracellular vesicles from urine samples 
 
Typically, 300 ml of pooled urine samples from control subjects was subjected 
to centrifugation at 400g for 10 min to pellet cells, followed by a further 2,000g for 
10 min to remove cellular debris. The resultant supernatant was then centrifuged 
at 200,000g for 1 h in order to collect all extracellular vesicles, after which pellets 
were re-suspended in 100–150 μl of PBS and their total protein quantified by 
micro-BCA protein assay (Pierce/Thermo Scientific). 
 
2.4.2 Determination of extracellular vesicle density 
 
Extracellular vesicle pellets (see above) were overlaid onto a continuous 
sucrose gradient of 0.2-2.5 M sucrose. Samples were centrifuged at 4°C 
overnight at 210,000g using an MLS-50 rotor in an Optima-Max ultra-centrifuge 
(Beckman Coulter). The refractive index of collected fractions was measured at 
20°C in an automatic refractometer (J57WR-SV, Rudolph Scientific) and from 
this, the density was calculated as previously described. Fractions were washed 
in PBS by ultracentrifugation at 150,000g in a TLA-110, and pellets resuspended 
in a small volume before being aliquoted into 3 different microtubes: MES buffer 
was added to the first prior to coupling to microbeads for flow cytometric analysis, 
SDS loading buffer was added to the second prior to Western blot analysis and 
the last was used for miR extraction. 
 
2.4.3 Flow cytometric analyses of exosome-coated beads 
 
For analysis of sucrose gradient fractions, 10 μl (of a total of 40 μl) of each 
fraction was coupled to 0.5 μl of stock beads (surfactant-free, aldehyde sulfate 
3.9 µm beads, Interfacial Dynamics) that had been washed twice in MES buffer 
(0.025 M MES, 0.154 M NaCl, pH 5). Exosome beads were incubated in a final 
volume of 100 μl of MES buffer at room temperature for 1 h on a shaking 
platform, followed by rolling overnight at 4°C. Beads were blocked by incubating 
them with MES buffer + 1% BSA for 2h at room temperature. Blocking buffer was 
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washed away and beads were resuspended in MES buffer + 0.1% BSA. Primary 
monoclonal antibodies against CD9 (R&D Systems, Abingdon, Oxfordshire, UK) 
and CD81 (AbD Serotec, Kidlington, Oxfordshie, UK) were used (at 2–10 μg/ml) 
for 1h at RT. After one wash, goat anti-mouse Alexa Fluor 488-conjugated 
antibody (Invitrogen, Life Technology) diluted 1:200 in MES buffer + 0.1% BSA 
was added for 1h. After washing, beads were analysed by flow cytometry using a 
FACS-Canto instrument configured with a high throughput sampling module 
running FACSDiva Version 6.1.2 software (BD Biosciences, Oxford, UK), and 
median fluorescence values were plotted. 
 
2.4.4 Western blotting 
 
One half of each gradient fraction was analysed by Western blotting. Proteins 
were solubilised by the addition of 50 mM Tris-HCl, 2% SDS, 20 mM DTT and 
0.002% (w/v) bromophenol blue. Samples were electrophoresed through 4 –12% 
Bis-Tris gels (Invitrogen, Life Technology) and transferred to PVDF membranes. 
Blots were blocked overnight (3% non-fat milk, in PBS + 0.05% Tween 20) then 
probed with antibodies against classical exosome markers TSG101 and Alix 
(Santa Cruz Biotechnology via Insight Biotechnology, Wembley, Middlesex, UK). 
After 3 washes (PBS + 0.05% Tween 20) blots were stained with goat anti-mouse 
IgG-HRP conjugated antibody (1:15,000 in PBS + 0.05% Tween 20, Santa Cruz 
Biotechnology). Bands were visualized using the ECL+ system and photographic 
film (GE Healthcare, Chalfont St Giles, Buckinghamshire, UK). 
 
2.4.5 Nanoparticle tracking analysis (NanoSightTM) 
 
Vesicles present in urinary samples were analysed by nanoparticle tracking 
using the NanoSight LM10 system (NanoSight Ltd, Amesbury, Wiltshire, UK) 
configured with a 405 nm laser and a high sensitivity digital camera system 
(OrcaFlash2.8, Hamamatsu C11440, NanoSight Ltd). Videos of 60s were 
collected and analysed using NTA-software (version 2.2) with the minimal 
expected particle size set to 30 nm, and minimum track length and blur set to 
automatic. Each sample was diluted in nanoparticle-free water (Fresenius Kabi, 
Runcorn, Cheshire, UK) to a concentration of between 2 x 108 and 9 x 108 
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particles/ml. This was carried out in triplicate for pre-ultracentrifuged urine, and 
for 4 replicates following 200,000g ultracentrifugation. 
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2.5 Protein analysis  
2.5.1 Argonaute 2 (AGO2) immunoprecipitation 
 
For each sample, 200 μl of Magna Bind goat anti-mouse IgG Magnetic Beads 
(Thermo Scientific, Cat. No 21354) were washed 3 times with PBS solution (300 
μl), and incubated with 10 μg of mouse monoclonal anti-Ago2 (ab57113; Abcam) 
or mouse IgG (Santa Cruz Biotechnology, Cat. No sc-2025) antibodies for 2 h at 
4°C. The preincubated beads and antibody were then added to 400 μl of urine 
(prepared as previously described) and incubated overnight at 4°C. Beads were 
washed 3 times with 1% Nonidet P-40 buffer (1% Nonidet P-40, 50mM Tris-HCL, 
pH 7,4, 150mM NaCl, 2mM EDTA), resuspended in 200 μl of PBS and then split 
in half. One half of each sample was eluted in Loading Buffer, followed by 
SDS/PAGE and immunoblotting. The other half of each sample was eluted in 750 
μl of QIAzol plus Carrier RNA (MS2 RNA, Roche) and processed for RNA 
isolation miR-16 detection. The cell line HEK-293 was used as positive control for 
AGO2 in the immunoblotting. Rabbit polyclonal anti-AGO2 antibody (ab32381; 
Abcam) was used to detect AGO2 in the immunoblotting 
2.5.2 Albumin immunoprecipitation 
 
For each sample 50 μl of Dynabeads Protein G (Invitrogen Cat. no. 10003D) 
were incubated with 10 μg of Anti-Human Serum Albumin antibody (ab10241; 
Abcam) or mouse IgG (Santa Cruz Biotechnology) antibodies diluted in 200 μl 
0.1% PBS-Tween-20 for 15 min at room temperature. 400 μl of Control and 
Patient urine samples were added to the preincubated beads and antibody and 
incubated for 4 h at 4°C. The respective manufacturer’s instructions were 
followed. Dynabeads-Ab-Ag complex were resuspend in 100 μl of washing buffer, 
transferred to a clean tube and then split in half. One half of each sample was 
eluted in Loading Buffer, followed by SDS/PAGE and immunoblotting. The other 
half of each sample was eluted in 750 μl of QIAzol plus Carrier RNA (MS2 RNA, 
Roche) and processed for RNA isolation and hsa-miR-16 detection. Human 
serum was used as positive control for Albumin in the immunoblotting. Albumin 
Antibody (H-126) (sc-50535 Santa Cruz Biotechnology) was used to detect 
Albumin in the immunoblotting. 
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2.5.3 Western blotting 
 
Immunoprecipitated AGO2 and albumin were detected by Western blotting. 
 
SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed by the method of Laemmli [204] 
 
Composition of polyacrylamide gel – Resolving gel 7.5% 
Water                   9.9 ml 
Resolving Buffer: 1.5M Tris-HCl pH 8.8             4.5 ml 
10% (w/v) SDS                180 μl 
40% Acrylamide/Bisacrylamide              3.37 ml 
10% APS (Ammonium Persulfate) (0.05g/0.5ml of water)           90 μl 
TEMED                 12 μl 
Composition of polyacrylamide gel – Stacking gel 
Water                   6.45 ml 
Stacking buffer 0.5M                2.5 ml 
10% (w/v) SDS                100 μl 
40% Acrylamide/Bisacrylamide              980 μl 
10% APS (Ammonium persulfate) (0.05g/0.5ml of water)           75 μl 
TEMED                 10 μl 
Composition of loading buffer – reducing buffer 1 x 
Water                    4 ml 
Stacking buffer 0.5M                 1 ml 
Glycerol                  0.8 ml 
10% (w/v) SDS                 1.6 ml 
0.05% Bromophenol blue                0.2 ml 
ß-mercaptoethanol                 0.4 ml 
 
Composition of running buffer 10 x 
0.25 M Tris-HCl                  30 g/l 
1.92 M Glycine                  144 g/l 
1% SDS                   10 g/l 
pH 8.3 
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Composition of transfer buffer 10 x 
0.25 M Tris-HCl                  30 g/l 
1.92 M Glycine                  144 g/l 
pH 8.3 
 
Composition of transfer buffer 1 x 
Transfer buffer 10 x                100 ml/l 
Methanol                 200 ml/l 
 
Immunoprecipitates were resuspended in 30 μl of 1 x reducing buffer, heated 
at 95°C for five minutes and cooled on ice. The tubes were placed on the magnet 
and the supernatant/samples were loaded onto a gel. Additionally, prestained 
protein ladder, broad range 10-230 kDa (Cat. No P7711s, New England bio labs) 
was loaded in one of the wells. The electrophoresis was carried out in a BioRad 
Mini Protein II apparatus, in (1X) Running Buffer, firstly at 100 V for 20 min and 
then 150 V for 40 min. 
 
Protein transfer to nitrocellulose membrane 
Following SDS-PAGE, separated proteins were transferred onto nitrocellulose 
membrane (GE Healthcare, Amersham, UK) using BioRad Mini Blot II apparatus. 
The membrane, filter paper, and pads were pre-soaked in 1X Transfer Buffer. 
The transfer cassette was assembled in the following order:  
(-ve charge) – pad – paper – gel - membrane – paper – pad – (+ve charge) 
 
The cassette was placed in the holder, and then in the transfer apparatus filled 
to the top with pre-chilled 1 x transfer buffer and containing an ice pack and 
stirring bar. The transfer was performed for 1 h at 100 V. 
 
Incubation with antibody 
The nitrocellulose membrane was blocked to prevent non-specific antibody 
binding for 1 h with 5 % (w/v) skimmed milk in PBS containing 0.1 % (v/v) Tween-
20. Subsequently, the membrane was incubated overnight at 4°C with primary 
antibodies in PBS-Tween (0.1 %) and 1 % bovine serum albumin (BSA). After 3 
quick washes and additional 3 x 15 min washes with PBS-Tween (0.1%), an 
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appropriate horseradish peroxidase (HRP)-conjugated secondary antibody 
solution in PBS-Tween (0.1%) and 1% BSA was added to the membrane. This 
step was completed with incubation at room temperature for 1 h, 3 quick washes 
and 3 x 15 min washes.  
 
Detection 
Antibody binding was visualised using enhanced chemiluminescence (ECL) 
detection (Luminogen, GE Healthcare). The substrate for HRP was prepared by 
mixing reagents A and B, and added to the drained membrane and left for 1 min. 
Then, the membrane was wrapped in cling film and exposed to Amersham 
Hyperfilm ECL (GE Healthcare) for 0.5 - 5 min, as required. 
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2.6 Statistical analysis 
 
Data from the miRNA profiling experiment were analysed using DataAssistTM 
Software, NormFinder Software and GraphPadPrism 5 version 5.0a. 
 
Pearson Correlation Coefficients (PCC) was used to detect clusters of 
similarity in miRNA Ct between each pool group in patients, and between each 
pool group in controls. Relative quantification of miRNA expression to 
normalization to a suitable reference gene is routinely used to compensate for 
experimental variation in RT-qPCR analyses. NormFinder is an algorithm for 
identifying the optimal normalization gene among a panel of putative reference 
genes. This algorithm ranks each candidate according to its stability of 
expression in analysis of the same experimental samples. 
 
To identify a suitable reference gene for the normalization of miRNA 
expression in this study, the NormFinder algorithm was applied to the expression 
data obtained from the Human TaqMan miRNA Arrays A v2.1 and B v3.0. Using 
DataAssist Software, the Ct levels of the first 10 miRNAs with the lowest stability 
value i.e. the most stability expressed candidate reference genes were evaluated. 
In addition, this analysis also included miR-16, RNU-48 and MammU6, the 
endogenous controls included in the Array Card A for data normalization, and 
RNU-48, U6, the endogenous controls included in the Array Card B for data 
normalization. 
 
Analysis comparing miRNA levels between subjects with DN and controls was 
carried out using GraphPad Prism version 5.0. Linear regression analyses were 
performed for matched miRNAs expression levels and the following variables: 
eGFR, Proteinuria, Creatinine and Blood Glucose levels. p-values <0.05 were 
considered statistically significant. 
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2.7 In silico network analysis 
 
All networks were created using Cytoscape (National Institute of General 
Medical Sciences, NIH, US), a general-purpose modelling environment for 
integrating bimolecular interaction network and states [205]. Molecular species 
were represented graphically as nodes and intermolecular interactions as links 
(edges) between nodes. Parameters describing network topology were computed 
using the Network Analyzer plug-in for this software. CyTargetLinker is a 
Cytoscape plugin that extends biological networks with regulatory interaction as 
miRNA-target gene information. The regulatory interaction network (RIN) is 
derived from an online interaction database; these consists of two nodes, a 
source and target biomolecule, which are connected through one directed edge. 
 
The RINS used in this study to create the miRNA network were:  
• TargetScan (release 6.2) [206] 
• microcosm (version 5) 
• miRTarbase (release 3.5) [207] 
• miRecord [208] 
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Chapter 3 – Isolation of urinary miRNA and investigation of 
their stability 
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3.1 Introduction 
 
Diabetic nephropathy is the leading cause of chronic kidney disease in the UK 
and the second one of end-stage renal disease. Since the classical indicators of 
diabetic nephropathy, namely GFR, proteinuria, macroalbuminuria and creatinine 
clearance, are not specific and sensitive enough to predict the outcome for 
individual CKD patients, new biomarkers to help predict outcome in this disease 
are required [43]. An ideal biomarker requires robust and reproducible assays 
that work in clinically available samples as well as archived material.  
miRNAs are endogenous, short, non-coding single-stranded RNA transcripts 
that regulate gene expression at the post-transcriptional level and unlike mRNAs 
and long ncRNAs, appear to be stable in tissue and biological fluids, even under 
adverse conditions such as extreme pH, long-term room temperature storage, 
multi freeze-thaw cycles and RNase activity [166,167,170]. Urine represents an 
important biological sample type for investigating the potential of miRNAs as 
biomarkers, since it is easy and non invasive to obtain in large amounts and its 
composition also reflects directly changes in the functions of the kidney and 
urogenital tract [209]. At the beginning of this study not much was known about 
miRNA abundance, efficiency and reproducible recovery in urine samples and 
moreover a well-established urinary miRNAs extraction and detection protocol 
was not available. Bravo and colleagues, in 2007, studied the stability of four 
murine miRNAs, belonging to different miRNAs families, and their cDNAs, in RNA 
preparation using mouse insulinoma ß-cell line and mouse liver. Three days after 
RNA isolation these molecules were significant degraded, and they concluded 
that the preparation method yielded highly unstable miRNAs [210]. Further article 
published in 2009 investigated the miRNAs stability in clinical samples of B 
lymphocytes using different RNA isolation methods after 14 days and over a 
period of 10 months at -80°C. Their findings were completely different from 
Bravo, the extraction using TRIzol/TRI-Reagent was a robust reproducible 
method and miRNAs and their cDNAs were highly stable [211]. Therefore it was 
clear to us that the quality and reproducibility of miRNA expression profiles 
obtained by quantitative reverse transcription PCR (RT-qPCR) would depend 
largely on the RNA extracted and isolation method. Because of their small size, 
standard molecular techniques were modified to allow for the detection of small 
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miRNAs species. The main approaches available at the beginning of this study 
for miRNAs isolation were: 
• A monophasic solution of phenol and guanidinium isothiocyanate (e.g. 
TRI Reagent) considered a standard approach for extraction of mRNA 
and miRNA for analysis. Urine was homogenised with TRI Reagent 
solution by repeated pipetting, and the mixture was separated into 
aqueous and organic phases by addition of chloroform and centrifugation. 
RNA was partitioned to the aqueous phase, DNA to the interphase, and 
proteins to the organic phase. RNA was then precipitated from the 
aqueous phase using isopropanol, and was finally washed with ethanol 
and then solubilized. However, it was unknown whether such 
precipitation-based extraction techniques would be robust in the context 
of tiny quantitates of RNA found in urine samples. 
• Norgen’s urine microRNA Purification kit that uses Norgen’s proprietary 
resin as the separation mix. A Lysis Solution lysed the urine sample and 
after adding ethanol the microRNA bound to the column’s resin while 
most of the contaminating cellular proteins are removed in the flow 
through or retained on top of the resin. The bound RNA is then washed to 
remove any remaining impurities and the purified urinary microRNA is 
finally eluted.  
• miRNeasy Mini (Qiagen) that integrates phenol/guanidine-based lysis of 
samples with silica-membrane–based purification of RNA from 
approximately 18 nucleotides. Initially the sample is lysed and the RNases 
solution inhibits by the phenol-guanidine thiocynate solution. DNA and 
proteins are then removed from the lysate by organic extraction and 
RNA/miRNAs are purified using the spin columns. 
Real time PCR is the main technique used for studying expression of single 
miRNAs or to validate observations resulting from genome wide expression 
profiling of miRNAs [212]. Although alternative techniques, such as Northern 
Blotting, may be used to quantitate miRNAs, these require input amounts of RNA 
that preclude their use in small samples such as those obtained from clinical 
isolates. There are two main systems:  
• The Exiqon product, miRCURY LNATM Universal RT microRNA PCR. This 
is a system designed for miRNA detection by quantitative real-time PCR 
using SYBR® Green. The method is based on universal reverse 
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transcription (RT) where a poly-A tail is added to the mature miRNA 
template; cDNA is synthesized using a Poly-T primer with a 3’ degenerate 
anchor and a 5’ universal tag. The cDNA template is then amplified using 
miRNA-specific and LNATM-enhanced forward and reverse primers, while 
SYBR® Green is used for detection.  
• The quantification using Applied Biosystems TaqMan® Small RNA 
Assays. This is done using two-step RT-PCR. The cDNA is reverse 
transcribed from total RNA samples using a small RNA-specific, stem-
loop RT primer that binds to the 3′-portion of miRNA molecules. In the 
PCR step, PCR products are amplified from cDNA samples using the 
TaqMan® Small RNA Assay. The assay contains primers specific 
(forward and reverse) for the target miRNA and a probe that contain a 
report dye (FAM™ dye) linked to the 5’ end of the probe, a minor groove 
binder (MGB) at the 3’ end of the probe and a non-fluorescent quencher 
(NFQ) at the 3’ end of the probe. 
Publications detecting mainly RNA or miRNAs in urine samples as potential 
markers of different pathologies or diseases were available but none of them 
described a reliable miRNA detection protocol. In most cases, these early papers 
describe analysis of miRNA expression in urinary sediment obtained after a spin 
at 3000g for at least 20 minutes, and not in the supernatant as our focus was 
[213-217]. Therefore the first aim of the present chapter was to investigate a 
robust and non-toxic technique for urinary miRNAs extraction and detection.   
As already discussed in chapter 1 (see 1.3.5) protection of miRNAs from 
degradation may occur as a result of packing in microparticles such as 
exosomes, microvesicles and apoptotic bodies; or by association with RNA-
binding proteins, or lipoprotein complexes [168,169,218]. The second aim of this 
chapter was then to study the stability of urinary endogenous miRNAs in samples 
from unaffected individuals and CKD patients, since an investigation of the 
physiological state of circulating miRNA in human urine had not yet been 
reported. 
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3.2 Results 
3.2.1 Development of a robust technique for urinary miRNA detection 
 
3.2.1.1 Optimisation of extraction of urinary miRNAs 
 
In order to establish a robust and non-toxic technique for urinary miRNA 
detection, three different approaches for RNA isolation and two different 
approaches for miRNA detection were tested on control urine samples, and the 
quality and reliability of extracted RNAs was compared (2.1.1 and 2.2.1). 
Evaluation was based both on the amounts of total RNA/miRNA measured and 
the mean A260/280 ratio (RNA integrity) obtained with the different extraction 
protocols. 
TRI-reagent solution combines phenol and guanidine thiocyanate in a 
monophasic solution to rapidly inhibit RNase activity. TRI Reagent recovered the 
highest RNA yield, but with wide yield variability. Achieved concentrations of RNA 
were low (Fig 3.1). Lack of a visible RNA pellet during the extraction, and 
unreliable precipitation of such low concentration RNA may have contributed to 
the variability. 
 Norgen purification was based on spin column chromatography using a 
proprietary resin as the separation matrix binding RNA in an ionic concentration-
dependent manner. 
Small RNA molecules were preferentially purified from other cellular 
components such as ribosomal RNA without the use of phenol or chloroform. Our 
data show a difference in RNA recovery (range between 3.27 and 59.78 ng/μl) 
and a low A260/A280 ratio (range between 0.61 and 1.34) indicating probable 
protein contamination.  
Followed by these observations, and previous work suggesting that in low 
abundance clinical samples, affinity column-based RNA extraction offers 
advantages [202], miRNeasy Mini (Qiagen) protocol with minor modifications 
(see 2.2.1.1) was selected for further analyses (Figure 3.1). 
 64 
 
Figure 3.1. RNA/miRNA extraction using three different protocols 
RNA/miRNA was extracted using three different approaches: Tri-Reagent, miRNeasy 
Mini (Qiagen) and Norgen. A: The graph shows the mean value of total yield. Standard 
Error of the mean (SEM) is respectively 61.25, 5.062 and 12.38 B: mean A260/A280 
ratios: this ratio is used as a measure of RNA purity. A ratio of 2 signifies appropriate 
purity to analyse. SEM is respectively 0.26, 0.07 and 0.15. 
 
 
Two different RT-qPCR techniques, Applied Biosystems and Exiqon, were 
then used to detect miR-16 and thereby evaluate RNA/miRNA extracted by the 
three methods described above. miR-16 was selected since it is a ubiquitously 
expressed miR and it is commonly used as a reference miRNA to normalize RT-
qPCR expression data [219]. 
Figure 3.2 represents the Ct of miR-16 obtained using RNA extracted by the 
three different techniques described above, and provides a comparison of the 
recovery of urinary miRNAs using these three different isolation methods. There 
was no statistically significant difference in abundance of miRs detected, 
suggesting that there was no important difference in efficiency of extraction by 
the three methods. However, a consistent observation in my experiments was 
that the miRNeasy kit led to the lowest level of variance in the data, suggesting 
that this approach gave the most consistent RNA extraction (Fig 3.2). Similarly, 
although similar Ct values were achieved using both TaqMan and LNA/SYBR 
Green-based detection approaches, the data obtained using TaqMan chemistry 
were consistently less variable. Therefore, for my future work, I used the TaqMan 
approach. 
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Figure 3.2. Ct value for miR-16 obtained using two different RT-qPCR techniques 
Ct values for miR-16 obtained using two different RT-qPCR techniques, Applied 
Biosystems TaqMan (A) and Exiqon (B), on RNA samples isolated using three 
approaches described above. Graphs show the mean of four replicates. Difference were 
not statistically significant but miR extraction with miRNeasy Mini appeared more robust 
and with less SEM in both RT-qPCR techniques. (A) Standard error: TRI-Reagent = 3.51, 
miRNeasy Mini = 0.91, Norgen = 1.04. (B) Standard error: TRI-Reagent = 3.16, 
miRNeasy Mini = 1.59 Norgen = 1.64. (C) Comparison of mean of miR-16 CT between 
Applied Biosystems TaqMan® (ABI) and Exiqon with miRNeasy Mini isolation protocol. 
Statistical differences were not observed, but lower Ct values and reduced SEM was 
achieved with Applied Biosystems’s reagent. SEM: Applied Biosystems TaqMan® (ABI) = 
0.91 Exiqon = 1.59. RTqPCR was performed in duplicate. SEM= standard error of the 
mean.  
 
Determination of the RT-qPCR assay efficiency is critical for accurate data 
interpretation. A PCR efficiency of 100% corresponds to a slope of –3.32, as 
determined by the following equation: 
Efficiency = 10(-1/slope) –1 
Ideally, the efficiency (E) of a PCR reaction should be 100%, meaning that the 
template doubles after each cycle during exponential amplification. Calculation of 
actual reaction efficiency provides valuable information. The presence of PCR 
inhibitors in one or more of the reagents can produce efficiencies of greater than 
110%. A good reaction should have efficiency between 90% and 110%, which 
corresponds to a slope of between –3.58 and –3.10.  
To calculate RT efficiency, serial dilutions from one urinary total extract were 
used to perform qPCR following the protocol (2.2.2.2) (Figure 3.3 A). The slope 
was 3.288 with an efficiency of 101.44%. qPCR efficiency was calculated using 
serial dilutions from 1 sample following reverse transcription, data show a slope 
of 3.230 with an efficiency of 103.98% (Figure 3.3 B). 
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Figure 3.3. Calculation of RT and PCR efficiency 
A: Serial dilutions were generated from a RNA sample isolated using miRNase Mini 
approach and added on the RT step to evaluate the retrotranscription’s efficiency. Later, 
Ct for miR-16 at the indicated dilution points were detected using qPCR. B: Serial 
dilutions were produced from a RT product to analyse qPCR’s efficiency for miR-16.  
Both graphs show the log of made dilutions. RT’s efficiency (A)= 101.44% and r2= 0.9999 
while qPCR’s efficiency (B)= 103.98% and r2= 0.9981. 
 
3.2.1.2 Extraction assay variability studies 
 
In order to quantify the robustness and reproducibility of RT-qPCR of urinary 
miRNAs, of RT-qPCR technique, intra-assay variability and biological variability in 
miRNA detection in urine samples were investigated and coefficients of variation 
(CV) were calculated. CV (standard deviation / mean) is a measure of the 
variability of the result for the same sample evaluated repeatedly in the same 
assay run, and in separate assay runs, respectively. The goal for any assay is 
the smallest possible coefficient of variation; generally a variability of less than 10 
to 15% is acceptable. miR-16 and miR-192 were analysed since miR-16 is 
expressed abundantly and ubiquitously ,while miR-192 was chosen as previous 
work from our laboratory has demonstrated that it is down-regulated in diabetic 
nephropathy [220]. Intra-assay variability was determined by performing a 
sextuplicate reverse transcription reaction on RNA extracted from one urine 
sample followed by duplicate qPCR analysis, the coefficients of variation were 
0.47% for miR-16 and 0.78% for miR-192. In addition, to assess the stability of 
miRNAs, RT-qPCR analysis was performed for miR-16 and miR-192 from freshly 
isolated RNA samples stored at -80°C over 6 days. The coefficients of variation 
were again less than 10% for all control samples; respectively 3.9%, 6.49% and 
1.95% for miR-16 3.64, 7.33 and 3.94% for miR-192. Experimental data (Figure 
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3.4) show that miRNA stored under these conditions did not degrade and small 
differences appeared to be secondary to technical variability of the RT-qPCR 
itself.  	  
 
Figure 3.4. Study of the extraction variability assay 
A-B: Reverse transcription reaction performed in sextuplicate and qPCR in duplicate to 
evaluate intra-assay variability for miR-16 and miR-192 detection from one control urine 
sample. The scatter dot plot represents the mean of the Ct value for miR-16 and miR-
192; the CV are respectively 0.48 for miR-16 and 0.78 per miR-192. C-D: RT-qPCR 
analysis of miRs from control urine samples stored at -80°C over 6 days. The coefficients 
of variation were less than 10 % for all control samples; respectively 3.9% for control 1, 
6.49% for control 2 and 1.95% for control 3 for miR-16, and 3.64, 7.33 and 3.94% for 
miR-192. 
 
 
Biological variability for miR-16 and miR-192 was evaluated using RT-qPCR 
from fresh urine samples collected every day for 6 days from the same 4 
volunteer control subjects. The coefficients of variation for biological variability for 
the 4 samples were 6.28, 4.78, 5.63 and 8.58% for miR-16 and 2.08, 5.52, 
8.39,4.49% for miR-192 (Figure 3.5).  
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Figure 3.5. Analysis of biological variability 
RT-qPCR analysis of miRNA samples from fresh urine samples from the same individuals 
over 6 days. The graphs represent the mean of miR-16 and miR-192 Ct. CV were 
calculated found to be below 10% for all samples. 
 
3.2.1.3 RT-qPCR tolerance to urine 
 
Molecular diagnosis, where nucleic acids are measured in the context of a 
disease, is a multistep process requiring collection, storage, and extraction of a 
sample prior to analysis. Urine, as already discussed, has advantages in this 
context, being easy to collect and homogeneous. Since PCR has been used by 
scientists, qPCR inhibitors have been an obstacle to success since a RNA 
sample that is not clean and free from any residual buffers or urine components 
may have repercussions on the entire process and/or modify the salt 
concentration of the buffer. This is usually not a problem when using spin column 
kits instead of manual extraction techniques. 
In order to exclude important inhibition of RT-qPCR efficiency by carryover of 
urinary components, different percentages of urine were added in the reverse 
transcription reaction as possible qPCR inhibitor. Synthetic C. elegans miR-39 
stem-loop (cel-miR-39) was spiked-in to provide an internal control for RNA 
isolation, cDNA synthesis and PCR amplification. To be certain that the spike in 
control did not itself alter miRNAs detection, exogenous cel-miR-39 was spiked 
into a control urine sample at 0.05, 0.5, 5 and 50 pM. Endogenous hsa-miR-16 
and exogenous cel-miR-39 were then detected by RT-qPCR, and showed that 
the introduction of the synthetic miRNA into the RNA extraction resulted in no 
significant difference in detection (Figure 3.6 A). Exogenous 0.05pM cel-miR-39 
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was then spiked into 4 control urine samples. RNA was extracted and then 
different percentages of urine (0, 0.1, 0.5, 1 and 5%) were added to the RT 
(reverse transcription) step to analyse inhibition. Endogenous miR-16 and 
exogenous miR-39 were then detected by RT-qPCR and the data normalized 
versus 0% of urine. As showed in figure 3.6, percentages of urine between 0.1 
and 5 in the RT step did not interfere and did not have consequences on miR-16 
or miR-39 expression. 
 
 
Figure 3.6. Analysis of RT-qPCR tolerance to urine 
A: Exogenous cel-miR-39 was spiked into control urine sample at 0.05, 0.5, 5 and 50 pM. 
miR-16 and cel-miR-39 were detected by RT-qPCR. B: Exogenous cel-miR-39 was 
spiked into 4 control urine samples at 0.05pM. Urine at 0, 0.1, 0.5, 1 and 5% were added 
to the RT step to analyse inhibition. Endogenous miR-16 and cel-miR-39 were detected 
by RT-qPCR and data were normalized to 0% urine. 
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3.2.2 Stability of urinary miRNAs 
3.2.2.1 Endogenous urinary miRNAs are resistant to RNase digestion 
 
Having developed a robust technique for urinary miRNA detection, samples 
from control subjects and proteinuric patients were analysed in order to 
determine whether proteinuria altered miRNA stability. Human urine contains 
active ribonuclease (RNase) [221]; to test if miRNAs are protected from this 
ribonuclease action, urine samples from control and diabetic nephropathy 
patients were maintained at room temperature for 24h. Furthermore, to 
understand if this mechanism was exclusive to endogenous urinary miRNA, 
spiked-in exogenous synthetic cel-miR-39 was added to all urine samples and 
monitored under the same conditions. Synthetic cel-miR-39 was spiked-in at time 
zero into the urine samples and detection of ubiquitously expressed endogenous 
control miR-16 and exogenous cel-miR-39 was compared after 1, 2, 4, 8 and 24 
hours (Figure 3.7). In urine samples from controls and patients > 60% of the time 
zero miR-16 signal was detected by RT-qPCR analysis after 24h at room 
temperature (Figure 3.7 A, B), while cel-miR-39 expression decreased to <10% of 
its time zero signal after 1 hour (Figure 3.7 C, D). These data suggest that a room 
temperature dwell-time of 4 hours is acceptable for studies of urinary miRNAs 
expression. Second, the data suggest that there are specific mechanisms of 
stabilisation that pertain to endogenous urinary miRNAs, and not to exogenous or 
spiked-in miRNAs. miRNAs stability is specific to endogenous miRNAs and not, 
more generically, a miRNA’s characteristic. 
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Figure 3.7. Stability of urinary miRNAs 
Relative expression of miR-16 (A-B) and cel-miR-39 (C-D) in urine samples from control 
subjects (A-C) and diabetic nephropathy patients (B-D) stored at room temperature over 
24 h. The data represent mean ± SEM of urine samples from 6 control and 4 diabetic 
nephropathy patients normalized against each respective zero time-point. SEM= standard 
error of the mean 
 
 
Since urine contains active RNases, detection of miRNAs suggested that 
these transcripts are resistant to RNase digestion. Data in Figure 3.7 showed that 
miR stability was not intrinsic to their small size or chemical structure but 
suggested that it occurred by additional external factors. To investigate this 
observation further, RT-qPCR detection of endogenous miR-16 and exogenous 
miR-39 was compared in urine samples from control subject treated and not 
treated with exogenous RNase at time points up to 1 h incubation at 37°C, 
followed by analysis of both control and patient urine samples at the 30 min time 
point. Results in Figure 3.8 show that synthetic cel-miR-39 expression decreases 
rapidly both in the presence or absence of RNase being wholly degraded after 10 
min in the absence of RNase, and after 1 min in the presence of enzyme (Figure 
3.8 D-F). miR-16 expression detection was stable in urine untreated with RNase 
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(Figure 3.8 A); after 15 min RNase treatment around 15% of miR-16 expression 
was still detectable (Figure 3.8 A). Endogenous urinary miRNAs were resistant to 
exogenous RNase both in patient and control urine samples with a significant 
difference of p=0.04 in patients’ urine and p=0.02 in controls’ urine. (Figure 3.8 B-
C) 
These results confirmed the sensitivity of synthetic exogenous miRNAs to 
degradation in urine and that endogenous transcripts exist in a form that is 
partially resistant to urinary RNase activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Treatment of urine samples with RNase 
Relative expression of endogenous miR-16 (A-C) and exogenous cel-miR-39 (D-F) in 
urine samples from 6 control subjects and 4 diabetic nephropathy patients following 
treatment with RNase A. Data are normalized to their respective zero time-points and 
they are presented as mean value ± SEM. SEM= standard error of the mean 
 
 
0 5 10 15 20 25 3050 55 60
0.0
0.5
1.0
1.5 untreated with RNAse
treated with RNase
Time (min)
Re
lat
ive
 ex
pr
es
sio
n h
sa
-m
iR
-1
6 
(v
s h
sa
-m
iR
-1
6 t
im
e 0
)
A!
time 0 time 30 time 30 
0.0
0.5
1.0
1.5
RNase              -  +
                     Controls
Re
lat
ive
 ex
pr
es
sio
n h
sa
-m
iR
-1
6 
(v
s h
sa
-m
iR
-1
6 t
im
e 0
)
p = 0.02 !
B!
time 0 time 30 time 30 
0.0
0.5
1.0
1.5
RNase                                  -  +
                                       Patients
Re
lat
ive
 ex
pr
es
sio
n h
sa
-m
iR
-1
6 
(v
s h
sa
-m
iR
-1
6 t
im
e 0
) p = 0.04 !
C!
0 5 10 15 20 25 3050 55 60
0.0
0.5
1.0
1.5 untreated with RNAse
treated with RNAse
Time (min)
Re
lat
ive
 ex
pr
es
sio
n c
el-
m
iR
-3
9 
(v
s c
el-
m
iR
-3
9 t
im
e 0
)
D!
F!
time 0 time 30 time 300.0
0.5
1.0
1.5
RNase     -  +
                              Patients
Re
la
tiv
e 
ex
pr
es
si
on
 c
el
-m
iR
-3
9 
(v
s 
ce
l-m
iR
-3
9 
tim
e 
0)
E!
time 0 time 30 time 30 
0.0
0.5
1.0
1.5
RNase     -  +
                               Controls
Re
la
tiv
e 
ex
pr
es
si
on
 c
el
-m
iR
-3
9 
(v
s 
ce
l-m
iR
-3
9 
tim
e 
0)
 73 
3.2.2.2 Urinary exosomes isolation 
 
In the absence of a stabilising influence, degradation of urinary miRNAs would 
be predicted. Mechanisms by which urinary miRNAs are protected from 
endogenous RNase degradation were therefore investigated. Firstly, urinary 
extracellular vesicles were isolated from control samples and analysed by 
nanoparticle tracking (see 2.4). This method visualises and analyses particles in 
liquids by relating the rate of Brownian motion (random moving of particles 
suspended in a fluid) to particle size. Movement is related only to the viscosity of 
the liquid and is not influenced by temperature, particle density or refractive 
index. This technique provides a size distribution and particle count. The data 
demonstrated that ultracentrifugation pelleted ≈88% of urinary nanoparticles and 
that the majority of these nanoparticles were detected in the typical exosomal 
range around 100 nm (Fig 3.9). 
 
 
Figure 3.9. Nanoparticles analysis by NanoSight 
Urinary nanoparticles were analysed using the NanoSight LM10 system, data (A) reveal 
that that the majority of nanoparticles was recovered around the size of 100nm, typical of 
exosomes while the graph in (B) shows that approximately 88% of urinary nanoparticles 
were pelleted using this protocol. 
 
 
The total post-spin urine pellet was applied to a continuous sucrose gradient 
and ultra-centrifuged at 4°C overnight at 210,000g to obtain sub-fractions and to 
isolate urinary exosomes. Since it is know that the classical exosome density 
range is between 1.1-1.2 g/ml [222]; to find out which sub-fractions contain 
exosomes, refractive index of each subfraction was detected in each samples 
and density was calculated. These data suggested that fractions 3-5 contained 
vesicles with the typical exosome density (Figure 3.10). In addition, flow 
cytometric analysis showed that classical exosomally-expressed tetraspanins 
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CD9 and CD81 were abundant in fractions 3, 4 and 5, as were multivesicular 
bodies markers tumour susceptibility gene (TSG)101 and programmed cell death 
6-interacting protein (Alix), detected by Western blotting analysis.  
 
Figure 3.10. Exosomes characterization 
Extracellular vesicle pellets were overlaid onto continuous sucrose gradients of 0.2-2.5 M 
sucrose and their refractive index (A) and density (B) determined to identify fractions 
containing exosomes. Since exosome-density range is between 1.1-1.2 g/ml the 
exosomes were isolated in fraction 3,4 and 5. Validation of these data was carried out 
using exosome-expressed tetraspanins CD9 and CD81 identified by flow cytometry (C 
and D) and identification of multivesicular body markers TSG101 and Alix by Western 
blotting (E). (C and D) Graphs represent the median fluorescence intensity for CD9 and 
CD81 with of IgG2b isotype control subtracted.  
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3.2.2.3 Protein association stabilises extra-vesicular urinary miRNAs 
 
Detection of miR-16 and miR-192 was then carried out in the fractions 
prepared by density gradient ultracentrifugation. High relative abundances of 
these two miRNAs were detected in these exosomal fractions (Figure 3.11 A and 
B), suggesting that in urine, these miRNAs were protected from endogenous 
RNase degradation via association with exosomes.  
miR-16 and miR-192 were also detected in the non-sedimented urinary 
miRNAs in the supernatant. Data obtained via RT-qPCR showed detection of 
supernatant miRNAs with a Ct=34.09 for miR-16 and Ct=36.02 for miR-192. The 
Ct average from the total pellet for miR-16 was 32.2, and 32.09 for miR-192, 
showing that detectable portions of urinary miRNAs were likely protected from 
RNase degradation by association with proteins. A more conservative conclusion 
was that urinary miRNAs were detected both in sedimented and non-sedimented 
urinary fractions.  
 
 
 
Figure 3.11. miR-16 and miR-192 detection is sedimented urinary miRNAs 
(A and B) miR-16 and miR-192 were detected using RT-qPCR from extracellular vesicles 
fraction obtained by ultracentrifugation.  
 
 
To investigate if the non-sedimented miRNAs were protected from degradation 
by association with proteins, we compared miR-16 recovery in control and patient 
urine samples incubated at 55°C over 60 min alone, or in the presence of 
proteinase K. Results in Fig 3.12, show that endogenous miRNA was 
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destabilised and not detected following proteinase K digestion while around 
100% of miR-16 was recovered in urine samples not treated with proteinase K. 
Further analysis at the 30 min time-point showed that this effect was statistically 
significant in control and patient urine samples. These data suggest support the 
hypothesis that non-sedimented miRNAs resist RNase degradation via 
association with ribonucleoprotein complex. 
 
 
Figure 3.12. Treatment of urine samples with Proteinase K 
(A and B) Control urine untreated (A) or treated (B) with proteinase K over 60 min at 
55°C resulted in degradation of endogenous urinary miR-16. (C and D) The same 
experiment was repeated using 5 control and 5 CKD patient urine samples, data showed 
that this effect was statistically significant in control (p=0.002) and patient (p=0.02) urine 
samples. Data were normalized to the respective zero time-point. 
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3.2.2.4 Urinary miRNAs are associated with AGO2  
 
Although not yet studied extensively in urine, it is well established that miRNA 
function involves association with the multi-protein RNA-induced silencing 
complex (RISC). Argonaute (AGO) proteins are the core effectors of the miRNA 
pathway and effectors of RNAi that incorporate mature miRNAs following 
processing of their respective primary transcripts [170,223]. To establish if AGO2 
protein was present in urine and if miRNAs were associated with it, RNA-
immunoprecipitation was performed followed by immunoblotting from controls 
urine samples (Figure 3.13). Detergent was not added during 
immunoprecipitation to avoid potential lysis of urinary vesicles. Western blotting 
analysis and quantification of these data by densitometry showed a significant 
difference (p=0.008) between urinary AGO2 immunoprecipitate and the negative 
control mouse IgG reactions. RT-qPCR analysis for miR-16 and miR-192 in these 
samples revealed that it was significantly recovered in greater abundance in the 
AGO2 immunoprecipitation than in the negative control mouse IgG with  
respective p-values of 0.01 for miR-16 and 0.02 for miR-192. 
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Figure 3.13. Urinary AGO2 immunoprecipitation 
(A) Immunoprecipitation (IP) from urine sample using anti-AGO2 antibody detected 
AGO2, with negative normal mouse IgG and positive HEK-293 control reactions. The blot 
shown here is representative of a total of 5 experiments, each of which yielded similar 
results. (B) Densitometry analysis of AGO2 immunoprecipitation data from all 5 
experiments. (C and D) RT-qPCR detected increased miR-16 and miR-192 in Ago2 
immunoprecipitates in comparison with untreated urine input and mouse IgG reactions. 
Error bars represent mean ± SEM. 
 
 
3.2.2.5 Urinary miRs are not associated with albumin 
 
The appearance of increased quantities of urinary albumin is an important sign 
of damage of the glomerular filtration barrier. Albumin is a type of protein found in 
large amounts in the blood. Because it is a small molecule, it is one of the first 
proteins able to pass through the kidney into the urine when there are kidney 
problems. The presence of a small amount of albumin in the urine is called 
microalbuminuria. As the amount of albumin the urine increases, the condition 
progress from microalbuminuria to albuminuria or proteinuria. Detection of 
microalbuminuria is used widely as a biomarker for renal injury in diabetes and 
other disease-related contexts. Patients with conditions leading to glomerular 
damage such as diabetic nephropathy may exhibit grossly increased urinary 
protein losses of several grams per day, in sharp contrast with an average value 
of <100 mg/day in unaffected individuals. To investigate if miRNAs were 
associated with albumin under normal or grossly proteinuric conditions an RNA-
immunoprecipitation of urinary human albumin was performed. Data in Figure 
3.14 show that albumin was recovered by immunoprecipitation from both control 
and patient urine samples, a statistical significant difference was found between 
specific recovery in comparison to negative control data in both control 
(p=0.0004) and patients (p=0.004). In contrast with data regarding AGO2 
recovery (Fig. 3.13), miR-16 and miR-192 were detected in very low quantities in 
both albumin immunoprecipitation samples (Fig 3.13 E-H). Figure 3.14 A and C 
show the presence of albumin concentration in the urine of unaffected individuals. 
This event is not unexpected since, with a molecular weight of 67 KDs, complete 
exclusion by the glomerular filtration barrier (GFB) is far less effective than for 
larger proteins like AGO2 (97KDa). 
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Figure 3.14. Urinary albumin immunoprecipitation 
(A and B) Immunoprecipitation (IP) detection of albumin in control and patient urine 
samples, using IgG as negative control and human serum as positive control. The gels 
shown are representative from a total of four experiments, all of which yielded similar 
results. (C and D) Relative densitometry analysis of albumin immunoprecipitation data. 
(E-H) miR-16 and miR-192 were detected using RT-qPCR in whole albumin 
immunoprecipitates samples, in the untreated urine used as input and mouse IgG 
negative control reactions. Data were normalized versus the input and are presented as 
mean values ± SEM. 
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3.3 Discussion 
At the beginning of this project, the utility of urinary miRNAs as biomarkers for 
non-invasive diagnostic/ prognostic testing for CKD had not been established. 
However, recovery of sufficient miRNAs of appropriate purity, following RNA 
extraction from biological fluids, for effective quantitative downstream analyses 
could to be problematic. The work carried out in this chapter therefore provided a 
starting point by establishing a robust protocol for the extraction of urinary 
miRNAs. 
 
Development of a RT-qPCR protocol for the quantification of individual urinary 
miRNAs was followed by investigation of intra- and inter-assay variation, and 
urinary miRNA stability. Three different RNA extraction protocols were compared 
and RT-qPCR was used to assess recovery of miRNA species.  
 
The most valid and reproducible technique for extracting and detecting 
miRNAs from urine was the miRNeasy Mini (Qiagen) protocol followed by Applied 
Biosystems TaqMan® detection. This method was robust and provided 
consistent results when used to study intra-assay and biological variability in 
different urine samples. Coefficients of variation were calculated at less than 
10%, showing that the assay was sufficiently robust for the subsequent work 
described in this thesis.  
 
Having established a robust urinary miRNA detection protocol, endogenous 
urinary miRNA stability in urine samples from unaffected individuals and CKD 
patients was investigated. Preliminary data showed that urinary miR-16 degraded 
over extended storage at room temperature. Given that samples have likely been 
stored in the bladder at 37°C for several hours prior collection, this result 
appeared surprising. However, in the light of this finding, the approach for urine 
collection was modified. Second pass, rather than overnight urine samples were 
used to minimise bladder dwell time, after which samples were placed on ice and 
processed immediately.  
 
Concordance of miRNA expression in urine samples collected from the same 
individual on successive days was demonstrated, showing that the modified 
collection protocol yielded robust expression data. Indeed, in urine stored at room 
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temperature over 24 h; more than 50% of the time zero miR-16 signal was still 
detected. On the basis of the above data, a maximum room temperature dwell-
time of 4h was included in our standard urinary miRNA analysis protocol. 
 
The finding that the degradation of urinary miRNAs following the addition of 
exogenous RNase was lower when compared to spiked-in cel-miR-39 controls 
provided compelling evidence of a stabilising mechanism, or mechanisms, 
protecting endogenous urinary miRNAs from degradation. 
 
Following 16 h ultra-centrifugation at 200,000 g, sedimented urinary miRNAs 
were associated with microvesicles, including exosomes, while a percentage of 
non-sedimented urinary miRNAs remained in the supernatant. Microvesicle 
association provided a readily conceivable means of protection from RNase 
degradation, but the persistence of the apparently “free” miRNAs required a 
different mechanism.  
 
In an early study, Diederichs and Haber showed that argonaute proteins 
enhance production or stability of mature miRNAs. In addition, using AGO2 
mutation, they demonstrated that direct interaction between miRNA and AGO2 
increased expression of mature miRNAs [223]. In the present study, protein-
conferred urinary miRNA stabilization was tested by incubation with proteinase K, 
and increased miRNA degradation suggested that at least some of the non-
sedimented urinary miRNAs were stabilised in this way. RNA 
immunoprecipitation analysis identified RISC component protein AGO2 as a 
urinary binding partner that appeared to be responsible for protection from 
miRNA degradation. 
 
Association between miRNA and Ago2 has been reported previously in 
plasma [170,189]. Arroyo et al. confirmed that some plasma miRNA, obtained by 
size-exclusion chromatography, were microvesicle-associated, but these 
represented a minority of total plasma miRNAs [170]. Indeed, more than 90% of 
miRNA in the plasma and serum were bound to a ribonucleoprotein complex and 
transcript degradation increased following proteinase k digestion, suggesting that 
association with the protein complex was a stabilising mechanism for miRNA in 
the RNase-rich circulation [170].  
 82 
Results obtained by Turchinovich et al. conducted in human peripheral blood 
and cell culture media showed that >97% of miRNAs were exosome-free and that 
only small amounts of miRNAs were sedimented by centrifugation. These authors 
also reported that extracellular miRNAs were bound to 96kDa AGO proteins, 
AGO2 in particular [189]. 
 
Li and colleagues analysed 8 miRNAs with high expression levels in human 
plasma that remained stable after treatment with 20 μg/ml of RNase A. Following 
separation of plasma into (MV) multivesicular and multivesicular-free fractions, 
they found that most of them were localized in the MV. MV disruption using 0.1% 
Triton X-100 and subsequent RNase A treatment led to decreased miRNA 
detection, but resistance to degradation by RNase A was still apparent. Indeed, 
only after adding proteinase K were all miRNAs were degraded, and AGO2 was 
identified as a key protein apparently protecting the secreted miRNAs in the MV 
fraction. Together, these results suggest that both MVs and protein contributed to 
the resistance to RNase A of secreted miRNAs [224].  
 
By contrast, recent work found that plasma-borne miRNAs from patients with 
stable coronary artery disease, as well as acute coronary syndrome were 
associated with microparticles, and that only a small proportion of the total 
miRNA component was microparticle-free [225]. Similarly, Gallo et all reported 
that the majority of the miRNAs in human biologic fluids were not freely 
circulating but enclosed in microvesicles, primarily exosomes [226]. Elsewhere, 
protection of urinary miRNAs from degradation may be a product of association 
with extracellular vesicles such as exosomes [227]. The above reports describe 
different mechanisms for miRNA protection from RNase degradation, with most 
of these studies carried out in cell lines and/or plasma or serum samples. 
 
Understanding the molecular mechanisms stabilising urinary miRNAs has 
important implications for the utility of urinary miRNAs as a novel class of non-
invasive CKD biomarker. Association with microvesicles such as exosomes 
would be predicted to result in exclusion from glomerular filtration. Similarly, 
association of miRNAs with AGO2 protein suggests that miRNA are not freely 
filtered at the glomerulus. The commonly accepted upper molecular mass 
threshold to cross the glomerular filtration barrier is around 67kDa. This 
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corresponds to partial filtration of albumin, a protein commonly measured in the 
urine as a marker of disruption of the glomerular filtration barrier. On this basis 
association of miRNAs with AGO2, which has a molecular mass of 97kDa, would 
be expected to exclude circulating miRNAs from the glomerular ultrafiltrate.  
 
If association with AGO2 or microvesicles such as exosomes excludes 
circulating miRNAs from the urine, then the miRNAs in urine are predicted to 
originate solely from the cells of downstream of the glomerular filtration barrier. A 
previous study suggested that RISC protein GW182 play a role in protecting 
AGO-bound miRNAs [191]. The addition of the GW182 protein to associated 
miR-AGO2 size would increase its molecular mass by 182kD, making trans-
glomerular filtration barrier passage even less likely. However, this work was 
carried out in HEK293 cells, in which most miRNAs were associated with 
exosomes, and thus cell phenotype and context-specific considerations are also 
likely to be significant [191].  
 
In summary, the results presented in this chapter show that miRNAs are 
stabilised in urine by association with both exosomes and AGO2. The size of the 
resultant protein:miRNA complex or miRNA incorporation in exosome makes it 
possible to predict that miRNAs do not freely cross the glomerular filtration barrier 
and this has important implications for the use of urinary miRNAs as biomarkers.  
 
The time available to conduct this study was sufficient to analyse association 
of miR-16 and miR-192 with exosomes or AGO2 protein in control urine samples. 
However the selected miRNAs do not represent the whole miRNA population, 
and profiling of urinary exosome miRNAs would be a more complete approach. In 
addition isolation and characterisation of urinary exosomal miRNAs from DN 
patients, as well as their association with AGO2 proteins, might have important 
implications for the development of biomarker and functional studies. 
 
A reliable miRNA isolation technique to obtain sufficient quantity and quality 
urinary RNA and the stability of stored miRNA samples isolated by this method of 
needed to be established. Reliable detection of these transcripts provides a novel 
method for understanding kidney disease with the potential to identify new 
diagnostic biomarkers. 
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Chapter 4 – miRNA Profiling in diabetic nephropathy 
patients 
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4.1 Introduction 
 
CKD is a leading cause of death worldwide and diabetic nephropathy (DN) is a 
progressive kidney disease secondary to diabetes. Patients with either type 1 or 
type 2 diabetes are at risk of DN and the disease eventually effects 
approximately 50% of diabetics. Diabetic nephropathy is the leading cause of 
End Stage Renal Disease in the western world, and remains a major contributor 
to increased morbidity and mortality among individuals with diabetes [228,229]. 
CKD is typically diagnosed by the presence of a reduced creatinine-based 
estimated GFR, together with typical clinical correlates including increased levels 
of urinary albumin, and presence of other complications such as retinopathy, 
although these factors are not able to indicate the type of renal injury with 
certainty [230]. In addition, significant renal disease can occur with minimal or no 
change in creatinine [230] or albumin level [231]. Renal biopsy will provide 
detailed diagnostic and prognostic information in the patient with CKD, but is an 
invasive test, with significant risk of complications, and repeated kidney biopsy to 
monitor progression is not practicable or desirable in the majority of CKD 
patients.  
Uncontrolled high blood sugar along with high blood pressure can induce 
kidney damage; however the exact molecular pathways leading to diabetic 
nephropathy are still not fully characterised. The molecular pathophysiology of 
diabetic nephropathy is multifactorial, involving hemodynamic factors (Vascular 
Endothelial Growth Factor, Renin-angiotensin-aldosterone and Endothelin 
systems), proinflammatory (e.g. Interleukin IL-1, 6, 18) and profibrotic cytokines 
(such as TGF-ß) [232]. Therefore a reliable non invasive biomarker reflecting 
disease severity is urgently needed in the clinical management of patients with 
CKD [233]. 
Having developed a protocol for miRNA extraction from urine (see Chapter 3), 
it was then possible to examine differences in miRNA expression patterns within 
groups, and between cases and controls.  
Ideally, miRNA profiling will allow early detection of kidney injury and the 
prediction of disease progression in CKD as well as predisposing conditions such 
as diabetes and hypertension. miRNA profiles offer some potential advantages 
over mRNA or protein-based urinary profiles, and appear to be very stable in 
tissues and biological fluids, even under adverse conditions such as extreme pH, 
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long-term room temperature storage, multiple freeze-thaw cycles and RNase 
activity [166,234].  
Results in Chapter 3 showed that urinary miRNAs, via association with 
exosomes or with AGO2 protein, are resistant to RNase digestion, underlining 
their potential as attractive, non-invasive biomarkers. Continuing progress in 
miRNA research presents opportunities not only for better understanding of the 
pathophysiological mechanisms in kidney disease, but also for the identification 
of new diagnostic biomarkers. Several studies on renal diseases of varying 
origins have shown differences in miRNA expression between diabetic, and it is 
therefore possible that a ‘molecular signature profile’ could be developed to 
provide insights into diagnosis and progression of renal disease [235-238]. 
This considerable potential of miRNAs as biomarkers for renal injury is 
exemplified by the discovery of statistically significant correlation between 
circulating miRNA levels and various clinic-pathological endpoints [235,239,240]. 
Urine is an ideal source of biomarkers for disease of the kidney and urinary tract, 
since it can be conveniently collected in large amounts without risk to the patient 
[129,160,241].  
The goal of the work described in this chapter was to investigate differences in 
urinary miRNA expression between patients with diabetic nephropathy and 
healthy individuals, and thereby identify potential disease biomarkers. 
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4.2 Results 
4.2.1 Diabetic Nephropathy patients and healthy controls 
 
Twenty urine samples from diabetic nephropathy patients and twenty from 
unaffected people were obtained by Dr. Alexa Wonnacott at the University 
Hospital of Wales. The group included patients from CKD stage 3 and eGFR of 
43.3 ml/min to patients with CKD stage 4/5 and eGFR of 12.9 ml/min. Urine 
samples from healthy individuals were collected and the urine protein value was 
assessed. Patients and controls data are summarised in Table 4.1. 
 
 CKD Patients Controls 
Sex (Number of male) 17 10 
Age (year) ± SEM 73.97 ± 2.10 47.70 ± 2.46 
eGFR(min/ml) ± SEM 28.96 ± 1.90 / 
Urine Protein (g/l) ± SEM 0.6 ± 0.17 0.07 ± 0.003 
Protein Creatinine ratio (mg/mmol) ± SEM 115 ± 33.89 9.2 ± 1.293 
Blood Glucose (mM) ± SEM 9.99 ± 1.16 / 
                 
Table 4.1 CKD Patients and control data.   
Urine samples from CKD patients and controls used in miRNA profiling. eGFR- 
estimated glomerular filtration rate. 
 
miRNAs were isolated using the technique developed as part of the work for 
this thesis and described in Methods (see 2.2.1). Expression of the ubiquitously 
higly-expressed miR-16 was then examined by TaqMan stem-loop RT-qPCR in 
those samples to confirm efficient miRNA extraction. The miRNA yield could not 
be analysed due to the use of carrier RNA in the extraction process. A constant 
volume of RNA extract was therefore added to each reaction, as opposed to a 
constant amount of RNA. The difference in quantity of miR-16 detected in 
patients and controls was not large and the signal was of good quality (Table 
4.2). Those samples were therefore used to study for miRNA profiling using the 
TaqMan Array Human microRNA Cards A and B (see 4.2.2). 
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PATIENT ID miR-16 Control ID miR-16 
P12-001 30.805451 C11-001 28.7321695 
P12-002 32.36779 C11-004 30.291439 
P12-003 30.5314245 C11-005 29.6346905 
P12-004 24.506028 C11-006 28.6871605 
P12-005 31.8052535 C11-007 30.83218 
P12-006 33.0815065 C11-008 32.1867215 
P12-007 29.196855 C11-010 31.8608955 
P12-012 29.694537 C11-011 27.6741025 
P12-013 30.8973805 C11-012 29.155841 
P12-015 25.310432 C11-013 31.8025055 
P12-016 31.8492775 C11-014 29.500789 
P12-017 26.411887 C11-015 28.340759 
P12-018 33.2512475 C11-016 29.8473185 
P12-019 32.0732385 C11-017 31.506639 
P12-020 29.6275905 C11-018 29.628817 
P12-022 31.978774 C11-019 33.280744 
P12-024 31.6938305 C11-020 31.5154165 
P12-025 32.470422 C11-021 37.345173 
P12-026 31.5945915 C11-022 28.6830085 
P12-027 30.233753 C11-023 29.6868515 
Patient Mean ± SEM 30.46 ± 0.55 Control Mean ± SEM 30.51 ± 0.48 
 
Table 4.2 miR-16 detection in urine samples from diabetic nephropathy patients 
and control urine.      
miR-16 detection in urine samples from patients and controls to evaluate the 
possible use of those samples in future experiments. 
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4.2.2 Urinary miRNA profiling 
 
For initial screening of urinary miRNA expression, TaqMan Array Human 
microRNA Cards A and B were used, permitting simultaneous analysis of 754 
small noncoding RNAs in eight RNA extracted pooled samples. Each of four 
pools contained RNA from five diabetic nephropathy patients, the other four pools 
contained RNA from corresponding control subjects (see 2.2.2.4). Pearson 
correlation coefficient (R2) was calculated to determine the linear dependence 
between each miRNA Ct obtained in all patient and control groups analysed. The 
data in Figure 4.1 and 4.2 show evidence for positive correlation between two 
variables for each group, increasing together with a R2 between 0.83 and 0.94 for 
the Card A in patients, and between 0.83 and 0.91 in controls (Figure 4.1A and 
4.1B). For Card B, R2 was between 0.92 and 0.96 in patients and between 0.86 
and 0.93 in controls (Figure 4.2A and 4.2B). The p-values below 0.0001 obtained 
from all data sets showed the statistical significance of the correlations, rejecting 
the hypothesis that these similarities were due to random sampling. A positive 
Pearson correlation supported by statistically significant p-values was also found 
for comparisons between controls and patient groups with CKD stage 3 
(R2=0.85), or CKD stage 4 and 5 (R2=0.8477) or the whole patient group 
(R2=0.8571) for Card A (Figure 4.1C). Positive correlations were also observed 
for corresponding analyses for Card B miRNAs (controls versus CKD stage 3 
R2=0.91, controls versus CKD stage 4 and 5 R2=0.9222 or the whole patient 
group R2=0.9202) (Figure 4.2C). The Pearson correlation values for all samples 
is summarised in Table 4.3 for Card A and Table 4.4 for Card B. 
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Figure 4.1. Histogram Plot relative to the Pearson correlation in Array A. 
Pearson correlation was calculated using the Ct obtained in each pooled urine group 
used to run the TaqMan Array Human microRNA Cards A. Patients were divided in 4 
groups on the basis of the CKD stage and eGFR (A), controls on the basis of age and 
gender (B). (C) Pearson correlation was calculated comparing controls and patients with 
stage 3 CKD, controls and patients with stage 4/5, and controls versus the whole CKD 
patients. 
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Figure 4.2. Histogram Plot relative to the Pearson correlation in Array B. 
Pearson Correlation among Ct level was calculated using the Ct obtained in each pooled 
urine groups used to run the TaqMan Array Human microRNA Cards B. Patients were 
divided in 4 groups on the basis of the CKD stage and eGFR (A) while the controls on the 
basis of age and sex (B). On (C) Pearson correlation was calculated comparing controls 
and patients with stage 3 CKD; controls and patients with stage 4/5 CKD and controls 
versus the whole CKD patients. 
 
 
10 20 30 40
10
20
30
40
 Ct
CKD3 (eGFR 35-31)
Ct
CK
D3
 (e
GF
R 
43
.3-
36
)
10 20 30 40
10
20
30
40
Ct
CKD3 (eGFR 43.3-36)
Ct
CK
D4
/5 
(e
GF
R 
22
-1
2.9
)
10 20 30 40
10
20
30
40
Ct
CKD3 (eGFR 35-31)
Ct
CK
D4
/5 
(e
GF
R 
22
-1
2.9
)
10 20 30 40
10
20
30
40
Ct
CKD3 (eGFR 43.3-36)
Ct
CK
D4
/5 
(e
GF
R 
27
.3-
23
)
10 20 30 40
10
20
30
40
Ct
CKD3 (eGFR 35-31)
Ct
CK
D4
/5 
(e
GF
R 
27
.3-
23
)
10 20 30 40
10
20
30
40
Ct
CKD4/5 (eGFR 27.3-23)
Ct
CK
D4
/5 
(e
GF
R 
22
-1
2.9
)
A!
10 20 30 40
10
20
30
40
Ct
Mature Female
Ct
Yo
un
g F
em
ale
10 20 30 40
10
20
30
40
Ct
Young Female 
Ct
Ma
tu
re
 M
an
10 20 30 40
10
20
30
40
Ct
Mature Female
C
t
Y
o
u
n
g
 M
a
n
10 20 30 40
10
20
30
40
Ct
Young Female 
C
t
Y
o
u
n
g
 M
a
n
10 20 30 40
10
20
30
40
Ct
Mature Female
Ct
Ma
tu
re
 M
an
10 20 30 40
10
20
30
40
Ct
Young Man
C
t 
M
a
tu
re
 M
a
n
B!
10 20 30 40
10
20
30
40
Ct
CKD3 (eGFR 43.3-31)
Ct
Co
nt
ro
ls
0 10 20 30 40
10
20
30
40
Ct
CKD4/5 (eGFR 27.3-12.9)
Ct
Co
nt
ro
ls
0 10 20 30 40
10
20
30
40
Ct
CKD Patients 
Ct
 
Co
nt
ro
ls
C!
 92 
 
 
CKD3 
(eGFR 35-31) 
CKD3 
(eGFR 43.3-36) 
CKD 4,5 
(eGFR27.3-23) 
CKD3 (eGFR 35-31) R
2
=0.8322 
(p<0.0001) 
R
2
=0.9488 
(p<0.0001) 
R
2
=0.8590 
(p<0.0001) 
CKD3 (eGFR 43.3-36) / R
2
=0.9494 
(p<0.0001) 
R
2
=0.9135 
(p<0.0001) 
CKD 4,5 (eGFR27.3-23) / / R
2
=0.8441 
(p<0.0001) 
 Young Female Young Male Mature Male 
Mature Female R
2
=0.9180 
(p<0.0001) 
R
2
=0.8389 
(p<0.0001) 
R
2
=0.8470 
(p<0.0001) 
Young Female / R
2
=0.8625 
(p<0.0001) 
R
2
=0.9237 
(p<0.0001) 
Young Male / / R
2
=0.8805 
(p<0.0001) 
 
CKD3 
(eGFR 43.3-31) 
CKD4/5 
(eGFR 27.3-12.9) 
CKD Patients 
Controls R
2
=0.8531 
(p<0.0001) 
R
2
=0.8477 
(p<0.0001) 
R
2
=0.8571 
(p<0.0001) 
 
Table 4.3 Pearson Correlation value Array A 
Pearson Correlation coefficients and p-values for patient and control groups for Card A 
analysis 
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CKD3 
(eGFR 35-31) 
CKD3 
(eGFR 43.3-36) 
CKD 4,5 
(eGFR27.3-23) 
CKD3 (eGFR 35-31) R
2
=0.9494 
(p<0.0001) 
R
2
=0.9542 
(p<0.0001) 
R
2
=0.9338 
(p<0.0001) 
CKD3 (eGFR 43.3-36) / R
2
=0.9463 
(p<0.0001) 
R
2
=0.9675 
(p<0.0001) 
CKD 4,5 (eGFR27.3-23) / / R
2
=0.9280 
(p<0.0001) 
 Young Female Young Male Mature Male 
Mature Female R
2
=0.9000 
(p<0.0001) 
R
2
=0.9051 
(p<0.0001) 
R
2
=0.8684 
(p<0.0001) 
Young Female / R
2
=0.9020 
(p<0.0001) 
R
2
=0.9305 
(p<0.0001) 
Young Male / / R
2
=0.9186 
(p<0.0001) 
 
CKD3 
(eGFR 43.3-31) 
CKD4/5 
(eGFR 27.3-12.9) 
CKD Patients 
Controls R
2
=0.9103 
(p<0.0001) 
R
2
=0.9222 
(p<0.0001) 
R
2
=0.9202 
(p<0.0001) 
 
Table 4.4 Pearson Correlation value Array B 
Pearson Correlation coefficients and p-values of patients and control groups used to run 
Card B. 
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4.2.2 Identification of suitable endogenous control genes for miRNA 
gene expression analysis   
 
The goal of this miRNA RT-qPCR expression profile analysis was to identify 
differences between controls and diabetic nephropathy patients. Data 
normalization is used to minimise detection of variation between groups and 
therefore assist identification of genuine disease-related differences. Accurate 
normalization is therefore a critical factor in quantitative gene expression 
analysis.  
Criteria used to identify suitable miRNAs to normalize the array data were: 
- The miRNA must be highly expressed in most, if not all, pooled samples 
- The miRNA must be expressed consistently in all pools 
- The miRNA must be detectable by commercially available RT-qPCR assay. 
Preference was given to miRNAs identified independently as suitable 
reference miRNAs.  
On the basis of these criteria, data from Card A and B, each representing 377 
miRNAs, were inspected using the NormFinder algorithm to assess the variance 
in expression levels [242]. NormFinder analyses expression data, identifying 
transcripts that are expressed consistently across different test groups, and are 
therefore potential reference genes for normalization of that set of expression 
data. It calculates both intragroup variance, describing the stability of gene 
expression within each group, and intergroup variance, which describes the 
stability of the gene expression between the groups. Genes that have the least 
inter and intragroup variation and lowest slope value are considered the most 
stable. This toll was used in previous studies to identify the stability candidate 
miRNA and small RNA reference gene experiments. A slope value of 0.176 for  
miR-23a was identified in a microarray study performed on uterine cervical 
tissues [243], 0.312 for let-7a in a gene expression analysis in human breast 
cancer [244] and 0.192 for miR-191 in a study conducted in normal and 
cancerous human solid tissues [245]. 
Table 4.5 shows the top 8 miRNAs identified by NormFinder as potential 
reference miRNAs, together with the 3 most used Card A housekeeping miRNAs, 
each with its corresponding slope value. 
Figure 4.3 shows a plot of Ct values of the candidate miRNAs in the 8 RNA 
pools. NormFinder ranked miR-422a, miR-342-3p, miR-454 and miR-191 as the 
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most stably expressed miRNAs across the all groups; and miR-191 had the 
lowest Ct values. Two published studies have also suggested the use of miR-191 
as optimal reference miRNA for normalization in profiling data from analysis of 
human uterine cervical cancer [243] and in normal and cancerous human solid 
tissues [245]. As a result of the above, microarray RT-qPCR data were 
normalised against miR-191 expression. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5. NormFinder slope value data for analysis of miRNAs in Array A  
The top 8 miRNAs identified by NormFinder as suitable reference genes, and the 3 most 
common miRNAs currently used to normalize RT-qPCR data: miR-16, RNU48 and 
MammU6. 
 
 
 
 
 
Figure 4.3. Representation of possible housekeeping gene for Array A 
The top 8 miRNAs identified by NormFinder as suitable reference genes, and the 3 most 
common miRNAs currently used to normalise RT-qPCR data: has-miR-16, RNU48 and 
MannU6. 
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35!
36!
37!
 Young Male!  Mature Male!  Young Female!  Mature Female! CKD3 (eGFR 36-43.3)! CKD3 (eGFR 31-34.7)! CKD4/5 (eGFR 23-27.3)!CKD4/5 (eGFR 12.9-22)!
Ct
!
hsa-miR-191!
hsa-miR-548a-3p!
hsa-miR-422a!
hsa-miR-342-3p!
hsa-miR-454!
hsa-miR-323-3p!
hsa-miR-628-5p!
hsa-miR-106b!
hsa-miR-16-4373121!
RNU48-4373383!
MammU6-4395470!
 NormFinder Slope value 
has-miR-422a-4395408 0.013 
has-miR-342-3p-4395371 0.013 
has-miR-454-4395434 0.015 
has-miR-191-4395410 0.016 
has-miR-323-3p-4395338 0.017 
has-miR-548a-3p-4380948 0.017 
has-miR-628-5p-4395544 0.018 
has-miR-106b-4373155 0.018 
RNU48-4373383 0.035 
MammU6-4395470 0.046 
has-miR-16-4373121 0.053 
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Table 4.6 shows data for Normfinder analysis of the TaqMan Array Human 
microRNA Cards B, featuring the top 9 miRNAs selected on the basis of slope 
value data and the two miRNAs suggested by the microarray manufactures as 
endogenous controls. Figure 4.4 shows the Ct values of Card B miRNA 
expression. Normfinder identified miR-1276 with the lowest slope value. miR-30a-
5p had the lowest Ct value and a low slope value, however the expression of this 
miRNA was know to be increased in serum and urine in children with idiopathic 
nephrotic syndrome [165] and its use as reference gene has not been reported. 
By contrast, there was no evidence suggesting variation of miR-1276 expression 
in nephropathy, and this miRNA was therefore used to normalize RT-qPCR data 
for Card B. 
 
 
 
 
 
 
 
 
 
 
Table 4.6. NormFinder slope value Array B 
The top 9 miRNAs identified by NormFinder as suitable reference genes, and the 2 most 
common currently used at the moment to normalize the RT-qPCR data: U6 and RNU48. 
 
 
 
 
 
 
 
 
Figure 4.3 Candidate reference genes for Array B 
The top 9 miRNAs identify by NormFinder as suitable reference genes, and the 2 most 
common small-nucleolar RNAs currently used: RNU48 and U6 
 
 NormFinder Slope value 
has-miR-1276-002843 0.014 
has-miR-30a-5p-000417 0.018 
has-miR-19b-1*-002425 0.019 
has-miR-520c-3p-002400 0.019 
has-miR-151-3p-002254 0.024 
has-miR-1305-002867 0.027 
has-miR-432-001026 0.028 
has-miR-625*-002432 0.029 
has-miR-572-001614 0.033 
U6 snRNA-001973 0.044 
RNU48-001006 0.084 
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4.2.3 Urinary miRNA expression from patients with diabetic 
nephropathy 
 
miRNA expression data generated using the TaqMan Array Human microRNA 
Cards A and B were normalized to the corresponding endogenous controls using 
DataAssist software. Figures 4.4 and 4.5 are presented as volcano plots and show 
log2-fold changes between DN patients and controls (y-axis) and –log10p-value 
(x-axis). This plot provides a means of rapid identification of miRNAs with the 
largest changes in expression between patients and controls that are statistically 
significant.  
Candidate miRNAs were excluded if: 
• They showed a large fold change but failed to reach statistical 
significance since this may be the result of one or more outliers with large 
fold-change values in one group. These miRNAs are seen below the blue 
line. 
• Statistically significant test data resulted from a low fold change in 
expression. These data are shown as black points. 
On Card A, a total of 47 miRNAs were significantly differentially expressed 
when comparing diabetic nephropathy patients to the controls, with 35 urinary 
miRNAs downregulated and 12 upregulated (Figure 4.4 B). On Card B, 12 
miRNAs showed significantly different expression; expression of 10 of these 12 
transcripts was upregulated in DN (Figure 4.5 B). The most highly characterised 
miRNAs were analysed on Card A, while Card B contained many more recently 
discovered miRNAs along with miRNA* sequences.  
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Figure 4.4. miRNA profiling of TaqMan Array Human microRNA Card A in diabetic 
nephropathy patients.  
(A)Volcano Plot of fold-change and statistical significance for miRNA expression between 
compared urine of diabetic nephropathy patients (n=20) and urine of unaffected 
individuals (n=20). The y-axis is the negative log10 of p-values (a higher value means 
greater significance) and the x-axis is log2 of the difference in expression between the two 
experimental groups. The horizontal blue line represents a p-values boundary of 0.05. (B) 
Fold change of miRNAs with statistically significant differential expression between 
patients and controls. 
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Figure 4.5. miRNA profiling TaqMan Array Human microRNA Card B in diabetic 
nephropathy patients.  
(A)The Volcano Plot of fold-change and statistical significance of miRNA expression 
compared between urine of diabetic nephropathy patients (n=20) and urine of unaffected 
individuals (n=20). The y-axis is the negative log10 of P values (a higher value means 
greater significance) and the x-axis is log2 difference in expression between the two 
experimental groups. The horizontal blue line represents a p value boundary of 0.05. (B) 
Fold change of miRNAs with statistically significant differential expression between 
patients and controls. 
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4.2.4 Validation TaqMan Array Human microRNA Cards A by qPCR 
 
For further analysis the first 5 miRNAs that showed the greatest statistically 
significant difference in expression between diabetic nephropathy patients and 
control urine samples (miR-29b, miR-212, miR-126, miR-218 and miR-155) and 
two miRNAs whose expression was down-regulated in patients (miR-200b and 
miR-192) were selected, the latter two have being previously studied in our 
laboratory as miRNA correlated with tubulointerstistial fibrosis [220]. To replicate 
the array data, these 7 miRNAs were quantified in all 40 individual urine samples 
with stem-loop RT-qPCR assay and using miR-191 as reference gene to 
normalize the RT-qPCR data. 
Six out of these seven miRNAs showed significant differences between 
patients and controls, confirming the previous array data (Figure 4.6 – 4.11). In 
each case the findings from array data were replicated in individual assay with 
the exception of miR-218. Due to technical difficulties, this miRNA was not 
analysed further.    
Determining a threshold value for a diagnostic laboratory test separating a 
diagnosis of affected from one of unaffected is not straightforward. Plotting a 
receiver-operator characteristic (ROC) curve helps to visualize and understand 
the relationship between sensitivity and specificity when discriminating between 
clinically normal and abnormal diagnostic test values. Sensitivity can be defined 
as the fraction of people with disease that the test identifies correctly (true 
positives), specificity as the fraction of people without the disease that the test 
identifies correctly (true negatives). The area under the ROC curve (AUC) 
quantifies the overall ability of the test to discriminate between affected and 
unaffected individuals. An undiscriminatory test has an area of 0.5, while a 
perfect test has an area of 1. ROC curves were plotted to assess the diagnostic 
potential of the six candidate miRNAs. 
Figures 4.6 – 4.11 shows that the AUC was 0.77 or greater for each miRNA, 
suggesting that they had potential as diabetic nephropathy biomarkers. The p-
values obtained confirmed the statistical significance of the discrimination 
between patients and controls.  
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Figure 4.6. Confirmation of statistically significant miR-29b expression microarray 
data using stem-loop RT-qPCR and ROC curve analysis  
miR-29b expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls (p-value 
=0.0024). Receiver operating characteristic curves analysis displays the diagnostic power 
to predict diabetic nephropathy of miRNAs miR-29b (B) with an AUC= 0.84 and a p-value 
=0.0002. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
 
 
 
 
Figure 4.7. Confirmation of statistically significant miR-212 expression microarray 
data using stem-loop RT-qPCR and ROC curve analysis  
miR-212 expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls (p-value 
s=0.0002). Receiver operating characteristic curves analysis displays the diagnostic 
power to predict diabetic nephropathy of miRNAs miR-212 (B) with an AUC= 0.90 and a 
p-value <0.0001. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
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Figure 4.8. Confirmation of statistically significant miR-126 expression microarray 
data using stem-loop RT-qPCR and ROC curve analysis  
miR-126 expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls p-value 
s=0.0087). Receiver operating characteristic curves analysis displays the diagnostic 
power to predict diabetic nephropathy of miRNAs miR-126 (B) with an AUC= 0.77 and a 
p-value =0.003. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
 
 
 
 
Figure 4.9. Confirmation of statistically significant miR-155 expression microarray 
data using stem-loop RT-qPCR and ROC curve analysis  
miR-155 expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls (p-value 
=0.0002). Receiver operating characteristic curves analysis displays the diagnostic power 
to predict diabetic nephropathy of miRNAs miR-155 (B) with an AUC= 1 and a p-value 
<0.0001. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
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Figure 4.10. Confirmation of statistically significant miR-200b expression 
microarray data using stem-loop RT-qPCR and ROC curve analysis  
miR-200b expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls (p-value 
=0.0012). Receiver operating characteristic curves analysis displays the diagnostic power 
to predict diabetic nephropathy of miRNAs miR-200b (B) with an AUC= 0.81 and a p-
value =0.0006. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
 
 
 
 
Figure 4.11. Confirmation of statistically significant miR-192 expression microarray 
data using stem-loop RT-qPCR and ROC curve analysis  
miR-192 expression (A) was examined in individual urine samples that were pooled for 
use in miRNA profiling (20 controls and 20 DN patients) by stem-loop RT-qPCR, using 
miR-191 as endogenous control. Data are presented using a box-and-whiskers plot with 
minimum and maximum of all the values. RT-qPCR data for all miRNAs showed 
significant difference between diabetic nephropathy patients and controls (p-value 
=0.011). Receiver operating characteristic curves analysis displays the diagnostic power 
to predict diabetic nephropathy of miRNAs miR-192 (B) with an AUC= 0.8 and a p-value 
=0.001. AUC= Area under the curve. Unpaired t-test with Welch’s correction. 
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Subsequently, the relationship between the expression of each miRNA and 
urine protein/creatine ratio (PCR) or eGFR was investigated. Correlations 
between PCR and miR-212, miR-126, miR-155 and miR-200b (Figure 4.12) were 
found to be significant. Moreover statistical correlations were observed between 
eGFR and the selected miRNAs (Figure 4.13). 
 
Figure 4.12. Correlation of miRNA expression with protein/creatinine ratio 
Relationship between protein/creatinine ratio and miRNAs expression in diabetic 
nephropathy patients and controls. Significant correlations were found for (B) miR-212 
(r2=0.13; p-value 0.02), (C) miR-126 (r2=0.2; p-value =0.003), (D) miR-155 (r2=0.13; p-
value 0.02) and (E) miR-200b (r2=0.11; p-value =0.04). 
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Figure 4.13. Correlation of miRNA expression with eGFR 
Relationship between eGFR and miRNAs expression in diabetic nephropathy patients 
and controls. Significant correlations were found for (A) miR-29a (r2=0.24; p-value 
=0.001), (B) miR-212 (r2=0.34; p-value <0.0001), (C) miR-126 (r2=0.23; p-value =0.02), 
(D) miR-155 (r2=0.4; p-value <0.0001), (E) miR-200b (r2=0.22; p-value =0.002) and (F) 
miR-192 (r2=0.14; p-value =0.01). 
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4.3 Discussion 
 
The experiments described in this chapter were designed to identify urinary 
miRNAs with the potential to act as non-invasive and robust biomarkers in 
diabetic nephropathy. Expression profiles of urinary miRNAs were compared 
between diabetic nephropathy patients and controls. 
 
As discussed in Chapter 3, analysis of miRNA expression has some 
methodological advantages over mRNA expression analysis, particularly in the 
clinical setting. Obtaining high yields of intact, long mRNA transcripts from urine 
samples is difficult due to the high RNase concentrations that lead to RNA 
degradation. By contrast, short mature miRNAs are more stable against nuclease 
degradation as described in chapter 3.  
 
Between the miRNAs statistically differentially expressed and detected using 
TaqMan Array Human microRNA Cards A, there is a trend showing a reduction of 
miRNA expression with 35 miRNAs down-regulated from a total of 47. 
Nevertheless, we identified a group of miRNAs that were differentially expressed 
in controls in comparison to patients. Some of these miRNAs (miR-29b, miR-212, 
miR-126 and miR-155) presented higher differences in fold change in the over-
expressed and two miRNAs (miR-192 and miR-200b) down-regulated were 
selected for further investigation. Statistically different expression of these 
miRNAs was replicated by RT-qPCR using single assay. 
 
Protein creatinine ratio was found to be associated with an increase level of 
miR-212, miR-126, miR-155 and decreased expression of miR-200b. In addition 
increase of miR-29b, miR-212, miR-126, miR-155 and reduction of miR-200b and 
miR-192 expression correlates with reduction in eGFR from patients with DN. 
However, the data show a weak correlation, with r2 not exceeding 0.4, between 
miRNA expression and both P:Cr ratio and eGFR. Therefore, studies of larger 
patient groups are needed to clarify the association of these variables. ROC 
curve analysis supports the possibility of using those miRNA as new biomarkers 
for the diagnosis of DN. 
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Expression levels of miRNAs in body fluids may reflect tissue-specific injury or 
expression, making them strong candidates for use as disease biomarkers [167]. 
Profiling of urinary miRNA expression by TaqMan®Array Human MicroRNA 
Cards has detected specific organ and tissue miRNAs such as liver-specific miR-
122 [246,247] in plasma samples [170,248,249]. However, miR-122 was not 
detected in our urine samples from controls or CKD patients. Similarly, miR-208, 
a heart-specific miRNA [250], has been detected in plasma but was not found in 
urine samples in our laboratory or elsewhere [227]. 
 
The absence of detectable levels of systemic miRNAs in the urine supports 
the idea of miRNA being unable to freely cross the intact glomerular filtration 
barrier. If the systemic and urinary miRNA populations exist in isolation, specific 
cell types throughout the nephron would form the source of urinary miRNAs, and 
their expression might therefore be associated with biological function. 
 
An example is miR-126, that has been detected in plasma and serum of 
healthy individuals [170], and is known as an endothelial-specific miRNA [251]. 
Loss of miR-126 expression was found in plasma samples of DM patients [154]. 
In the present study, miR-126 was detected at low level in control urine samples 
and much higher level in the patients’ urine. A similar profile of miRNA expression 
was demonstrated for miR-29b. A number of reports have implicated members of 
the miR-29a/b/c family in the pathogenesis of renal fibrosis. It was demonstrated 
that under high glucose condition, TGF-ß1 decreases the expression of miR-
29a/b/c in tubular epithelium-like cells and podocytes, and that this was 
associated with increased expression of collagens I, III and IV [141,143]. Both of 
these miRNAs are particularly promising as possible biomarkers for the diagnosis 
of DN and will be the focus of Chapter 5. 
 
miR-212 is mainly known, until now, for its regulation and functions in the 
neuronal context [252] even if lately some studies have recognized a role in 
hypertension [253] and cardiac hypertrophy and autophagy [254]. It has similar 
mature sequences to miR-132, with which it shares a seed region, and is 
therefore predicted to largely overlap in terms of targets [252]. Both of these 
miRNAs, targeting the AMP-response element binding (CREB), were found to 
have a key role in the development and function of neuronal cells [255-258]. In 
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addition, loss of miR-212 expression was linked to disorders related to the brain 
such as anencephaly, Huntington’s disease and Alzheimer’s disease [259-261]. 
Up or down-regulation of miR-212 was also found in relation to different cancer 
types but also to cancer treatments [262-264]. In addition, work conducted by 
Ucar showed that both miR-212 and miR-132 were necessary for mammary 
growth in mice and highly expressed in the stroma, where they were targeting 
matrix metalloproteinase 9 (MMP-9) regulating therefore the epithelial-stromal 
interaction [258]. A recent paper demonstrated that miR-212/miR-132 were highly 
expressed in a mouse model of cardiac stress and in an in vitro model of cardiac 
hypertrophy suggesting that these play a key role in cardiac hypertrophy and 
heart failure [254]. 
 
miR-155 is mainly known as an “inflammatory” miRNA since it was first found 
within the exon of the B cell integration cluster (BIC) [265] and several papers 
found that this non coding RNA was involved in innate and adaptive immunity, 
inflammation and tumorigenesis [266,267]. miR-155 is up-regulated in 
macrophages and other immune cells by inflammatory cytokines, such as IL-1-ß 
via TNF-α, NK-kB or other Toll-like receptors (TRL) [268,269]. In addition, it was 
found that activation of miR-155 by pro-inflammatory signalling can also intensify 
macrophage activation [268]. Work conducted by Chenhe and colleagues 
showed that miR-155 has an anti-HBV effect by targeting suppressor of cytokine 
signaling 1 (SOCS1) and increasing innate antiviral immunity by promoting 
JAK/STAT signalling pathway [270]. miR-155 has also a role in the regulation of 
the inflammatory response in endothelial cells via angiotensin-II [271] and an 
increase of miR-155 was observed in human umbilical vein endothelial cells  
(HUVECs) treated with TNF-α [272]. Reduction of miR-155 expression was found 
in plasma samples of patients with ESRD in comparison to healthy controls [273].  
 
miR-200b, belongs to miR-200 family, is known to both have an high 
expression in kidney samples from patients with hypertensive glomerusclerosis 
and plays a role in DN and also in regulating the EMT by targeting ZEB1 and 
ZEB2, transcriptional repressors of E-cadherin [123]. miR-200b reduction was 
also detected in a renal fibrosis model of unilateral ureteral obstruction (UUO) 
[274] and confirmed in another study where proximal tubule cells where treated 
with TGF-β [275]. Opposite results were obtained by Kato in a study conducted in 
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glomeruli from type 1 and type 2 diabetic mice as well as in mouse mesangial 
cells (MMC) treated with TGF-β [147]. The same authors found also an increase 
of type IV collagen mRNA in MMC by miR-200b and TGF-β [147]. An additional 
role of miR-200b is the induction of hypertrophy and fibrosis in diabetic kidney via 
phosphatidylinositol-3-kinase (PI3K) activation by targeting Fog2, PI3K inhibitor 
[276]. 
 
miR-192 was shown to be detectable in serum samples [170], and this study 
and also previous publications from our laboratory showed that this miRNA is 
down-regulated in diabetic nephropathy [220]. More specifically, these data have 
shown that miR-192 is down-regulated by key fibrotic mediator TGF-β1 in renal 
proximal tubular epithelial cell [277] and exhibits pleiotropy in the kidney [278]. 
The pleiotropic role of miR-192 in renal homoeostasis and in the fibrotic kidney 
has been studied extensively [278]. Urinary levels of miR-192 were found to be 
down regulated in patients with IgG nephropathy [215]. Krupa et al. previously 
demonstrated a down-regulation of miR-192 in renal biopsies from advanced 
diabetic nephropathy patients and a correlation between low miR-192 expression 
and tubulointerstitial fibrosis and reduced estimated glomerular filtration rate 
[220]. Incubation of human renal PTCs with TGF-β1 in vitro decreased miR-192 
expression [20]. Enforced ZEB1 and ZEB2 (zinc finger E-box-binding homeobox 
proteins 1 and 2) are down regulated by miR-192 expression in PTCs and thus 
opposed TGF-β1-mediated suppression of E-cadherin expression, an early key 
step in TGF-β1-mediated renal fibrogenesis [220]. 
 
Down-regulation of miR-192 by TGF-β1 in PTCs and in kidneys from diabetic 
apoE (apolipoprotein E)-deficient mice and rat PTCs has also been reported by 
Wang et al., and linked to TGF-β1-mediated repression of E-cadherin [137]. 
However, the opposite was found by Kato et al. in mouse mesangial cells. This 
group showed that TGF-β1 increases miR-192 expression, and that repression of 
ZEB1 and ZEB2 expression by miR-192 facilitates collagen synthesis, enhancing 
matrix deposition and glomerulosclerosis [134]. 
 
 
Changes in urinary miRNAs levels may be reflective of pathologies in the 
kidney or urinary tract. Hanke et al. explored the possible use of urinary miRNAs 
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as a novel and robust technique to analyse small RNAs to detect urothelial 
bladder cancer [32]. They found that the RNA ratio of miR126:miR152 was a 
sensitive method of detecting this tumour [213]. Similarly, Snowdon et al. have 
found a decrease of miR-125 and an increase of miR-126 in urine samples from 
patients with low- and high-grade urothelial cancer [279]. The use of miRNAs as 
novel sensitive biomarkers was investigated in other pathologies such as 
myocardial injury [280], prostatic cancer [281], systemic lupus erythematosus 
[282] or hepatocellular carcinoma [283]. 
 
Many studies have reported that miRNAs play an important role in regulating 
glucose and lipid metabolism in diabetes, and their level in blood or urine reflects 
the disease process and predicts clinical course [284]. Argyropoulos et al. found 
that micro-albuminuria is associated with decreased levels of miR-323b-5p and 
increased urine concentration of miR-429 in patients with long standing type 1 
diabetes [164]. Interestingly, in another study, it was shown that miR-429 
correlates with the level of proteinuria and renal function in renal disease such as 
IgA nephropathy [215,285]. Analysing serum and urinary miRNAs from nephrotic 
syndrome children, Luo et al. found that miR-30a-5p, miR-151-3p, miR-150, miR-
191 and miR-19b were highly increased in the serum of patients compared with 
controls while in urine only miR-30a-5p was increased [19]. The concentration of 
these serum and urinary miRNAs decreased with the clinical improvement of the 
patients and they concluded that these miRNAs could represent potential 
diagnostic and prognostic biomarkers for idiopathic paediatric nephrotic 
syndrome [165].  
 
Hitherto, published studies have only sporadically focused their attention on 
the use of urinary miRNA detection for the diagnosis of CKD, and in each case 
detected miRNAs that had already been reported as being involved in renal 
fibrosis and CKD progression. For example, Szeto et al. studied patients who 
underwent kidney biopsy, excluding those with acute renal failure or active 
glomerulonephritis; and studied the urine pellet obtained after centrifugation at 
13,000 g [42]. These authors found that urinary miR-21 and miR-216a expression 
correlated with the rate of decline in renal function and risk of progression to 
dialysis-dependent renal failure and, more generally, the miRNA analysed had 
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different expression in the different diagnosis group analysed (IgA nephropathy, 
diabetic nephrosclerosis and hypertensive nephrosclerosis) [140]. 
 
microRNA expression in mesangial cells exposed to high glucose rather than 
TGF-ß was investigated by Wang et al. [43]. miR-377 expression was 
upregulated in human mesangial cells under those conditions, as well as in 
mouse diabetic nephropathy models in vivo. This miRNA was associated with 
increased expression of matrix proteins such as fibronectin and led to reduced 
expression of p21-activated kinase and superoxide dismutase, which enhanced 
fibronectin protein production [286]. Another study on mesangial cells showed 
that TGF-ß activates Akt by inducing the miR-216 and miR-217, both of which 
target phosphatase and tensin homolog (PTEN), an inhibitor of Akt activation 
[287]. 
 
To investigate renal expression profiles of microRNAs and their potential 
involvement in early diabetic nephropathy, Chen and colleagues induced a 
diabetic model in Dilute Brown Non-Agouti (DBA/2) mice [45]. Nine miRNAs 
(miR-1187, miR-320, miR-214, miR-34a, miR-762, miR-466f, miR-720, miR-744 
and miR-1937b) were increased significantly. While other 9 miRNAs (miR-1907, 
miR-195, miR-568, miR-26b, miR-703, miR-1196, miR-194, miR-805 and miR-
192) were decreased markedly in these diabetic mice [45]. These workers also 
found that miRNA-195 expression was negatively related to glomeruli diameter, 
mesangial score and extracellular matrix (ECM) accumulation, plus its inhibition 
protected mesangial cells from apoptosis and promoted the cellular proliferation 
in vitro. [288]. 
 
Wang et at. found that miR-10a and miR-30d, as well as other miRNAs in miR-
1 and miR-30 families, were relatively enriched in kidney tissue in comparison to 
other mouse organs analysed such as, heart, spleen, kidney, colon and lung [49]. 
Importantly, using both ischemia reperfusion-induced acute kidney injury and 
Streptozotocin (STZ)-induced kidney damage, animal models were able to show 
that changes in the levels of urinary miR-10a and miR- 30d occurred as a result 
of renal damage [49]. Furthermore, the substantial elevation of the urinary miR-
10a and miR-30d levels was also observed in focal segmental glomerulosclerosis 
(FSGS) patients compared to healthy donors [163]. Strong up-regulation of miR-
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21 in kidneys of mice with unilateral ureteral obstruction, and also in the kidneys 
of patients with severe kidney fibrosis, was established by Glowacki and 
colleagues [129]. 
 
The above suggests that miRNAs play an important role in the pathogenesis 
of diabetic nephropathy and in the initiation of renal glomerular mesangial cell 
dysfunction, and therefore miRNA can modulate the pathogenesis of diabetic 
nephropathy by affecting various different pathways. Most of the work described 
above was conducted in different cell lines and animal models, focusing the 
attention on miRNAs previously associated with disease. The approach taken in 
this study for the identification of a cohort of miRNAs that are up-regulated or 
down-regulated in the diabetic nephropathy takes into consideration the analysis 
of this noncoding RNA family in the urine of DN patients in comparison with those 
expressed in urine from healthy people.  
 
Preliminary analyses on control and patient urine samples confirmed that the 
miRNA could be readily detected by RT-qPCR. The final miRNA profiling 
experiment using RT-qPCR-based array, in addition to demonstrating that global 
miRNA expression can be analysed in urine samples, revealed multiple 
differences in miRNA expression in the CKD stage and eGFR levels.  
  
The results presented in this chapter identified miRNA for further study, and 
suggest that miRNA quantification might provide useful prognostic information for 
patients with diabetic nephropathy. The major finding was that expression of miR-
29b, miR-212, miR-126 and miR-155 was upregulated, and expression of miR-
200b and miR-192 was down-regulated in urinary DN samples.  
 
This work arrives at a different conclusion in comparison to all the work 
previously mentioned with exception of miR-192 down-regulation, as also 
reported by Krupa [220]. The data also imply that these changes in miRNA 
expression found in the experiment are very likely to be meaningful and will be 
fruitful for further investigations. Sadly, limitations in time and materials permitted 
only a detailed characterization of some miRNAs potentially important in this 
disease and unfortunately, it was not possible to validate any of the miRNAs 
identified in the array B.  
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In addition the relatively small sample size and the advanced CKD stage of 
the patients (Stage 3, 4 and 5) meant that the prognostic value of the data was 
limited. Larger validation analyses, including DN patients with CKD Stage 1 and 2 
will be required to evaluate the utility of urinary miRNAs in this context. Moreover, 
it will be useful to investigate the miRNAs expression in patients suffering from 
diabetes (T1DM, T2DM) and also other types of renal disease (IgA nephropathy, 
polycystic kidney disease, glomerusclerosis, acute kidney disease) to investigate 
the specificity of those miRNAs as biomarkers for DN. 
 
Investigation of the origin and function of these miRNAs will be the focus of 
Chapter 5. 
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Chapter 5 – Source and possible cause of miRNAs 
secretion in urine 
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5.1 Introduction 
 
Defining miRNA expression pattern by specific cell-type will help to clarify their 
function and involvement in the regulation or maintenance of physiological 
characteristics of various tissues. Thanks to Landgraf et al. it is possible to know 
cellular expression pattern for 51 miRNAs. Surprisingly only a few of them were 
expressed in individual cell types [289]. Comparing those data with the results 
obtained in Chapter 4 made it possible to have a general idea of miRNAs tissue 
localization. For example, an increase of miR-126 was identified in the 
cardiovascular system, miR-192 in the respiratory system and liver, and miR-155 
in the hematopoietic system, connective tissue and kidney. A limitation of this 
work is its reliance on cell lines rather then tissue. Unfortunately, results obtained 
from the mentioned work and also after a detailed literature search, were not able 
to clarify the tissue/cell line source for miR-29b, miR-212, miR-126, miR-155, 
miR-200b and miR-212 in the kidney. The first goal of this chapter was therefore 
to identify in which nephron tissue region and more precisely from which kidney 
cell type, those miRNAs were highly expressed.  
Because the pathogenesis of diabetic nephropathy (DN) is a multifactorial 
event that involves hyperglycaemia, hyperlipidaemia and hypertension [290], 
mechanisms responsible for the development and progression of this disease are 
not yet fully known. Inflammatory cytokines like TNF-α, INFγ, IL-6 may have a 
critical role in development of this disease [88]. Also haemodynamic and 
metabolic factors [291] such as vasoactive hormone pathways including the renin 
angiotensin system [292] or fibrotic cytokines such as TGF-ß or various growth 
factors including VEGF could be involved with diabetes nephropathy’s evolution. 
The second goal of this chapter was to incubate cells with different stimuli 
implicated in initiation of DN, and then analyse the expression of selected 
miRNAs in cell lines from various nephron segments and miRNA content in 
conditioned media.  
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5.2 Results 
 
5.2.1 miRNAs expression in different nephron sub-compartments by 
LCM  
 
LCM (laser capture microdissection) is a method for isolating target cells from 
multicellular tissue samples [293]. Using this technology, the cells of interest are 
visualised by microscopy while a thermoplastic transfer film is attached to a 
plastic cap lying on top of the cells. Laser energy is then transferred to the film, a 
polymer-cell complex is formed, and the cells of interest are removed from the 
sample section. The cells isolated by LCM maintain their morphology and their 
DNA, RNA and proteins remain intact. 
 
LCM was used to identify the sources of 4 target miRNAs found to be highly 
expressed in urine samples from diabetic nephropathy patients plus 2 miRNAs 
with significantly down-regulated expression in patients when compared to 
unaffected individuals.  
 
CD10 antigen is expressed at the surface of glomerular and proximal tubular 
cells, but not distal tubular cells (Figure 5.1.). Duplicate 6 μm sections were used 
to isolate glomeruli, proximal tubular and distal tubular cells from five renal 
biopsies by LCM. Cells of interest were identified on the basis of morphological 
characteristics. The staining process can result in tissue cross-linking between 
nucleic acid and protein that could interfere with RNA analysis. Therefore, two 
consecutive biopsy sections were cut from each sample, one of which was 
stained with anti-CD10 antibody while the other one was used to isolate the 
above-mentioned sub compartment’s nephron. Subsequent RNA isolation was 
carried out using a dedicated extraction kit as describe in 2.2.1.2.  
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Figure 5.1. Isolation of nephron sub-compartments using LCM 
Images captured using the Arcturus Pixcell IIe system on two renal biopsy tissues. A and 
D: The 6μm renal sections were stained with antigen anti-CD10 to easily identify the 
glomeruli and proximal tubular cells. For downstream analyses, glomeruli, proximal and 
distal tubules were isolated from a contiguous, unstained section using the sections 
outlined by staining as a guide. The remains of renal biopsy tissue following B and E: 
glomerular extraction, C: proximal tubular extraction and F: proximal and distal tubular 
cells. 
 
 
Expression of putative disease-associated miRNAs (see Chapter 4) was then 
analysed in glomerular, proximal and distal tubular RNA extracts. As seen in 
Figure 5.2, expression of miRNAs -29b, -212 and -126 was greatest in the 
glomerulus, with 30-fold greater glomerular expression of miR-126. Expression of 
miRNA-155 was approximately equally expressed in each nephron sub-
compartment, miR-200b was significantly greater in the distal tubule section and 
miR-192 expression was highest in the proximal tubule (Figure 5.2). 
A! B! C!
D! E! F!
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Figure 5.2. miRNA expression in nephron sub-compartments 
A-C: Greater levels of miR-29b, -212 and -126 expressions were detected in glomerular 
extracts, for miR-126 this reached statistical significance (p = 0.0056). D: miR-155 was 
equally expressed in all nephron regions. E: miR-200b expression was statistically higher 
in distal tubular samples (p = 0.0008). F: miR-192 was expressed principally in the 
proximal tubule. Glomerular, proximal tubular and distal tubular subcompartments were 
isolated from 5 renal biopsies of healthy individuals and miRNA expression analysed by 
RT-qPCR. One-way ANOVA analysis was carried out with Tukey’s multiple comparison. ∗ 
p ≤ 0.05, ∗∗∗ p ≤ 0.001. 
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5.2.2 miRNA cell line expression 
 
The architecture of the nephron is complex and the nephron is composed of a 
variety of cell types with specific functions. The Bowman’s capsule contains 
parietal epithelial cells, podocytes that cover the outer aspect of the glomerular 
filtration barrier, fenestrated endothelial cells that are in direct contact with blood, 
and mesangial cells that sit between the capillary loops. The renal tubule is made 
up of the proximal convoluted tubule (proximal tubular cells), loop of Henle 
(simple squamous epithelial cells) and distal convoluted tubule (distal tubular 
cells). In addition the renal interstitium is composed of renal support cells, and 
fibroblasts are the most abundant [294].  
Glomerular, proximal tubular and distal tubular nephron subcompartments 
were isolated by LCM, but isolation of 3-dimensional structures from sections 
cannot be absolutely precise. Therefore cell-specific miRNA expression was 
investigated in renal cell lines HK-2 (immortalized proximal tubule epithelial cell 
line from normal adult human kidney), conditionally immortalized podocytes and 
glomerular endothelial cells (CiGEnCs), and fibroblasts. 
Unfortunately, I did not have the possibility to analyse miRNAs expression in 
other cell type such as mesangial cells, parietal epithelial cells or distal tubule 
cells.  
As shown in Figure 5.3, cell line miRNA expression data supported the 
observations from LCM-isolated nephron regions (Figure 5.2). miR-29b and miR-
126 was significantly increased in CiGEnC, while miR-212 expression in 
fibroblasts increased significantly in comparison with other cells. The magnitude 
of miR-155 expression was similar in each cell line. miR-200b was most highly 
expressed in HK-2 cells and podocytes, while miR-192 was expressed primarily 
in HK-2 PTCs (Figure 5.3). 
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Figure 5.3. miRNA cell line expression 
Expression of 6 putative disease-associated miRNAs was analysed by RT-qPCR in HK-2, 
fibroblast, podocyte and CiGEnC cells. (A) Elevated miR-29b expression in CiGEnC in 
comparison to podocytes (p = 0.03). (B) Abundance of miR-212 was found in fibroblast 
cell line (p-value < 0.001). (C) Statistical increase of miR-126 expression was detected in 
CiGEnC in comparison to the other cell lines (p-value= 0.0002). (D) Similar expression of 
miR-155 across the different cell lines. (E) Increase of miR-200b in HK-2 and podocyte 
cell lines (p-value < 0.001). (F) miR-192 was mainly expressed in HK-2 cells (p-value < 
0.001). One-way ANOVA with Tukey’s multiple comparison test. Stars are representative 
of the Tukey’s multiple comparison test value; ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. 
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5.2.3 Glucose-dependent expression of miR-29b and miR-126  
 
The data generated to this point describe a cohort of miRNAs that are 
differentially expressed in urine samples from diabetic nephropathy patients and 
show varied nephron sub-compartment localization. miR-126 and miR-29b were 
both highly expressed in urine samples from diabetic nephropathy patients, 
microdissected glomeruli and CiGEnC. Further analyses were then carried out to 
analyse if these expression changes were dependent on glucose concentration.  
miR-29b and miR-126 expression was analysed in CiGEnC treated with 5.5 
mM glucose (homeostatic glucose), 20 mM L-glucose (osmotic control) or 20 mM 
D-glucose concentration (hyperglycaemic glucose). No statistically significant 
difference was observed (Figure 5.4).  
 
	  
Figure 5.4. CiGEnC treated with different glucose concentrations 
CiGEnC were treated with 5 mM glucose (LG), 20 mM L-glucose (OC) or 20 mM D-
glucose (HG) for 4 h, following by RT-qPCR to detect miR-29b and miR-126. Average 
values from three samples ± SEM are shown. No statistically difference was observed. 	  
 
The effects of glucose on miR-29b and miR-126 expression was also 
investigated in the kidney of non-obese diabetic (NOD) mice that have a 
susceptibility to develop type 1 diabetes following spontaneous autoimmune 
destruction of β cells. After the beginning of the hyperglycemia, the survival of 
these animals is dependent on insulin treatment. A summary of the detail of the 6 
diabetic and 6 non-diabetic NOD mice analysed are shown in Table 5.1. 
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 Diabetic NOD Non-diabetic 
NOD 
p-value 
Sex (Number of female) 5 4  
Age (weeks) ± SEM 16.47 ± 2.83 13.12 ± 2.41  
Blood Glucose (mmol/l) ± SEM 30.07 ± 9.87 5.6 ± 0.57 0.03 
 
Table 5.1 Data for NOD mice analysed 
 
 
As shown in figure 5.5, no significant differences in expression of either miR-
29b or miR-126 were observed between diabetic and non-diabetic mice.  
 
 
 
Figure 5.5. Expression of miR-29b and miR-126 in diabetic and non-diabetic NOD 
mice. 
6 RNA samples from diabetic NOD mice and 6 from non-diabetic NOD mice were used to 
evaluate miR-29b and miR-126 expression by RT-qPCR. No statistical difference was 
observed.  
 
 
To further study the possible mechanisms underlying the increase in specific 
microRNAs that I had detected in urine from DN patients, I examined miRNA 
expression in a cohort of patients with polycystic ovarian syndrome. These 
samples were obtained as part of a collaboration with Dr Aled Rees, Consultant 
Endocrinologist, and are part of an on-going study of endocrine and metabolic 
parameters in patients with polycystic ovarian syndrome in whom insulin 
resistance has been confirmed by laboratory studies of glucose and insulin 
metabolism (Dr Aled Rees, personal communication). Baseline characteristics of 
these patients are summarised in Table 5.2.  
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 PCOS  Control 
Number 17 15 
Age (year) ± SEM 30.76 ± 1.48 29.33 ± 1.60 
BMI ± SEM 29.77 ± 1.53 28.35 ± 1.71 
Waist ± SEM 91.29 ± 3.6 85.47 ± 3.7 
WHR ± SEM 0.81 ± 0.01 0.82± 0.03 
Hip ± SEM 111.3 ± 3.97 103.7 ± 3.08 
Glucose ± SEM 4.7 ± 0.10 4.68 ± 0.22 
Table 5.2 Control subject and patient data 
Mean and SEM values for selected variables in PCOS patients and unaffected control 
subjects. 
 
 
 
Figure 5.6. miR-29b and miR-126 expression PCOS patients and controls 
Expression of miR-29b and miR-126 was analysed by RT-qPCR in urine samples from 17 
PCOS patients. No statistically significant differences were observed. 
 
 
No statistical significant difference was observed in miRNA expression 
between patients and controls (Figure 5.6). 
These data suggest that the increase in miR-29b and miR-126 detected in the 
urine of diabetic nephropathy patients with decreased eGFR is not related to 
systemic insulin resistance. Having also demonstrated that in the kidney, these 
microRNAs are expressed almost exclusively in the glomerular endothelial cell, I 
next evaluated their synthesis and release by glomerular endothelial cells 
subjected to injurious stimuli known to be relevant to the glomerular insult that 
occurs in diabetic nephropathy. 
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5.2.4 CiGEnC characterization   
 
The conditionally immortalised CiGEnC cell line used in this study was initially 
characterised by detection of endothelial cell-specific markers [196]. To ensure 
these characteristics had been maintained through long-term storage, CiGEnCs 
were analysed following culture at the non-permissive temperature of 37°C for 5 
days for selected endothelium-specific and matrix-related genes. RT-qPCR was 
used to quantify expression of platelet endothelial cell adhesion molecule-1 
(PECAM1), vascular endothelial growth factor receptor-2 (VEGFR2), Von 
Willebrand factor (vWF) and plasminogen activator inhibitor (PAI-1). As shown in 
Figure 5.7, CiGEnC expressed these specific endothelium markers, while HK-2 
and podocytes did not. 
 
Figure 5.7 Expression of endothelium-specific and matrix-related genes in 
podocytes, CiGEnC and HK-2 cells.  
Expression of endothelial specific markers VEGFR2, vWF, and PECAM-1and matrix 
related gene (PAI-1) were analysed by RT-qPCR using SYBR green chemistry. 
Upregulated expression of each gene was seen in CiGEnC compared to HK-2 cells or 
podocytes. One-way ANOVA with Tukey’s multiple comparison test was used. VEGFR2 
p-value < 0.0001, vWF p-value < 0.0001, PECAM-1 p-value = 0.0012 and PAI-1 p-value 
= 0.0018. Asterisks are representative of the Tukey’s multiple comparison test value; ∗∗ p 
≤ 0.01, ∗∗∗ p ≤ 0.001. Expression data were normalised to expression of the reference 
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
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5.2.5 CiGEnC treatment with different cytokines stimuli 
 
While persistent elevation of systemic glucose concentration underlies the 
pathophysiology of DN, the exact molecular and/or cellular mechanisms have not 
yet been characterised. Cytokines have also been strongly implicated in the 
development of diabetes, playing a significant role in the progression of 
neuropathy, retinopathy and nephropathy [88,295,296]. Pro-inflammatory 
cytokines implicated in the pathogenesis of diabetic nephropathy include 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). 
Others disease-related cytokines include the fibrotic mediator transforming 
growth factor (TGF-ß), and the potent inducer of vasopermeability and 
angiogenesis, vascular endothelial growth factor (VEGF).  
To investigate these stimuli, CiGEnC were maintained at a non-permissive 
temperature of 37°C for 5 days, growth-arrested for then cultured in 5mM or 
25mM of glucose in the presence or absence of VEGF (20ng/ml), TNF-α 
(10ng/ml), TGF-ß1 (1ng/ml) or IL-6 (1ng/ml) for 24h. Total RNA was isolated from 
cells and conditioned culture medium, then expression of miR-29b, miR-126 and 
miR-191 (used as reference gene) was detected by RT-qPCR.  
Figure 5.8 shows that statistically significant down-regulation of miR-29b 
expression was observed following incubation with 25 mM glucose plus VEGF, 
TNF-α and TGF-ß1, but no change was seen in the presence of IL-6. Similarly, 
miR-126 expression decreased in all cases except following IL-6 addition.  
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Figure 5.8. Relative expressions of miR-29b and miR-126 in CiGEnC cultured in 
high glucose +/- selected cytokines.  
Confluent CiGEnC were cultured for 24 h in control medium with 5 mM glucose, or in 25 
mM glucose, together with: VEGF (A and E), TNF-α (B and F), TGF-ß1 (C and G) and IL-
6 (D and H). Downregulated expression of both miR-29b (A-D) and miR-126 (E-H) was 
shown by RT-qPCR analysis with all cytokines except IL-6. miR-191 was used as 
reference gene. One-way ANOVA analysis with Tukey’s multiple comparison test was 
used, miR-29b: VEGF, p = 0.02; TNF-α, p-value p < 0.0001, TGF-ß1, p = 0.018; miR-
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126: VEGF p = 0.0002, TNF-α p = 0.01 and TGF-ß1 p = 0.01. ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ 
p ≤ 0.001. Error bars represent SEM, n=4. 
 
Figure 5.9 shows a significant increase in miR-29b expression in the 
conditioned medium of TGF-ß1 -treated CiGEnC at both glucose concentrations. 
Statistically significant up-regulation of miR-126 was also seen in 5 mM glucose 
medium in cells cultured with 10 ng/ml TNF-α. By contrast, miR-126 expression 
was significantly downregulated in the presence of IL-6 and 25 mM glucose. 
The above data allowed direct comparison between miR-29b and miR-126 
expression in cytokine-treated cells cultured in homeostatic and elevated glucose 
and the conditioned CiGEnC medium from these experiments. Expression of 
miR-29b following TGF-ß1 treatment, and miR-126 in the presence of TNF-α, 
was significantly decreased in CiGEnC and significantly increased in conditioned 
culture medium (Figures 5.8C and 5.9C and Figures 5.8F and 5.9F). Significant 
down-regulation of miR-126 expression was observed in conditioned medium in 
the presence of IL-6 (Figure 5.9H). 
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Figure 5.9. Relative expressions of miR-29b and miR-126 in CiGEnC conditioned 
medium with high glucose +/- selected cytokines. 
Confluent CiGEnC were cultured for 24 h in control medium with 5 mM glucose, or in 25 
mM glucose, together with: VEGF (A and E), TNF-α (B and F), TGF-ß1 (C and G) and IL-
6 (D and H) for 24h. Expression in conditioned culture medium was analysed by RT-
qPCR for miR-29b (A-D) and miR-126 (E-H). miR-29b expression was upregulated 
significantly in TGF-ß1 -treated CiGEnC medium (C; p = 0.0003). Upregulated 
expression of miR-126 was detected in medium containing TNF-α (F; p = 0.008), while 
miR-126 expression in medium containing IL-6 was downregulated (H; p = 0.02). ANOVA 
with Tukey’s multiple comparison test was used: ∗ p ≤ 0.05, ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.001. 
The error bars represent SEM, n=4. 
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5.2.6 miR-29b and miR-126 association with exosomes and AGO2 
 
Data from chapter 3 showed that both miR-16 and miR-192 were associated 
with both AGO2 protein and exosomes. Detection of miR-29b and miR-126 was 
carried out in extracellular vesicles and supernatant previously isolated (see 2.3- 
2.4 and 3.2.2.2-3.2.2.3).  
Figure 5.10A shows that miR-126 was detected in association with exosomes 
a mechanism by which miRNAs can evade RNase degradation. The RT-qPCR 
analysis in Figure 5.10B in urine samples immunoprecipitated with anti-AGO2 
antibody showed that this transcript was recovered in significantly greater 
abundance in the Ago2 immunoprecipitation than in the negative control mouse 
IgG.  
 
 
 
 
 
 
 
Figure 5.10. miR-126 association with exosome and AGO2 protein 
miR-126 was detected using RT-qPCR from extracellular vesicles fraction obtained by 
ultracentrifugation. RT-qPCR analysis of miR-126 showed that it was present in the 
extracellular vesicles and mainly in the exosome fraction (A). This miRNA was then also 
detectable in the ultra-centrifugation supernatant (B). Immunoprecipitation (IP) from 10 
urine samples using anti-AGO2 antibody detected AGO2, with negative normal mouse 
IgG. RT-qPCR detected increased miR-126 in Ago2 immunoprecipitates in comparison 
with untreated urine input and mouse IgG reactions with p-value=0.02 (C). Error bars 
represent mean ± SEM. 
 
 
Similarly, miR-29b was also detected both in association with exosomes and 
with AGO2 protein. Higher expression of this miRNA was found in the exosome 
fractions in comparison to the other fractions containing extracellular vesicles. 
Surprisingly, detection of miR-29b in the supernatant obtained after ultra-
centrifugation showed a Ct=38 suggesting that this miRNA is mainly expressed in 
the extracellular/exosome fraction. Analysis of this transcript was also carried out 
in the urine sample immunoprecipitated with anti-AGO2 antibody. Considerable 
variation in Ct was found across the 10 samples, in 6 of them miR-29b was not 
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detectable (Ct around 39) while in the others 4 the Ct was around 33. This 
difference is also observable by the large error bar for the relative expression in 
Figure 5.11. Similar results regarding this miRNA were found by Arroyo et al. in 
plasma samples [170].  
 
Figure 5.11. miR-29b association with exosome and AGO2 protein 
Exosome and extravesicle samples were obtained after ultracentrifugation and used to 
detect miR-29b by RT-qPCR. Data show that miR-29b is mainly expressed in the 
exosome fraction in comparison to the other one (A). No statistical variation for miR was 
identified in 10 urine samples immunoprecipitated with anti-AGO2 antibody. IgG were 
used as negative control (B). Error bars represent mean ± SEM. 
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5.2.7 In silico analysis 
 
miRNAs act as post-transcriptional regulators of gene expression by targeting 
mRNA targets and causing translational repression, with the potential to affect 
multiple biological pathways. Predicted and validated miRNA-target interactions 
were analysed in silico by Cytoscape with CyTargetLinker [205]. This software 
was used to visualise predicted targets for miR-29b and miR-126. Target 
predictions were cross-referenced with results from four databases: TargetScan, 
Microcosm, miRTarBase and miRecords. 
In Figure 5.12, miRNAs and miRNA-targets are represented as nodes and 
intermolecular interactions as lines connecting these nodes. Using this software it 
was also possible to identify mRNAs (in orange) that could be bound by both 
miRNAs. Table 5.3 lists mRNAs that are potential targets of both miRNAs. 
 
 
 
 
Figure 5.12. Extended miRNA networks for miR-29b and miR-126 
miR-29b and miR-126 are shown, respectively, as red and yellow circles with target 
mRNAs represented as yellow (miR-29b) and green (miR-126). Orange circles represent 
mRNAs targeted by both miRNAs.  
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C1orf131PAQR3MRPS18C
RBFOX2
SORL1
VIP
ARSFALS2CR7
TMEM151B
SUV420H1LGI2
DAXX CENTD3
GGA1
GCSH
SLC1A2
NP_001075144.1 MAD2L1BP
NP_001038941.1 
ZMYM2
CD248SIKE1NLP_HUMAN
ENPP2
FZD4
SPSB4
ACCN2
FGD2
OR52I2
PIK3R1SBNO1LAMTOR1
KDM5C
TRPM8
RNF144B
PCDHA5
CCAR1
EXOSC10
SREBF1
AKAP2
MLXIP
ARMC8
ESD
CACNA1B
IL23A
SLC35B3
STRN4
OSBP
CCDC88A COL4A4
ZNF524
ROD1EPS8L2
MIF4GDPIGB
C3orf21
ZBTB46DTWD1
TDRKHDMDCHMP6
CNIH
MXD1
RHAG
C5orf15
ZBTB43
EEFSEC
TYMS
C11orf31
SLC7A4
MED28
ZDHHC5
TTC21B
FAM101B
51726
ZNF671HOXC13COL21A1
FRAT2ANK1
SLC6A14
FKBP1A
CA2 ARNT
GOLGB1
SLC30A3
PGAP2LEPRE1
1789
EDG6
XKR6
Q8NAG9_HUMAN 
CMTM5
SGK494
NAV2
VGLL1
COL6A2ELF2
8202
NASP
1788
8115 EDF1
NLGN3
LAMC1
KIAA1199 USP34
FOXO4
NR3C1
C5orf13ZFAT1COL15A1
FUT10
YWHAE 2244
GPATCH3ADAMTS18
ARL4A
ZC3HAV1L
1021
SUV420H2
EPHA10
RMND5AMAPRE2
DTWD2
SYT7
ADAMTS7
XKR7
TRIM37
NAV1
CNN3
CTSE
RNF138
MLF1
SPTY2D1
STK19
CRISP2 HLXB9KPNB1
PDGFB
SIDT1KIAA0895L
C9orf86 BTG2
NKAIN1
FCGR2A
ZNF438PTHLH
C6orf204
NNMT
AQP11
KBTBD8
WWTR1
PTRF
LRCH3
SHROOM2
INTUHN1
SLC12A8
VPS25
CTPS
SH3PXD2B
PDZD3
MAP3K2
KIF26B
COL4A6
ZNF750FSCN1
DAAM2
FCRLA
PIK3C2B
ZNF496
SEMA5BLOC100507421
LTBRFAM126B
MAFG
GK5
ADAMTS19
TMEM183A
NRBP1AR P19
KIRREL
CEP68 C5orf24
XKR8
VHL
CDK2AP2
DDX46
EED
SCN7A
RYBP
RHOBTB1
ADAMTS9HMGCS2
NSUN3
SAP30L
CDCP2AMOT
CLRN3SYPL2
NUP160
PCGF3
C1orf226
UBFD1
MPST
PCDHA9
AIM1
KCNJ12
DCLK3
RFX7
MTMR4
GINS2
HLF
DIP2BRNF150
C5orf14ID1
CUEDC1
DPYSL2
NP_001073935.1 
LPPR4
ELL2
SNX5
CSPG4
POMZP3KLF4
PCDHA4
SETD3IER5L
METTL21D
GLIS3
G6PC
CLEC4D
C5orf33
IREB2
ZC4H2
ADPRHL2SNIP1
SLC22A7GOLPH4
NP_001035364.1 
WTAP
Q6A1A2_HUMANPCDHA7
MOG
FERMT2
USP31
WDFY1
PLXNA4
CHFR
RBCK1CXorf29
ARFGEF2CEACAM1
TRO
LYSMD1SH3BP5L
PAG1
FAM109BELMO2
SIAH3AICDA
BDH1
TNFRSF1A
PDGFC
KREMEN2
BCL2L2
TSPAN14
BBC3
RARB
TRPC6 TM7SF2
KCNMA1
Q96MC4_HUMAN 
ALOX5AP
HNRNPUL1
C16orf72
PPARD
RAB40C
ZDHHC21
KDM2A
TGM2NARF
UBE2K
AMFR
FREM1
PCDHA11
MBLAC2
ZNF133
ZNF518B
BSDC1
LSM14B
C6orf98
RAB14
SCAF11
SURF2
TFEB
AP4E1 CPT2
TADA2B
STAMBPDTX4
FBXW7CSF1R
MTSS1LVPS13C
PI15
KCTD20
SLC39A9
ARRDC3RNF19A
SNRKDDX56
IL32TRAF3
CLMN
C18orf62
C1QTNF6
SBF2
NFAT5
C1orf184
IGFBP6
FAM176ARPS6KB2
SLC25A2ZCWPW1
ULK2
USP42
Q8N7E7_HUMAN
IMPDH1AMMECR1
PSMD7
MARCH1
AKT3
TGFB3
C6orf129
MAP4K4
RNF152
CLIC1EML4
SLC25A15
AQP4
NCR1
PTP4A1PCDHA13
KCNIP2
KIF26A
PPP1R15B
CDC42SE1
BAK1
FAM70AKCNH7
SH3GLB2
UBE4B
DCAF12L1
HTR7
BCAT2
TAP1
NMNAT1
PCDHA12
KIAA2018
SH3PXD2A
GPR20
SUB1
BMF23368PCDHA8
CALM1
PHF14
SRCRB4DOL5A3C9orf92
TYW5
SMTNL2
HPGD
KCNRG
CCNYL1
GGPS1
1281 GSTA4
TFEC
PGAP1RIC8A
SCTR
ACBD5
MBD3 FAM123B
ZFP36L1MCA2_HUMAN
PAPOLG
HDGF
XR_019038.1
ARF5TXLNG BRWD3
SCAI
SETD5NCOR2
ZNF346
HMGCR
RHCGCNOT8
NEBLOTUB2
COL5A2
ISG20L2
OSBPL6
STAG2
RHBDD1
PDIK1L
HMGN3
FEM1B
TIMM8B
MESTGGCT
NAP1L3
ERAS
NCKAP5LUPK1BABHD4
MTCP1
CAMLG
RIOK3
DSC2ADSL
ISLR2CCDC117
CAMKK2
BCORL1
LPAL2
OR6Q1
LOH11CR2A
RAB30
CDSN
TMOD3NDS 1
Q9BVH8_HUMAN
MOBKL1A
ZNRF1
ANTXR2
REPS2
CCNE1
DLX5
TRIM9
ALKBH3
NP_872368.2
SNX11
PRR6
RAET1G
ANKRD52
STAT3
MAP6
C1orf135
NP_683701.2UMPS
SVEP1
OLFM1 UMOD
C2orf88BIRC2
BRMS1
PLP1ZDHHC15PEAK1 HRH2
NP_060505.1GSG2
C6orf168
FAM131B
NP_001073985.1 
FAM124A
TMEM33
ABHD7MGA
IFI30CRMP1
RLIMVTA1
COL5A2
DCP2
NPAS3
TSC22D3
IFNG
FOXN3EHMT1
ENAH
WWC1 GAB1NP_001034869.1 
EIF2S1EML6
ARD1AANKRD57
C20orf112
C12orf65
IFFO1
80312
SPATA2L
C1orf74
CHIC2
CAPRIN2KPNA4SETDB1
PHF21ACOMMD2
MAZ
ADAM19
JAZF1
CDY1
RIOK1
FAM83G
VAMP7
SCMH1
PHYHD1
RPUSD1
IGHV2-5IL10RB
PER3
HMCN1 CANXGRWD1NCKAP5
FBP1DCUN1D5
NFIB
TSPAN8
ING3
ZNF396DYNLRB1
RAB6BVPS36
CLK2
NKTR
MFAP3HDAC4
DOT1LITGB1
CAPN7
MAST4
SCAMP5
RNF214IDE
C17orf39
ANXA5MIER3
OTUD4CYCS ZHX3
FBXO41NP_775949.1
LNPEP
FAM53C MAPRE1
LRRC29 TRAF5
PALM2
ZNF167
XPNPEP1
PXDN SKI
CDCA42266 ETV4
SLC5A8
USP6NL KIAA1913
ZFX
CBX1 FMO1SERPINA4
ARHGAP19HSD17B6
RCOR1
FANCE
SARM1
C16orf88DNAJB7
MTF1
USP29
GDA
FAM167AHMGCS1
CNR1
ICOS
USP36
PALMTRIB2
ZNF385C
DLGAP2RND3
COL22A1
Q9UFV3_HUMAN
LPPR5
MBTD1
APP
I 17 D
LMLN
C10orf26
SLC37A1
GPR63
IL24
CCDC132
CCNDBP1AKAP10
CDC7
CD276
NFATC2
C11orf41
HBEGF
TMEM176ATTC14
ZNF469
RASAL2
DENND5B
A3QJZ6_HUMAN
ERP44
SAMD13
MANEALEMP2
LAMA2
TTLL11
HNRPL
ANKRD13B
RFWD2
BTG1
STX17
LENG9MLLT11
JOSD1
GPCPD1
EHD2
IRX1DPF1THRAP4
CPNE8
CAMSAP1L1
DSG3
DYNLT1COL16A1
TRIM7
ATAD5
DGKD
FBXL20PMP22SP L2BPTPN1
ITIH5
TBC1D7
TANC1PEX11G
XPO5 KDM6BCAV2
BRWD1HOXA10
COL24A1
C16orf77
SYT2
TAF11
C11orf30
PRRC2C
PRRG3
RTKN
TLR10
KR261_HUMAN
TCEA3HIPK3
MCTS1
TIGD4
TUBAL3 PARP16
Q8WUP8_HUMAN 
KRT84
SLC6A4
C10orf18
C10orf95
PDCD2
NDUFB6
PHOSPHO1
CACHD1
SEMA6D
WHSC2
RASGRF2
RBPJ
SLC9A6
C1QC WDR70
CNTNAP3
ZNF365
RAB26
PRRG2LATH_HUMAN
PCDHB2
FAM130A2
TNFRSF11B
NP_001001436.1 
SPP1
FBXO33ACYP1
TAF1
ZNF28
NP_079413.3
CXCL12
MAPKAP1
TMEM69
HIST1H2AK
A1L4H1_HUMANHCCSDDX5
PKD2
LSM7
OGFOD2C20orf28
NP_954697.1RANBP3L
YIF1ANIF3L1APOA4
CKMT2SUV39H2SLC24A3
PRICKLE1
C1orf201
ABCA12
5756
IARS
GFOD2
HSPA1B
AMT
WNT9A
FOLH1
LOC644994
CUTC ANKRD44
C7orf10
CLEC9A
TCF7L2TRM6_HUMANHOP_HUMAN
ANKS1A
ELL3CCDC71
DSCR8
EZH2
Q9Y2I9_HUMAN
PTPN21
HIPK4
ANGPTL6
SUSD4
FAP
ZNF650
PGR
NPAT
METTL6
BRUNOL5
ACOX2
BARX1
TPD52L1
C9orf131 IRX2
BTBD2
ALG141398
ANKRD9 HAS1
RGS16 6657PCDHB1
NP_061900.1
DHH
MDH1
NP_612147.1RAI14
GALNT11
PTPN9
MT-CYB
NP_612362.2
FAM124B
SHMT2HNRPM
CXorf26
RPL27AAMY2B
ZUBR1CXCR4
SPAG11A
GAPVD1
TRIM3 CHGAANKS1B
WRNIP1
THAP9
PQLC2
SLCO5A1
26207
5296
C10orf35
CD84GNRH1
CENTG1
SACM1L
TXNDC8SUSD1
FAM3B
CSHL1
LEO1
RPRML
ELOVL5
GRM3IFIT2NP_665806.1
NFKBIA
C9orf78
CRISP1
ADAM7
NISCH
LDHAL6B
TMEM161B
CCDC83
OR51S1 FXR2
CCDC5
IDH3G
DDX27ZC3H14
51162
FCRL5ZNF613GDF10
VDAC2NP_997260.1
DHX1
SGK3 TRGV8ADAM23
COQ4
SNX12CCDC18
HP1BP3
PPFIBP
Q658K6_HUMAN
GNL3L
RASGEF1C
TMED1
AKAP14
NT5DC4
FKBPL
PIK3C3
SUZ12KLHL4NP_115813.1 CENTD1
PLEKHG3
PPAPDC3
5778
KIAA1946
C1orf94
OR8U1
ZPBP2
ADCK1CCDC22
TELO2
KIAA1305IL13RA1
LRCH4
DCST1
ALS2CR2
7412MATN4UBR1
PHACTR1
Q6ZRX0_HUMAN
CCR8
SLC7A3
OTC
HDAC6
PMM1
SART1ZNF219
LXN
NR_003239.1
USP54
ATP5J2
TM9SF2
ANAPC11
CR1 CRHOPRM1
AFPEEF1A1
TNFSF11
Q6ZS52_HUMAN
PRTFDC1
KLHL31
CDKN2AIP
KANK2
PLCZ1
GOLPH3
ZRSR1 DCG13_HUMAN
IRF5
DIAPH1
PRY_HUMAN
TCEAL5CSTB
LTB
OR51B6
ZNF536
ATP9A
GPR151
FAM110ARPRM
SOX17
SEC13C9orf68
ANAPC1
TLN2
TCEAL8 AEBP1
CHST9
VPS54
CRKL
KCTD4
SLC39A6
Q9P1R7_HUMAN
FAM22BSLC16A8
WIBG
THUMPD1QDPRPCDH9
TXNRD2
CCL2
ICAM4
MAOB
NP_001073990.1 
5998ZADH2
TBCC
RASGEF1C
BMP8A
PCDH7ORC6L
FUNDC1
EPS15L1
SMARCAL1
ZNF599PSL2_HUMAN
MYO1B
FBXO25
NP_057583.2
PTMA
GSG1
F8A1
PRR8
ZNF738
CD72
PSMD5
ARID4B
85414
NOB1
CCT2
NP_981967.1
ZNF462
CASKSGTA
SFTPG
DUSP8
STOML1NPR2
PRELID1
RASSF2Q8IXE7_HUMAN
MBNL2
THAP4
EPSTI1
HSPA4LTPO
ADM
GTF2B
PIM3
STON1
ARMCX1C MSAP
ANP32B
HMOX2
PRKACG
PHTF2
OR51J1
FAM26B
PARP9
BUB1B
HES2
FAM108B1NANOS2
ADAMTSL2
C11orf67
TFDP1
ANKIB1
KLK14
SATB1
ITPR1
LYNX1
C15orf21
FAM22G
RXFP1
SLC9A6
SYDE2
RGS7
HGSNAT
CHD1L
C20orf85
PDGFA UXS1
HLX1 C15orf24
EIF2AK2
OPA3 ATP6AP2
UBQLN2TRAV13-2
NP_997306.1
C10orf96
FERD3L
SAMD11
TRGV1
10461
HERPUD1
STX8
TM6SF1
GBA2FHAD1
DJBP_HUMAN
Q9H8A7_HUMAN
MCOLN3
CCDC39
CCDC59MRPL43
CYSLTR1
SLC6A9ZNF212
SIPA1L2KRTAP20-1C14orf145
C14orf39ME3
PDSS1Q9Y2A2_HUMAN
ERBB3
TRAF7
ZSWIM2
RTN4RTMEM165
IGKC
TRIO
GALNTL4
TESC
FARP1
Q5TBN0_HUMAN
RASD1
GJA7
DEFB125
NPC2
PARP1
ING4
MCF2
ATF3 PDZRN3DYRK4
TSPYL2
IL21R
ZNF238
ZNHIT2
KISS1R
KIAA0907
SMARCA1
ATP6V1B1OR4C3
TTC6
AAMP
MPHOSPH6
RER1
KRTAP19-3
DNM1L
IL31 SLC30A7
TCEAL3 AHNAK2
WDR8 MYT1
HPDL
ABCC10B3GALTLMAGIX
DUSP27
TR112_HUMAN
NP_872380.1PLP2C20orf26
TLR9CLUL1
TSGA2
CYB5R2 SPAG17NSUN6TRAV41
LUZP4FKBP7
PCDHB11HTR2C
CHD6
FGFR2
FARSA
EFHD2
GPR39
ENOX1
HLA-DRB1
SLC7A5OR5D16
PRTN3
SLC15A4
OR2M3CAPN3
Q5FWF1_HUMAN
VPS37D
MAGEE1
Q96MU6-2
VAV1
GPR115
TMEM126B
HTR4PLXNB2
ISOC2
MCM5
SHH
C16orf44
10769
CNTNAP4PTPRB
PANK4
THAP6
161742
CACNA1D
LOC731944
PSMB9
DEPDC4
CIZ1
FARP2DDX25
SFRS11
ATP5D
BAD
SOX30ZNF169 LRRC36
10043PARP10
FCGR1A
C8orf58
LRP6
OR10R3P
AGPAT4
UBTD1
FBXO7
WDR49
ATP11C
PLOD2
TCN1WDR37
CABLES1
ISCU
PLAC8L1
NP_001036038.1 
PRKCD
RPAP1
RPL27A
DPPA4
DENND2A
C2orf25
ATAD3A
OR5T2
TXNRD1
C1orf101PAPD1
ING2
NT5C1A
NP_078924.1APOA4
KIAA1751
CAPN9
TMEM41B
THOC7
PTPRK
TXNL6
RFC2ZNF224
SERAC1
SAE2
RUNX1
RASA2
GAP43
IDH2
HEATR1
CCR6
AKAP5
CREB5
DOPEY1
FAM193B
DNM3
C8orf48
KCTD13
TIAL1
TMEM39B
PAQR9
3485
1869
CGRRF1
NP_996778.1ILK C7orf33Q6IQ01_HUMANABI1
IGFBPL1
GAL3ST2
11344
IDS
XYLT1
EDG3
ADAM9
NP_995324.1CNTN6
NR2C2
IRF3 DSE
PPP1R3B
PRKCB1
GCLC
SYT8
RASA3
ROR2
ZNHIT3CD97
C18orf34
3205
C1orf158
C1QL3
PBXIP1
PCSK6
BAG3SOX15RGS9
hsa-miR-126-3p 
TRIM67
YLPM1COX4NBCSNK1G3LRRC41
9134 PPIE
NP_001004306.1 
SLC25A44
GTPBP2
WASF2
ARMCX5
AMMECR1L
ANKRD13C
TNFAIP1
NAPRT1
MGAT4A
PRPF3
NANP
CCRL1
TTC30B
CRYGS
DCAF7
RAPH1
KDM5B
PIK4CA
USP2CARTPT
ROS1
HSPG2
ZMYM3
DRP2
LARP4B
ONECUT2
FCAR
NUCKS1
CCDC81FKHL18
CGREF1
KIAA1024 BRD3
TIAM1 GRHPRZBTB47LRRC17
ZKSCAN3
LRRC58
FAM57BHAPLN1MAU2
Q4G0S1_HUMAN
DDAH1CLCN2
EPS15ACACA
596
CTDSPL
ARPC5
NDUFS6 HIST1H1T
FRMD4A IFFO2GPATCH2
RALGPS1 LCE4A
BCL11B
MRPL3
TUBA4A
C12orf55 CNIH3
RAB31 CX3CL1
SLC16A2
PSEN1
BCL11A
PAN2HSP90AA6P
XKR4
AVPR1B
KCTD15
TNRC6B
USP37
LARP4FIGN
UNC13B
CMPK1PL-5283C18orf42
SNX8
MYCN
MMP8
MTX3
B3GALT1
SMEK2SPTLC2
DNAL1
ZNF541
LARP6 COL4A3
PKNOX2
BRD1
SFMBT1
CILP2ACPL2
SLC4A8
DEDD
HAND1HOOK3PLAG1
DPP4
GABRP
ZMIZ1
ZNF326
PLXNA1
NANOS1SH3GLB1
DBTNLRC3
STMN4DENND1B
STX16
UBTD2 MTF1QKI
TMEM236
ANGEL2PTX3
AFF4 ITGB2
DNAJC8
KIAA0776
SESTD1
CTC1
MAFB
HEPACAM
RBPJL
PHYHIPLGPR146
TP53INP2
CDRT15
SENP1
CLDN1 ADCYAP1R1CDK2AP1
STK36
EMP1CTDSPL2
STARD9
ACTR10
DLGAP1NOTCH2
LYCAT
POU2F1
C17orf83
CACNA1CDCUN1D4
KDM4B
KCNK10
DEFA4
NIPSNAP3B
ODF2
GCC2
CLCN5
ZBTB40
CTNND1
STK35
WDR81
STAMBPL1
SMAD6
GRIA3
ATP1B1
C19orf6
AHSG
DIP2C
DDX59
NAPB
NPAS4
KIAA1549RIT1
TUBB2B
CR1L
TET2
SLC26A6
NRSN1
U2SURPPPM1D
GPR37
7422AKAP13
HSPA12BFLCN USP7
COL4A5
CHMP4B DCBLD1
1786KPNA1HIF3A
CORT
RNF165
ADAMTS6
3667
SLITRK4
PEX5
ABCE1MARK3
FOXO3
HORMAD1
3845
PPIP5K2
PIR
STK38L
PPP1R16A
GRHL3
TIMELESS
WDR18
GNA13
CDKN2A
ATF2
RARRES2
C10orf68 THSD4
CHST1
8091
SGK69_HUMAN
C11orf9
BANP
EN1 MRPS26
NMI
FTCD
PHACTR2
ZBTB5ZER1FOS
ARHGAP36
UACA
EIF4E2
PHTF1
GRM4POLR1D
COL6A3
ADAMTS10
CSRNP2
LIPE
NAV3
CELF2
RNPEPL1
RIC3TFAP2CDHTKD1
PURG
OSTC
ZCCHC17TMEM65
CPS1
TMEM127
SOCS7
ANKRD49
SDK1
IGHV2-70
DIXDC1
FCHO1
ABTB1HBP1
SS18L1
ERC1
PRKRA
23621PIAS4
SLC16A14
PXMP2
1282SETDB2
ANGPTL4
INO80D
UBE1CSYCE2
GLIS2
LILRA4
C17orf103
RGAG4
SLC35B2
649
TMEM86A
MGAT4B
DICER1
BEAN1
FA 168B
MAP6D1
SAMD4A
C3orf41
IGLV7-43
SLC26A11
FBXL18
PPP1R3D
SIX5
ZBTB34
KIAA0895BAIAP2PENK ATG14
EOMESCLEC7A
ITGA11
KIAA0355IGF1
ASB2
ATXN1
TNFRSF9
PRRT4CASZ1
ZBTB10C20orf11
LOXL2ABHD5
MAGEB4
TMC7
TBX21
C20orf62GPX7 6421
CXADR
PCDHA3RINT1CTSF
ATAD2B
MLIP
CRISPLD1
CALU
FSTL1
TRAFD1
TRAV35
PNCK
CBR3
DLG2TIGD5DOLPP1SYT9
FGD4
RTKN2ZKSCAN4
LOC147670
SCML2
C1orf122
CIDEC
CCDC28B
C10orf31TMEM88
LALBA
IGF2BP1
GALNT14
SPRY4SPRY1 RALYSPAST
EDC3
C18orf51
BIN2 HSPA14PBX4TRAM2
EML2ZNF24
KIF5A
MAGEC1
DK
CPSF7
GDF15
PCYT1BOR9K2
URM1
7040
SLC43A1
KDELC1 EML5
CNOT6 HELZ
GNS
FAM13B
PLEKHB2
ADCY5GRIP1
NAT10 BTBD7
C8orf73
ELN NCSTNCXorf30
ADAMTS2
KDM5A
SLC7 6
CAMK1D
H2AFY
DMRT3HAO2
PITPNA
YPEL2
USPL1
ZNF519
PMS2L3
WIF1
C19orf22
OR10A4
CBX6
KIAA2022
NEGR1C20orf4Q6ZTH3_HUMAN
C1orf71
TGIF2
SLC16A1
REV3LC2orf28DDX3X
CENPK
GET1_HUMAN
NKIRAS2
ENTPD7
RAB15
DNHD2
RBM27
AK1
F11R
C14orf174UBN2
BVES
NXF1
ZNF704
ASPHD1
VASH1
MAD2L1BP
SERPINH1
LYPLA1
MYBL2
CYTH3
TMEM133
LIF
KLHDC3KIF24BCAT1 GAS2L3
ANK3
4170YY1BACH2
STRAPKLF12PRKG1
FBXO15
KIAA1191
VASH2
STX1A
CAPN10
LAMC2TMEM59
INA
LSM11
CCDC36
PLEKHF2
ZFP91
WAC
RAB12
HIP1UNKL
PRICKLE2
SLC26A10
BRAP
SPATC1
WISP1
TTLL2
INPPL1C14orf43
KLHL25
SERINC5
PLEKHA8
DHRS9NPM3
MEX3B
CBX5
YRDC
Q8N6X1_HUMAN
ADAMTS15DCLRE1A LOX
POLE3
C10orf6TMED9
CDRT1
ARSBHPCAL4
DIABLO
C1orf212
NLRX1
RPS10
ARRDC4
CEP152
C13orf23
DYM
C20orf135
SUN1
PLSCR3
CAPRIN1
GNG24324PITPNM3 GAK 2896SHROOM4
ZNF512B
KIAA1432
PHC1
ASAP2
ADAMTS20
NAT15
C11orf57
HIATL1
HIST1H2BB
LIMS1
AHR SPARC
IMPACT
ATP1B4
CCDC50 EBPL
PPIHROR1
SERPINB9PAIP2
ATP5G1RNF141
CALCR
CACNG4
CDC42BPA
OTUD1
XRN1UGTAP_HUMAN
VIPARPDGFRB10893
ASPH
MEGF6
GXYLT2
UHRF1BP1TACC1
ADA
C14orf148
FAM136A
CCNT2
DIRAS1DHRS2
PCDHA2DNPEP
PRR14LCHSY1
CAMK2BSPNS1
MORN3GMFB
ATP2B4
VSIG4PINX1_HUMAN
KIF3B
C17orf81ILDR2
TAX1BP1PRKAB2TSPAN4
MUC7
N4BP2L1
NP_659415.1
PCDHA6
CEP110NUDT3 NP_003299.2
C4orf17KCTD1
PIK3R3
ZNF609
PARG
CA5B
SLC36A1
ZNF532
CPEB3
GOT1
HAVCR1
C7orf60
HS3ST3B1MAP2K6
CEP97
KIAA0101CCND2
RDH5
GLB1L
ELP4
POLA2SHPRH ITGA5FRS2DCAF5 TPK1
OR2A7
HAPLN3 IQCJ-SCHIP1MSL1TRIM66LEP MCMBP
TRA2B
ARHGAP31
CHST11 PHLDB3
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GPLD1
STRN3
TOMM70ATMEM201
FRAS1
GTF3C1EIF2S2
C21orf91VPS37CVANGL1
ZFP36FOXJ2
CCNA2
LASP1
5728FBRS
NKRF
C4orf32
NID2
LDOC1LCLEC2L
HNF4G
ARHGAP20SPTAN1
NCOA4
DAB2IP
SAMD10
SLC25A22
SYT14
N4BP2
ULBP2DCLK1
BCL9L
ARRB1RSRC2
BAHD1
PCDHAC2
TATDN2
TNFAIP3
BLMH
POU2F2
CEACAM6
EFNA5
CTNNBIP1MAP2K4
DUS2L
RCC2
SUGT1
ZFYVE20
ELOVL4 ATG9A
TMEM163
IRGQ
TMTC3
SLC31A1
KLHDC5
PPIC
OSBPL3RNF169
RAP1GDS1COL2A
MTA2
FAM65B
KIAA1644
SNX24CASP7UNK
SIP1
DUSP22
CRIPAKMETAP2
DUSP2
DMKN
PITPNM2
PDP2
SGMS2
PCDHA1
RLFTPM1FAM116A
TMEM132ARAB6IP1
COL1A2IL1F9
TRAF4LOXL4GAS7
ZNF282 RNF39
DGKH
NFIAPCDHA10
NP_001012986.2 
MFAP2
GAL3ST1COL19A1
SRGAP2
HNRNPF
KLHL9
IL22
EFEMP1
CSDAARVCF
TET3
CENPE
NME5
VCLTMEM169TTC9FAM176B
4811
IGSF1
TTC124313
AFG3L2
HRH3
STRN
TDG
CORO6
PPAPDC1A
COX7A2LGJC1KLF2
PRR3
RESTADAMTS17
SVIL
MECRhsa-miR-29b-3p 
PRPF40A
ITGA6
PDHX
CLEC3A
KIFC2
HNRPH2C9orf697042
PLEKHH2
KIF5B
MUC19
MRPS7
COL5A1
RDH12
SPINT1
GTF3C5
KLHDC10
SENP5 MRE11A
JMY TTYH2
CECR2
IKZF4
TNRC18
ENHO
SLC43A2
ERCC6
BSNDEPHB3
UBE2HCDKL2
OTUD7A
CLEC2D
LYSMD2
SLC24A4
PC
C20orf96
RSC1A1
ZNF498RAET1L
SLC9A10
C18orf1
C1orf125
POLR2G
POLR3D
MAPKBP1GLP2R
GNB4LPGAT1
UQCR KCTD5
URP2_HUMAN
COL4A2
PVRL1
ZFYVE26
ZNF253
STMN2
ROBO1
COL6A6
S100A1
CELF6
FREM2
NP_001035830.1 
BCL7ALUZP1MYO16
MAL
GALNT8
DEF8
PSMA4
MYL6
ACO1
FNDC5COL7A1
C11orf87CMKLR1FCHSD1LPL
GPR85
ZFP91
HLA-DQA2
DCX
8038 ATP6V1A
PCDHAC1 DRD1
HAS3JARID2CNKSR2
ANGPTL7
GC FR
MED12L
DR1SLC6A17
SGK1
ETV6
C20orf24WFDC12
P2RY51277
FAM105B
NDNADAMTS5
XPO4
NUFIP2
SEZ6EFHC1
AP3M1 C1orf96
SCN3B
C20orf29
RAPGEFL1
DMRTB1
GRPEL2
LDLRAP1
HEYLRUNX1T1
PLEKHA1
KCTD3AACS
TGDS
SH3RF3
PTPRD
OLFM3
INSIG1
C12orf40
WFDC3SNTB2
AP1G1
L3MBTL4
ID3
PRMT2
C9orf7
DCAF12
DNAJB2 MORF4L2
ZNF614
TMEM229B
RAP1GAP2
NUDT11
TRI 63
C15orf27
TMEFF1
RNF13CCDC99
RGPD7
RPS15A
TRIM31 C11orf54
INVS
TP53INP1
CSNK1G1 6285
UBIAD1
NAA40
LRCH1
KLK11
FGF4
WASF1
MED26
H2AFY2
RORANP_001074008.1 
FAM190B
GSK3B
THAP8
RERE
GPR175
PRLHR
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Table 5.3. Predicted mRNA targeted by both miR-29b and miR-126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABCE1 CR1L IDH2 Q9NW00_HUMAN 
ACPL2 CREB5 IRS1 RARRES2 
ADAMTS6 DCBLD1 KDELC1 RDH12 
AFF4 DENND1B KIAA1546 RIT1 
AGPAT4 DIP2C KIF5B RNF165 
AHSG CREB5 KPNA1 SEMA5B 
AKAP13 DCBLD1 KRAS SGK69_HUMAN 
AKAP5 DENND1B LARP6 SLC26A6 
ANTXR2 DIP2C LRP6 SLC43A1 
ATF2 DNM3 MANEAL SLITRK4 
ATP1B1 DNMT1 MARK3 SMAD6 
BANP DOPEY1 METTL21D SR140_HUMAN 
BRD1 EDC3 MRPS26 STAMBPL1 
C10orf68 EN1 NAPB STK38 
C11orf9 FBXO7 NFATC3 SYT9 
C17orf68 FGD2 NMI THSD4 
C9orf92 FLCN NPAS4 TIMELESS 
CCR6 FOXO3A NRSN1 TMC7 
CDKN2A FTCD PCDHA11 TUBB2A 
CEACAM1 G6PC PDGFB UBTD1 
CHMP4B GAP43 PEX5 USP7 
CILP2 GNA13 PIR VEGFA 
COL4A5 GPR37 PPM1D WDR18 
CORT GRHL3 PPP1R16A ZNF524 
CPEB3 GRIA3 PTX3  
CR1L HEATR1 Q9HCM3_HUMAN  
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5.3 Discussion 
 
The first aim of the present chapter was to determine the feasibility of LCM in 
conjunction with miRNA detection by RT-qPCR, to identify miRNA expression 
from defined nephron segments. Previous work has shown that this technique 
can be used to study alterations in mRNA abundance in an animal model of renal 
disease [297]. A previous study on rats demonstrated that LCM was accurate in 
detecting variations in miRNAs expressed in 9 specific cell types in solid organs, 
suggesting that miRNAs may have tissue / organ-specific roles [298]. 
 
In the present study, LCM was used to isolate glomeruli, proximal tubular and 
distal tubular nephronic regions from 5 control biopsies. A statistically significant 
increase in miR-126 expression was observed in glomeruli in comparison to 
proximal and distal tubular tissue extracts. Although great pains were taken to 
ensure clear separation of nephron segments, it is hard to definitively prove that 
dissection of absolutely discrete nephronic regions by the above LCM method 
was not partly compromised by simultaneous sampling of underlying biopsy 
tissue. Analysis of miRNA expression was carried out from patients biopsies that 
were found to be disease free. Analysis of miRNA expression in kidney biopsy 
samples from DN patients will provide very valuable data in disease 
mechanisms. However, to further refine the LCM, analysis of putative disease-
associated miRNAs was carried out in podocytes and glomerular endothelial 
cells, HK-2 and fibroblast cell lines. 
 
Abundant miR-126 expression in LCM-dissected glomeruli was supported by 
almost exclusive expression of this miRNA in glomerular endothelial cells. A 
previous study has demonstrated that miR-126 expression appears endothelial-
specific [251]. Highly vascularised tissues such as heart and lungs have greater 
expression of miR-126, and it has also been shown to be vascular system-
specific in zebrafish, and to be expressed in primary human umbilical vein 
endothelial cells (HUVECs) and other endothelial cell lines [251,299,300]. 
Another study showed that miR-126 expression is restricted to the glomerular 
endothelial cells with little expression in mesangial cells and podocytes [301]. 
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The LCM results for miR-29b showed an abundance of this miRNA in the 
glomerulus. Analysis of cultured cells showed a statistically significant abundance 
of miR-29b expression in glomerular endothelial cells, and miR-29b was also 
detected in fibroblasts. The majority of previously published observations have 
shown miR-29b expression and function in fibroblasts from different origins [302-
304]. However, a tissue specific source for miR-29b in kidney tissue has not been 
described.  
 
The two miRNAs principally expressed in endothelial cell lines, miR-29b and 
miR-126, were further investigated to evaluate if differential expression in DN 
patients was glucose-dependent. Analyses were then carried out using three 
glucose-depend models:  
• CiGEnC treated with high glucose concentration 
• Diabetic NOD mice  
• Urine from PCOS females with insulin resistance 
Data obtained from these models suggest that the change of miR-29b and miR-
126 expression is not affected by variation in glucose concentration.  
 
Zampatetaki and colleagues analysed plasma miRNA profiles from patients 
with T2DM, one of the major risk factors for both cardiovascular disease and 
diabetic nephropathy and found a reduction of miR-29b and miR-126 [155]. 
Specifically, high glucose concentrations significantly decreased miR-126 levels 
in endothelial apoptotic bodies and in plasma [154]. Down-regulated miR-126 
expression was also detected in plasma from patients affected by coronary artery 
disease when compared to healthy controls [155], in endothelial progenitor cells 
from diabetic patients [305], and in bronchial brushings from cystic fibrosis 
patients [306]. Snowdon and colleagues reported increased expression of miR-
126 in urine samples from urothelial cancer patients [279]. The miRNAs analysed 
in this study were chosen on the basis of published literature on miRNA 
expression in solid bladder tumour and not after a profiling experiment [279]. 
 
Increased miR-126 expression has been shown in the aortas of CKD mice, 
along with a concomitant down-regulated expression of targets VCAM-1 and 
SDF-1 proteins, while miR-126 antisense treatment strongly enhanced the 
expression of these targets [307]. Surprisingly in light of the above findings, 
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induction of miR-126 expression resulted in increased abundance of the VCAM-1 
and SDF-1 mRNAs, possibly a result of other factors compensating for the miR-
126 inhibitory effect [307]. Using the diabetic Goto-kakizaki rat model, He and 
colleagues found increased miR-29a and miR-29b expression due to the 
hyperglycaemic and hyperinsulinemic conditions [308]. 
 
Our data presented in this thesis suggest that increased miR-126 and miR-
29b expression is not conditional on high glucose concentration in the models 
tested. However, this effect may be due to the influence of other mechanisms 
that play a role in diabetic nephropathy development and progression. 
 
The role of miRNAs in the fibrotic process during diabetic nephropathy and the 
involvement of inflammatory mechanisms in this disease have already been 
discussed in Chapter 1. Therefore, miR-29b and miR-126 expression was 
analysed in CiGEnC following treatment with VEGF, TNF-α, TGF-ß and IL-6 as in 
vitro models of DN. Decreased detection of both miR-29b and miR-126 was 
identified in cytokine-treated cells. Statistically significant increased expression of 
miR-126 expression was observed in conditioned media of TNF-α-treated 
CiGEnC and of miR-29b following TGF-ß1 treatment. 
 
De Jong and colleagues have shown that, following treatment with 10ng/ml of 
TNF-α, exosomes secreted by endothelial cells showed increased protein levels 
of intercellular adhesion molecule 1 (ICAM-1) and TNF-α, alpha-induced protein 
3 (TNFAIP3) [30]. By contrast, elevated concentrations of glucose or mannose 
did not lead to significant changes in mRNA level and only a few proteins are 
modified by these conditions [309]. These authors did not analyse changes in 
exosomal miRNA levels, and it is possible that the induction of miR-126 
expression by TNF-α in CiGEnC condition medium observed in this study might 
be exosome-associated. 
 
TNF-α treatment induces VCAM-1 protein synthesis predominantly in arteriolar 
and peritubular endothelial cells, where miR-126 regulates VCAM-1 expression 
[301]. miR-126 and VCAM-1 protein and mRNA levels were studied in the 
glomerular endothelium and arteriolar endothelium in the kidneys of C57BL/6 
mice. Elevated miR-126 levels in the glomerular endothelium corresponded with 
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low VCAM-1 protein expression. In contrast, in arterioles, low miR-126 levels 
were associated with high VCAM-1 protein levels [301]. These data suggested 
that in reaction to an inflammatory stimulus, less VCAM-1 protein was produced 
in the glomerular compartment [301]. VCAM-1 is also responsible for mediating 
leukocyte adhesion on the endothelial surface [310]. Therefore, inhibition of 
VCAM-1 expression by miR-126 may regulate leukocyte homing in the vessel 
wall, suggesting a role in vascular inflammation by reducing TNF-α-induced 
expression of VCAM-1 [311]. 
 
The E26 transformation-specific sequence (ETS) factors are a family of 
transcription factors that share a highly conserved DNA binding domain and 
regulate cell development, senescence, death, and tumorigenesis [312]. ETS1 is 
expressed in human endothelial cells and ETS1 protein expression is up-
regulated by TNF-α [313]. In HUVEC, Ets-1 and Ets-2 play a fundamental role in 
controlling the expression of miR-126 [314]. Essential roles for miR-126 in 
angiogenesis and maintenance of vascular integrity have been described, and its 
pro-angiogenic action is in part mediated by repressing negative regulators of the 
VEGF pathway including the Sprouty-related protein (SPRED1) and 
phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2) [315].  
 
VEGF is another cytokine that is induced by TNF-α [316]. Cantaluppi et al. 
demonstrated a protective effect of microvesicles released from endothelial 
progenitor cells in experimental acute kidney injury [317]. They found that 
microvesicles rich in miR-126 and miR-296 activated an angiogenic program that 
modulated proliferation, angiogenesis and apoptosis [317]. These vesicles were 
reported to enhance tubular cell proliferation and reduced leukocyte infiltration, 
and to provide protection from chronic kidney damage progression by inhibiting 
capillary rarefaction, glomerulosclerosis and tubular interstitial fibrosis [317]. 
 
It is therefore possible that TNF-α treatment of CiGEnC might induce VCAM-1, 
miR-126 expression and microvesicle production. Induction of VCAM-1 might 
mediate an immediate inflammatory response through regulation of leucocyte 
adhesion. By contrast, increased exosomal and miR-126 production may have a 
protective role from future chronic damage.   
  
 137 
The human miR-29b family includes hsa-miR-29a, hsa-miR-29b-1, hsa-miR-
29b-2, and hsa-miR-29c. miR-29b-1 and miR-29b-2 have identical mature 
sequences, referred to collectively as miR-29b. The gene encoding the 
precursors of miR-29b-1 and miR-29a is located on chromosome 7q32.3, while 
the gene encoding miR-29b-2 and miR-29c is on chromosome 1q32.2. Different 
reports have shown that the miR-29 family target a variety of mRNAs that encode 
the extracellular matrix-related proteins: a large number of collagen isoforms, 
laminin γ1, fibrilin 1, elastin, matrix metalloproteinase 2, and integrin ß1 
[130,318,319]. In addition, it has also been shown that expression of the miR-29 
family is TGF-ß mediated [319,320]. Qin and colleagues demonstrated that miR-
29 is a downstream target gene of TGF-ß/Smad3 in fibrosis, and was negatively 
regulated by TGF-ß/Smad3 [42]. This study also showed that miR-29 negatively 
regulated fibrosis by targeting the process of collagen matrix synthesis rather 
than by inhibiting myofibroblast accumulation [142]. Renal miR-29b 
overexpression in an established mouse model of unilateral ureteral obstruction 
(UUO) nephropathy showed a potential therapeutic effect on renal fibrosis, 
blocking tubulointerstitial fibrosis, collagen I and collagen III mRNA expression 
and protein accumulation [141]. 
 
Furthermore, it has been reported that induction of fibrosis in hepatic stellate cells 
correlates with a reduction of miR-29b expression and up-regulation of IGF-I and 
PDGF-C [321]. These data suggested that miR-29 acts as an antifibrogenic 
mediator by targeting collagen biosynthesis, and by interfering with profibrogenic 
cell communication via PDGF-C and IGF-I [321]. 
 
The above studies suggest that release of miR-126 and miR-29b by 
glomerular endothelial cells into the nascent glomerular ultrafiltrate may have 
important consequences for the downstream nephron. Further studies will be 
required to determine the precise consequences of this release by glomerular 
endothelial cells that my work uncovers. It will also be important to understand 
the molecular mechanisms leading to release of microRNAs.  
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Chapter 6 – General discussion 
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DN is the leading cause of CKD and the second most common cause of end-
stage renal disease. Classical indicators such as determination of eGFR, 
presence of proteinuria and screening for microalbuminuria are neither 
sufficiently specific nor sensitive to predict disease outcome in individual patients. 
Kidney biopsy, the gold-standard diagnostic test available at present, is an 
invasive procedure with a 3% of risk of major complications. Therefore, 
identification of more effective biomarkers for early detection and better screening 
is highly desirable. 
 
The aim of this thesis was to analyse miRNA expression in urine samples as a 
novel, non-invasive method for the diagnosis and prognosis of DN. At the start of 
this project in 2011, the key roles played by miRNAs in numerous physiological 
and pathological processes were becoming recognised. However, little was 
known regarding the detection of urinary miRNAs and the exploitation of this 
approach to identify putative DN biomarkers. 
The first goal of this project was to develop a reliable and robust technique for 
extraction and detection of miRNAs from urine samples. The experimental data 
showed coefficients of variation of less than 10%, confirming that the assay was 
suitably robust. Furthermore, appropriate stability of endogenous urinary miRNAs 
was established in samples from unaffected individuals and DN patients. This 
first part of the study was carried out analysing two miRNAs: miR-16 and miR-
192. miR-16 is expressed abundantly and ubiquitously, while previous data from 
the host laboratory has demonstrated down-regulation of miR-192 in severe DN 
and provided evidence of a potentially important role for this miRNA in renal 
fibrosis [136]. Data from the present study showed that both miRNAs are stable 
in urine samples maintained at room temperature for up to 4 hours, and 
demonstrated specific stabilising mechanisms for endogenous miRNAs, but not 
for the exogenous, spiked-in, cel-miR-39. These findings have important 
implications for routine analysis of urinary miRNA as disease biomarkers. 
The presence of at least two populations of urinary miRNAs: those associated 
with microvesicles, including exosomes, and those associated with protein 
AGO2. Each of these associations might explain protection from RNase 
degradation and proteinase K digestion respectively. Previous studies have also 
shown that, unlike mRNAs and long ncRNAs, plasma-borne miRNAs are 
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resistant to endogenous RNase activity, and that their resistance to degradation 
may be a product of association with extracellular vesicles like exosomes, or with 
protein complexes [166,170,189]. Exosome-associated miRNAs have been 
proposed as disease-specific biomarkers [322,323]. To evaluate the utility of 
exosome-associated miRNA as DN biomarkers a detailed characterisation of 
urinary exosome-associated miRNA populations will be required.  
Functionally active exosome- or protein-associated extracellular miRNAs may 
be taken up by recipient cells, regulating gene expression and working as cell-to-
cell messengers in both local and more distant micro communication 
mechanisms [324]. Indeed, exosomes can mediate diverse biological functions 
including the transfer of mRNAs and non-coding RNAs to neighbouring or distant 
cells [168]. It is therefore conceivable that these extracellular miRNAs might act 
therapeutically or pathogenically within the nephron, depending on the local 
environment. Critical factors are likely to include the identity and abundance of 
miRNAs in exosome or protein complexes released by cells, the capacity of 
exosomes to transfer miRNAs to recipient cells, and the end-result of miRNA 
uptake in the recipient cells. 
The maximum size of a molecule that can cross the healthy glomerular 
filtration barrier approximates to albumin, which has a molecular mass of 67 kDa. 
This threshold predicts that AGO2, at 97 kDa, would be excluded from the 
glomerular ultrafiltrate. In addition, recent evidence suggests that protein GW182 
(182 kDa) may play a key role in protecting AGO-bound miRs [191]. The addition 
of this protein would significantly increase the miR:AGO2 complex size, making 
trans-glomerular filtration barrier passage even less likely. It is therefore possible 
to speculate that urinary AGO2:miR complexes originate largely from the urinary 
tract in healthy controls. It seems unlikely that this relationship will hold true in DN 
patients where proteinuria is greatly increased, but further work will be required. 
The preliminary data generated in Chapter 3 suggested that urinary miRNAs 
are suitable candidates for further analysis as renal disease biomarkers. 
Therefore, urinary miRNA profiles were generated from samples from DN 
patients and healthy individuals. This analysis was carried out using a qRT-PCR-
based array (TaqMan Array Human microRNA Cards A and B), permitting the 
simultaneous analysis of 754 small non-coding RNAs. The decision to use this 
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technology instead of a hybridisation array-based approach was made on the 
basis of previous experiments carried out in our laboratory. These previous data 
showed that amplification-based technology was more sensitive, producing useful 
miRNA expression data from FFPE renal biopsy samples from nephrology 
patients after storage for 8-16 years (Aleksandra Krupa’s PhD thesis: The role of 
microRNAs in renal fibrosis). 
TaqMan Array Human microRNA Card A analysis identified a significant down-
regulation of 35 miRNAs expression from a total of 47. Of the miRNAs with 
significantly up-regulated expression in DN patients when compared to control 
subjects, miR-29b, miR-212, miR-126 and miR-155 showed greatest fold-
changes, with miR-192 and miR-200b the corresponding down-regulated 
miRNAs. These results were then replicated using single, miRNA-specific, qRT-
PCR assays. ROC curve analysis supported the possible utility of these miRNAs 
as DN biomarkers. However, for correlations between miRNAs expression and 
both P:Cr ratio and eGFR, the r2 failed to exceed 0.4. Future studies analysing 
larger case-control cohorts will be required to clarify the association of these 
variables and to compare the performance of these new markers to those 
presently in use. 
 
As discussed extensively in Chapter 4 (Section 4.3), different groups have 
investigated the role of miRNAs in DN and analysed their potential as novel 
biomarkers for kidney disease and other pathologies [280-283]. Validation of 
selected putative disease-associated miRNAs in larger DN patient cohorts will 
provide valuable information. Patients recruited for the present study were 
predominantly male, with CKD stages 3, 4 or 5. Future analyses should include 
increased numbers of both male and female patients at all CKD stages, including 
stages 1 and 2. It will also be interesting to correlate expression levels of target 
urinary miRNAs with disease progression and to evaluate their utility as 
prognostic indicators for DN.  
 
Since diabetes is the commonest cause of DN, further work will be required to 
dissect miRNA disease-related components specific to DM and DN, as well as 
shared components. In the present study, analysis of miR-126 and miR-29b 
expression was carried out in three diabetes-related models: CiGEnCs cultured in 
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an elevated glucose concentration, diabetic NOD mice, and urine samples from 
PCOS females with insulin resistance. The data obtained from these models 
suggested that changes in expression of these miRNAs were not affected by 
variation in glucose concentration. 
 
miR-29b and miR-126 were detected at low levels in control urine samples 
and at much higher level in the DN patients’ urine. Direct involvement of miR-126 
in DN has not yet been shown, but an increase in miR-126 has been 
demonstrated in the aortas of mice in a CKD model [307], and in urine samples 
from patients with low- and high-grade urothelial cancer [279]. Downregulation of 
miR-126 expression was observed in plasma samples of DM patients [154]. A 
number of reports have implicated members of the miR-29a/b/c family in the 
pathogenesis of renal fibrosis. In high glucose concentrations, TGF-ß1 
downregulates miR-29a/b/c expression in tubular epithelium-like cells and 
podocytes, and these changes are associated with increased expression of 
collagens I, III and IV [141,143,154]. To assess the specificity of target miRNAs 
as biomarkers for DN, it would also be useful to investigate their expression in 
patients affected by other kinds of renal disease such as IgA nephropathy, 
polycystic kidney disease, glomerusclerosis and acute kidney disease. 
 
In the present study, characterisation of miRNA expression in defined nephron 
compartments was achieved by LCM followed by miRNA detection by qRT-PCR 
on RNA extracts from the isolated nephron regions from 5 control biopsies. A 
statistically significant increase in abundance of miR-126 was detected in 
glomeruli when compared to proximal and distal tubular RNA extracts. Abundant 
miR-126 expression in LCM-dissected glomeruli was supported by almost 
exclusive expression of this miRNA in glomerular endothelial cells, while miR-29b 
expression was abundant in the glomerulus but also readily detectable in 
fibroblasts. These data correlated with previously published observations 
showing that miR-126 expression is endothelium-specific [299] and miR-29b 
expression is typical of fibroblasts from different origins [302-304]. 
However, it is important to note all LCM biopsies were taken from patients who 
were subsequently found to be disease-free. During this project, renal biopsy 
samples from DN patients were not available to analyse miRNA expression. LCM 
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of renal biopsy tissue from DN patients will be essential to investigate disease 
mechanisms and identify the sources of target miRNAs.  
As discussed above, the data presented in this thesis suggest that increased 
miR-126 and miR-29b expression is not dependent on high glucose 
concentrations in the models tested. However, this effect might be due to the 
influence of other mechanisms that play a role in development and progression of 
DN. For this reason, expression of miR-29b and miR-126 was analysed in 
CiGEnC following treatment with VEGF, TNF-α, TGF-ß and IL-6 as in vitro 
models of DN. Statistically significant up-regulation of miR-126 expression was 
observed in the conditioned medium of TNF-α-treated CiGEnC and of miR-29b 
following TGF-ß1 treatment. These data highlight the complexity of this pathology 
(see Chapter 1). 
 
The experimental data above suggest that miR-126 abundance may be 
involved in inflammation, while miR-29b expression is regulated by cytokines 
implicated in renal fibrosis. Additional studies will be needed to clarify the 
involvement of these miRNAs in the pathology of diabetic nephropathy, firstly to 
validate if miR-126 and miR-29b are regulated by TNF-α and TGF-ß1 treatment 
respectively, and secondly if they have a protective role in kidney damage. Up-
regulated expression of these miRNAs in urine samples of DN patients, in 
conditioned culture medium of in vitro DN models and increased expression in 
the glomerulus of healthy subjects is also worthy of further investigation, and 
might provide important information on downstream signalling in the nephron.  
 
DN is a complex condition in which a network of molecular, cellular, and 
physiological mechanisms play key roles in disease progression. A single miRNA 
can potentially regulate multiple components of one or more pathways via both 
autocrine and paracrine signaling. Therefore theoretically, miRNAs are credible 
candidates both for novel DN biomarkers and as druggable targets for disease 
treatment. The work presented in this thesis, together with the other published 
reports, provides a starting point to evaluate the use of miRNAs as future 
therapeutic, diagnostic and/or prognostic clinical tools. 
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